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ABSTRACT 
Medicinal uses of Galenia africana: A study of the antimicrobial, 
antifungal and anticancer properties 
Over the years, microorganisms have become resistant to commonly used antimicrobial agents 
leading to multidrug resistance. This is believed to occur even with new classes of therapeutic 
agents thus creating a challenge on the global healthcare system. The study of medicinal plants 
allows for their possible use as alternative therapeutic agents. Galenia africana (G. africana) is a 
South African medicinal plant with numerous health benefits.  
The purpose of this study was to evaluate the potential antimicrobial, antifungal and anticancer 
properties of the ethanolic extract of G. africana. Prior to evaluating these properties, in vitro and 
in vivo acute toxicity studies were conducted to assess the toxicity profile of G. africana.  
The toxicity profile of the G. africana extract was evaluated using acute toxicity studies 
conducted in animal and reconstituted human epidermis skin models. The results of the acute 
oral and dermal toxicity studies revealed that the median lethal dosage (LD50) for G. africana 
extract in Sprague-Dawley rats was considered to exceed 2000 mg/kg. In the dermal sensitization 
study, the stimulation index (SI) values for the mice treated with the G. africana extract at 
concentrations of 25% (50 mg/ml), 50% (100 mg/ml), and 100% (200 mg/ml), when compared 
to the control group, were 1.3, 0.9 and 1.3, respectively which did not result in an SI value of ≥ 3 
in any group. Hence, it did not elicit a hypersensitivity response. In the irritation test, the G. 
africana (concentrate) and G. africana (in-use dilution) extracts were non-irritant on the 
reconstituted human epidermis.  
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The antimicrobial activity of G. africana was evaluated against two Staphylococcus aureus 
strains namely methicillin-resistant (MRSA: ATCC 33591) and methicillin-sensitive/susceptibile 
(MSSA: ATCC 25923). Results of the broth microdilution assay showed that G. africana exerted 
good antimicrobial activity against the two strains with a minimum inhibitory concentration 
(MIC) of 3.12 mg/ml for both strains. Results of the minimum bactericidal concentration (MBC) 
determination showed that G. africana was bactericidal against both strains (MBCs of 3.125 and 
6.25 mg/ml for MSSA and MRSA, respectively). In addition, the checkerboard assay 
demonstrated that the combination of G. africana and ampicillin had an additive effect against 
MSSA and an indifference result against MRSA (fractional inhibitory concentration indices 
(FICI) of 0.64 against MSSA and 1.002 against MRSA). The combination of G. africana with 
several antimicrobial agents in the Sensititre susceptibility test also showed a reduction in the 
MICs of a number of the antimicrobial agents. 
Investigation of the antifungal activity of G. africana was done by evaluating its activity against 
Candida species (Candida albicans and Candida glabrata, ATCC 90028 and ATCC 26512, 
respectively). Results of the broth microdilution assay showed that G. africana possessed 
antifungal activity against the two Candida strains (MIC of 6.25 mg/ml for both Candida strains). 
Minimum fungicidal concentration (MFC) determination revealed that G. africana was 
fungicidal against both Candida strains (6.25 and 12.5 mg/ml for C. albicans and C. glabrata, 
respectively). Results of the checkerboard assay revealed that the combination of G. africana and 
fluconazole had a strong synergistic effect against C. albicans and an indifference result against 
C. glabrata when interpreted by the FICI (0.36 and 1.002 for C. albicans and C. glabrata, 
respectively). Results of the Sensititre susceptibility test also showed a reduction in the MICs of 
the antifungal agents when combined with G. africana. Microscopic analysis, using scanning 
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electron microscopy, showed that there was cell damage including a decrease in cell size after G. 
africana treatment for both Candida species. 
Evaluation of the anticancer properties of G. africana was done by investigating its cytotoxic 
potential in human breast cancer (MCF-7) and normal fibroblast (KMST-6) cell lines. The ability 
of G. africana to affect gene expression, apoptosis and cell cycle processes was also evaluated in 
MCF-7 cell lines. It was observed that G. africana had a greater anticancer effect against the 
MCF-7 than the KMST-6 cells as determined by the IC50 values. Results of the effect of G. 
africana on the gene expression, apoptosis and cell cycle of MCF-7 cells showed that genes, 
such as BCL2L11, CASP2 and CASP7/9, that are involved in apoptosis were up-regulated. It was 
also observed that genes involved in angiogenesis such as ANGPT1 and ANGPT2 were down-
regulated. In addition, genes involved in cell cycle processes, such as ACLY, ACSL4 and PFKL, 
were down-regulated. 
Collectively, these results suggested that G. africana possessed antimicrobial, antifungal and 
anticancer activities against medically important microorganisms as well as breast cancer. 
Furthermore, toxicity analysis results revealed that G. africana was not toxic when tested using 
animal and human skin models. This provides important information for the development of new 
therapeutic agents. 
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1 CHAPTER 1: General introduction 
1.1 Background 
Multidrug resistance has been described in microorganisms such as bacteria and fungi as well as 
in diseases such as cancer (Housman, Byler et al. 2014). Antimicrobial resistance (AMR) 
develops mainly as a result of misuse of antimicrobial agents, patients not adhering to treatment 
plans and patients stopping treatment once they experience side effects (Ayukekbong, Ntemgwa 
et al. 2017). Drug resistance in cancer normally develops by means of various processes such as 
drug efflux, DNA damage repair, drug target alteration, cell death inhibition and drug 
inactivation (Housman, Byler et al. 2014).  
The multidrug resistance crisis is worsened by the fact that a large number of pharmaceutical 
companies prefer to produce drugs for the treatment of chronic diseases, such as diabetes and 
hypertension, as this is more profitable for them. In addition, these companies believe that 
resistance to newly developed antimicrobial agents would still develop thus investing in this type 
of research would yield less profit (Brandenburg and Schürholz 2015). The increasing threat of 
drug resistance prompted researchers to explore the use of medicinal plants as alternative 
therapeutic agents for the treatment of diseases. Numerous studies have been conducted on 
medicinal plants to evaluate their effect on drug resistant microorganisms as well as cancer 
(Graidist, Martla et al. 2015; Anyanwu and Okoye 2017).  
Medicinal plants have been extensively used around the world for their nutritional value and 
ability to treat various diseases. A large proportion of the population worldwide, approximately 
60-80%, still depends on medicinal plants to treat diseases that are frequently encountered in the 
communities (Nile, Nile et al. 2017). They are also the main sources of bioactive compounds 
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which are incorporated in or used as herbal supplements and drugs (Ekor 2014). The bioactive 
compounds present in most medicinal plants include nitrogen compounds (such as alkaloids, 
amines and betalains), phenolic compounds (such as flavonoids, phenolic acids, tannins, 
stilbenes and lignans), vitamins, carotenoids as well as other compounds with a wide range of 
biological activities (Cai, Sun et al. 2003; Cai, Luo et al. 2004).  
For years, medicinal plants and plant products have been used as herbal medicines and are 
incorporated in complementary and alternative medicine (Hashempur, Heydari et al. 2015; Nile, 
Nile et al. 2017). The current need for treatment options that limit and manage the spread of drug 
resistant microorganisms and subsequently treat numerous infections is the basis for the 
continuous research being conducted on medicinal plants and plant products. 
1.2 Aims and objectives of the study 
The aim of this study was to evaluate the South African medicinal plant, G. africana, for its 
potential antimicrobial, antifungal and anticancer properties. This study was also aimed at 
investigating the toxicity profile of this medicinal plant. The current study was formulated with 
several objectives as follows: 
1. To assess the toxicity profile of G. africana in animal and reconstructed human epidermis 
models. 
2. To evaluate the antimicrobial activity of G. africana alone as well as its interaction with 
antimicrobial drugs against methicillin-sensitive (MSSA) and methicillin-resistant 
(MRSA) Staphylococcus aureus strains. 
3. To evaluate the anti-Candida activity of G. africana alone and in combination with 
antifungal drugs against Candida albicans and Candida glabrata. 
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4. To investigate the cytotoxicity of G. africana alone and in combination with doxorubicin 
in human breast cancer (MCF-7) and normal fibroblast (KMST-6) cell lines. 
1.3 Study rationale 
Multidrug resistance is a growing concern worldwide and the need to find ways to combat it is of 
utmost importance. The rate at which resistance develops is greater than the rate at which new 
drugs are being produced and this puts a strain on the healthcare sector. It is for this reason that 
alternative treatment options are being explored, in the form of medicinal plants, as a way of 
alleviating the burden created by multidrug resistant microorganisms. Medicinal plants have 
been used in the treatment of diseases and the study of these plants and plant products creates a 
platform to assess their potential as therapeutic agents. Nonetheless, despite their use as herbal 
medicines there is need for toxicology studies to be conducted to assess the safety and potential 
adverse effects associated with them. It is for this reason that the South African medicinal plant 
was selected in order to evaluate its potential beneficial health effects. 
1.4 The use of medicinal plants as therapeutic agents 
Natural products are still being used in drug development and they play a fundamental role in 
this industry. Approximately a third of the most common drugs originate from plants and plant-
based compounds (Ma, Zheng et al. 2009). It has been shown that at least 190 clinical trials are 
dedicated to the study of pure or combined plant compounds to assess their ability to treat a 
variety of diseases (Joray, Trucco et al. 2015). The World Health Organization states that 
approximately 70-95% of people in developing countries rely on medicinal plants for the 
treatment of most diseases. Herbal medicine is frequently used in rural areas because it is often 
the only treatment option available to them (Mabona and Van Vuuren 2013). Most people use 
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medicinal plants because they are considered to be cheaper alternatives, readily available and the 
indigenous knowledge makes them safer options for the local population (Street, Stirk et al. 
2008).  
In Southern Africa, plants that are used for skincare, such as Harpagophytum procumbens, 
Lobostemon fruticosus, Trichilia emetic and Warburgia salutaris, and being considered for 
commercialization still have not undergone phytochemical, toxicity and pharmacological 
efficacy testing (Vermaak, Kamatou et al. 2011). Furthermore, it has been observed that the 
skincare industry is incorporating a number of medicinal plants, such as Rooibos (Aspalathus 
linearis), Aloe ferox and Aloe vera, in most of their products (Mabona and Van Vuuren 2013). 
Medicinal plants predominantly found in Southern African have also been shown to have the 
ability to treat skin infections caused by pathogens such as Staphylococci species and Candida 
albicans (Mabona and Van Vuuren 2013). Studies conducted on medicinal plants used for the 
treatment of skin infections showed that they caused adverse effects which included 
phytodermatitis, an increased risk of photosensitization and allergic reactions (Reuter, Merfort et 
al. 2010). It has been shown that about 27 million South Africans rely on the use of medicinal 
plants for the treatment of a large number of infections (Street, Stirk et al. 2008). Even though 
South Africa has a variety of medicinal plants and affluent biodiversity, most of the plant species 
have not been extensively researched and validated (Springfield, Eagles et al. 2005).  
Medicinal plants used to treat numerous are usually considered to be safe and not toxic. This 
belief is as a result of their long term use in treating diseases and the indigenous knowledge past 
down from previous generations. Nevertheless, studies have shown that a large number of 
medicinal plants, currently being used as traditional medicines, have the ability to be mutagenic 
and carcinogenic (Fennell, Lindsey et al. 2004). The ability of medicinal plants to be potentially 
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toxic is generally as a result of the lack of proper identification, preparation of herbal 
formulations and due to poorly trained people administering these herbal medicines (Nasri and 
Shirzad 2013). It is for this reason that toxicity studies should be conducted, on medicinal plants, 
as they provide important information on their safety which is vital for their potential use as 
therapeutic agents (Manaharana, Chakravarthib et al. 2014). 
1.5 Galenia africana 
1.5.1 Description 
Galenia africana (G. africana, commonly known as “kraalbos” or “geelbos”) (Van Wyk, De 
Wet et al. 2008) belongs to the Aizoaceae family and is a fragrant, woody sub-shrub, that can 
grow to heights of 0.5-1 meters. Its leaves are green, about 5 cm long, hairless and arranged in a 
distinct fashion. The immature leaves are green but as they mature, they tend to turn yellow (Van 
der Lugt, Schultz et al. 1992). The tip of the twigs is the site at which inflorescence develops 
with the presence of a number of small yellow flowers. The flowers are approximately 1.5 mm 
wide with their blooming season usually being October and December. These flowers are 
yellowish green and are born in large loose heads (Figure 1.1)  (Le Roux, Kotze et al. 1994). 
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Figure 1.1: Pictures showing a G. africana shrub and the plant during flowering (Picture credits: 
Prof JA Klaasen, University of the Western Cape). 
 
1.5.2 Distribution and ecology 
Initially, G. africana was predominantly found in the Namaqualand region. However, over the 
years it has been found to be common in the Western and Southern Karoo (Figure 1.2) 
(Kellerman, Coetzer et al. 1988). This plant is mainly found in areas around the kraals, road 
sides as well as trampled veld (De Kock 1928; Kellerman, Coetzer et al. 1988). Not only can the 
presence of G. africana indicate that an area has been disturbed, this plant is also the first to 
colonize areas that were once disturbed or damaged. Even when other plant species are scarce in 
the veld, due to overgrazing, G. africana is the only plant species that is able to grow and thrive. 
When animals have to migrate between regions due to the changes in winter and summer rainfall, 
they become hungry and tend to feed on any plants they come across along the way. Nonetheless, 
a number of these plants are normally not suitable for the animals. In addition, farmers at times 
keep their livestock within or around pens for extended times. This causes the animals to become 
very hungry and as a result, they end up grazing on poisonous plants (Van Aardt 2004).  
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Figure 1.2: Distribution of G. africana in South Africa (Mukind and Eagles 2010). 
 
1.5.3  Indigenous knowledge and medical uses  
A number of health benefits associated with G. africana have been described. It has been 
documented that the indigenous Khoi-San (Hottentots) tribe of South Africa chewed on the plant 
in order to alleviate toothaches (Watt and Breyer-Brandwijk 1962; Mativandlela, Muthivhi et al. 
2009). G. africana is also used in the treatment of venereal disease, skin diseases and relieving of 
eye inflammation. It has been shown that ointments prepared by frying G. africana with other 
medicinal plants in butter have been used to treat wounds, particularly on the legs of women 
(Watt and Breyer-Brandwijk 1962). The aerial parts of G. africana have also been used to treat 
asthma, coughs including tuberculosis. The extensive ability of G. africana to treat various 
ailments demonstrates that it possesses numerous health benefits (Watt and Breyer-Brandwijk 
1962; Mativandlela, Muthivhi et al. 2009; De Beer and Van Wyk 2011). 
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1.5.4 Toxicity in animals  
Based on information gathered from farmers, if the plant and leaves are green, it is edible, 
pleasant and not poisonous. However, in the summer when the leaves are yellow and the plant is 
dry and woody, it is poisonous and not edible (Le Roux, Kotze et al. 1994). Furthermore, they 
state that the yellow leaves contain elevated amounts of acidic material which destroys the 
stomach lining when ingested by animals which eventually leads to death (Kellerman, Coetzer et 
al. 1988). In cases of severe drought, animals tend to feed on this plant which leads to liver 
damage and a condition known as ‘waterpens’ or ‘water belly’. This condition is commonly seen 
in animals such as sheep and goats (De Kock 1928; Kellerman, Coetzer et al. 1988). Waterpens 
is associated with severe abdominal expansion, weight loss and death. In addition, animals also 
fail to stand and tend to lay flat on the ground as a result of this condition (Van der Lugt, Schultz 
et al. 1992). It has been reported that ingestion of the plant by animals caused hepatic lesions 
which were thought to be compatible with cyanotic indurations of the liver believed to be caused 
by congestive heart failure (Van der Lugt, Schultz et al. 1992). The appearance of the liver in 
diseased animals depends on the extent of the disease. The liver may appear smaller or larger 
than normal, it may have a grayish-blue to yellowish-brown color, the morphology can either be 
unchanged or have nodular hyperplasia and/or certain parts of the live may become atrophic or 
hypertrophic (Kellerman, Coetzer et al. 1988). Researchers believe that the liver lesions are 
caused by an unknown toxin which enables the plant to be hepatotoxic (Van der Lugt, Schultz et 
al. 1992). 
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1.5.5  Antimicrobial and cytotoxicity studies 
Studies have shown that whole plant extracts of G. africana display antifungal characteristics 
against Botrytis cinerea (Vries, El Bitar et al. 2005). This pathogen causes gray mould on 
numerous agricultural and horticultural crops of economic importance such as fruits and flowers 
which leads to loss of revenue. This antifungal activity of G. africana makes it a potential agent 
for use as a fungicide (Fielding, Knowles et al. 2015). Medicinal plants are used across the world 
for the treatment of various diseases as they possess numerous health beneficial compounds such 
as alkaloids, tannins, tepenoids and flavonoids (Cha, Lee et al. 2014). Furthermore, a study 
evaluating the antimycobacterial activity of South African medicinal plants revealed that G. 
africana displayed the greatest antimycobacterial activity against Mycobacterium smegmatis and 
Mycobacterium tuberculosis with MICs of 0.78 and 1.2 mg/ml, respectively. Fractionation of the 
G. africana ethanolic extract revealed the presence of a flavone called 5,7,2'-trihydroxyflavone. 
This fraction displayed MICs of 0.031 and 0.10 mg/ml against M. smegmatis and M. tuberculosis, 
respectively (Mativandlela, Meyer et al. 2008).  
In vitro cytotoxicity studies showed that G. africana had an IC50 value of 118.2 µg/ml when 
tested against vero cells (mammalian kidney cells) (Mativandlela, Muthivhi et al. 2009). In 
addition, analysis of whole blood cultures using lactate dehydrogenase leakage (LDH) revealed 
that G. africana was not toxic at a concentration of 625 µg/ml and had an IC50 value of 975 
µg/ml. Analysis of LDH leakage in human breast adenocarcinoma cell lines (MCF-7) showed an 
IC50 value of 1127 µg/ml (Shoko 2010). Evaluation of the environmental toxicity of G. africana 
was done using the Vibrio fischeri bioluminescent test which produced EC50 values of 1 and 0.7 
µg/ml at exposure periods of 15 and 30 min, respectively. Another test known as the Daphnia 
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pulex test was employed to assess acute toxicity of G. africana. Results showed EC50 values of 
40 and 30 µg/ml at exposure periods of 24 and 48 h, respectively (Pool, Klaasen et al. 2009).  
1.5.6 Chemistry 
Phytochemical analysis of an 80% (ethanol: water) G. africana extract conducted by Ticha and 
colleagues revealed that this extract was mostly composed of flavonoids. It was shown that the 
purified fractions of G. africana contained flavonoids that were structurally identical to chrysin, 
sakuranetin and pinocembrin (Ticha, Klaasen et al. 2015). Furthermore, analysis of a 20% (w/v) 
G. africana extract (80% ethanol: water) revealed that it consisted of approximately 61 
compounds. The majority of these compounds are currently found in the human diet. The 
chemical composition of G. africana as well as the CAS number (where applicable), the 
International Union of Pure and Applied Chemistry (IUPAC) name, relative concentration and 
the percentage match against the spectral database are outlined in Table 1.1. The Table also 
includes the seven groups into which the chemical compounds where assigned. These groups 
included aliphatic, aliphatic triterpenoid (at), carbonyl, fatty acid, flavonoid, tocopherol and other 
(Gledhill and Holmes 2011) 
Table 1.1: Chemical components of G. africana. 
# Cas No Name % Conc % Match Group 
1  544-76-3  hexadecane  0.65  98  aliphatic  
2  593-45-3  octadecane  0.67  96  aliphatic  
3  502-69-2  hexahydrofarnesyl acetone  2.79  97  at  
4  1117-52-8  farnesyl acetone  0.43  95  at  
5  628-97-7  ethyl hexadecanoate  1.09  99  fatty acid  
6  544-35-4  linoleic acid ethyl ester  0.34  99  fatty acid  
7  1191-41-9  ethyl linolenate  0.64  97  fatty acid  
8  124-04-9  hexanedioic acid ( adipic 
acid)  
6.04  95  fatty acid  
9  629-99-2  pentacosane  0.30  95  aliphatic 
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10  88-99-3  o- phthalic acid  0.96  91  other  
11  630-01-3  hexacosane  0.38  98  aliphatic 
12  646-31-1  tetracosane  0.32  98  aliphatic 
13  24634-95-5  ethyltetracosanate  0.20  93  fatty acid  
14  111-02-4  squalene  0.21  94  at  
15  630-03-5  nonacosane  0.35  99  aliphatic 
16  77-96-19-2  2-heptacosane  0.19  96  aliphatic 
17  638-68-6  triacontane  0.22  99  aliphatic 
18  593-49-7  heptacosane  2.02  98  aliphatic 
19  103-30-0  trans-stilbene  0.49  97  flavonoid  
20  120-51-4  benzylbenzoate  0.51  97  other  
21  10191-41-0  (+/-)-alpha-tocopherol  0.52  95  tocopherol  
22  alpha tocopherolquinone  0.39  93  tocopherol  
23  vitamin e acetate  0.58  93  tocopherol  
24  4602-84-0  farnesol  1.20  74  at  
25  122-57-6  4-phenylbut-3-en-2-one  0.08  97  carbonyl  
26  140-10-3  trans-cinnamic acid  0.96  98  flavonoid  
27  544-63-8  tetradecanoic acid (myristic 
acid)  
0.06  96  fatty acid  
28  1002-84-2  pentadecanoic acid  0.42  99  fatty acid  
29  502-69-2  6,10,14-trimethyl-2-
pentadecanone  
<LOQ  99  aliphatic  
30  57-10-3  hexadecanoic acid (palmitic 
acid)  
0.66  98  aliphatic  
31  1019-41-0  vitamin e  <LOQ  98  tocopherol  
32  6538-02-9  ergostanol  0.14  86  flavonoid  
33  92-48-8  6-methylcoumarin  0.13  96  flavonoid  
34  305-01-1  6,7-dihydroxy-2-chromenone  0.51  59  flavonoid  
35  126-33-0  sulfolane  3.36  91  other  
36  629-59-4  tetradecane  0.35  98  aliphatic  
37  7786-61-0  2-methoxy-4-vinyl phenol  0.32  90  carbonyl  
38  784-62-3  thioflavone  0.92  86  others  
39  1776-30-3  chalcone  0.97  20  flavonoid  
40  2,6,10,14 
tetramethylheptadecane 
(pristane)  
1.02  98  at 
41 100-52-7  benzaldehyde  0.08  97  carbonyl  
42 119-84-6  3,4 dihydrocoumarin  0.04  94  flavonoid  
43  1-(3-methylphenyl)-2-(2‘-
hydroxyphenoxy) ethanone  
0.05  83  carbonyl  
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44  1-(2‘,4‘-dihydroxyphenyl)-3-
phenylpropan-1-one  
2.92  97  carbonyl  
45  2s-5-hydroxyflavanone  0.82  83  flavonoid  
46 100-52-7  benzaldehyde  0.09  97  carbonyl  
47 65-85-0  benzoic acid  0.36  95  carbonyl  
48 119-84-6  3,4 dihydrocoumarin  0.53  96  flavonoid  
49  1-(2‘,4‘dihydroxyphenyl)-3-
phenylpropan-1-one  
0.51  97  carbonyl  
50 100-52-7 benzaldehyde  0.31  97  carbonyl  
51  benzoic acid  1.05  93  carbonyl  
52  3,4 dihydrocoumarin  0.57  94  flavonoid  
53  1-(2‘,4‘-dihydroxyphenyl)-3-
phenylpropan-1-one  
0.66  97  carbonyl  
54 1776-30-3  2‘, 4‘-dihydroxychalcone  14.00  -  flavonoid  
55 666-86-7  7-hydroxyflavone  10.20  -  flavonoid  
56 531-95-3  equol  3.87  -  flavonoid  
57 480-39-7  pinocembrin  23.10  -  flavonoid  
58 67604-48-2  narengenin  0.44  -  flavonoid  
59 480-44-4  acacetin  0.40  -  flavonoid  
60  chrysin or aesculetin  0.54  -  flavonoid  
61 520-28-5 tectochrysin  7.07  -  flavonoid  
At: Aliphatic triterpenoid; LOQ: Limit of quantification; Conc: Concentration 
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2 CHAPTER 2: Literature review 
2.1 Assessing the potential toxicity of medicinal plants  
2.1.1 Introduction  
Medicinal plants have been used for centuries around the world for the treatment of various 
diseases. According to the World Health Organization (WHO), approximately 80% of people in 
Africa and Asia rely on herbal medicines for the treatment of diseases. This can be seen in 
developed countries as well where 70-80% of people rely on complementary or alternative 
medicine (Araújoa, Barcellosb et al. 2017). With the increase in the use of complementary and 
alternative medicine, it has become imperative to assess the safety of medicinal plants 
(Neergheen-Bhujun 2013). Medicinal plants are normally used as crude extracts and thus contain 
a wide range of compounds. However, the biological activities of these compounds are normally 
unknown (Konan, Bacchi et al. 2006). In addition, substances such as digitoxines, cyanogenic 
glycosides and strychnine, which are considered to be very toxic, can be found in plants. Thus, 
plant species have to be assessed for safety before they can be confidently used for medicinal 
purposes (Araújoa, Barcellosb et al. 2017).  This has led to numerous studies being carried out 
on medicinal plants to assess their safety, efficacy as well as validate their traditional uses 
(Menegati, de Lima et al. 2016).  
The organization of Economic Co-operation and Development (OECD) is an economic 
organization comprising the governments of 34 countries. It was established in 1961 to enhance 
economic development and world trade (Thybaud, Lorge et al. 2017). In 1981, the chemical 
testing program was formed in order to help countries harmonize methods used in the assessment 
of chemical safety as well as good laboratory practice (GLP). However, the methods used to test 
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the toxicity of chemicals are physically demanding and expensive (Thybaud, Lorge et al. 2017). 
In addition, it was noted that numerous countries were conducting toxicological tests on similar 
types of chemicals. It was for this reason that the OECD council implemented the Mutual 
Acceptance of Data (MAD). The MAD stated that test data produced by member countries, that 
followed the OECD test guidelines (TGs) and principles of GLP, would be accepted across all 
member countries and used to safeguard human health and the environment as well as for 
regulatory purposes (Thybaud, Lorge et al. 2017). 
Nevertheless, the OECD TGs are not complete testing procedures but are instead intended to 
offer assurance of test results. However, the test results might differ depending on the test 
chemical or member country. Furthermore, each member country’s regulatory authority is 
responsible for outlining the tests required for the registration or demonstration of safety of test 
chemicals (Thybaud, Lorge et al. 2017). The OECD TGs incorporate both in vivo and in vitro 
assays. The frequently used TGs have undergone revisions, over the years, to allow for modern 
scientific knowledge, improved techniques as well as improved knowledge of the assay 
limitations. The aim of these revisions was to offer well-rounded testing methods, improve data 
interpretation and statistics and guarantee consistency among guidelines (Thybaud, Lorge et al. 
2017). In addition, animal welfare was also taken into consideration when revising the TGs for in 
vivo tests by reducing the number of animals used in studies without compromising the quality of 
the data produced. The revisions also incorporated the use of animals of a single sex as opposed 
to both sexes, reviewed the number of animals in each group and reduced the need for 
simultaneous positive controls. The revision of TGs is an on-going process that relies on current 
scientific knowledge and improved techniques (Thybaud, Lorge et al. 2017).  
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2.1.2 In vitro and in vivo toxicity studies 
2.1.2.1 Acute Oral Toxicity – Acute Toxic Class Method 
2.1.2.1.1 Animal selection 
The acute oral toxicity study is carried out using a set of guidelines outlined by OECD No. 423 
and is aimed at providing adequate information on the acute toxicity of a test substance using the 
smallest number of animals per group (OECD 2001). The animals in the experimental groups 
receive the test substance through oral administration at one of the pre-defined doses established 
by the Global Harmonized System (GHS) based on LD50 values (OECD 1998). These guidelines 
define the quantity of a given chemical or substance that an animal can consume that would kill 
50% of that animal or test model and this is referred to as the Lethal Dose (LD50).  
The animals used in this study are usually rats though other rodents can be used (OECD 2001). 
They are normally 3 per group and can be confined to one sex (usually females) (Roll, Höfer-
Bosse et al. 1986). Female rats are generally used because literature reviews of LD50 tests prove 
that females are more sensitive. Nonetheless, the variation in sensitivity between male and 
female rats is minimal (Lipnick, Cotruvo et al. 1995). The guidelines state that doses should not 
induce noticeable pain and distress to the animals and if such happens then they should be killed 
humanely (OECD 2000; OECD 2001). The strains of animals should be those generally used in 
the laboratory and they should be young adults in a healthy state. The females must be 
nulliparous and not pregnant. At dosing, the age of each animal must be between 8 and 12 weeks 
and their weights should be within acceptable limits (OECD 2001). 
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2.1.2.1.2  Management of animals and dose preparation 
The animal housing should be kept under the following standard conditions: temperatures of 
22°C (± 3°C); humidity of 50-60% (it can be a minimum of 30% but not more than 70%) and 
artificial lighting of 12 h of light and 12 h of dark (OECD 2001). The usual laboratory diets can 
be used and drinking water can be given to the animals without limitations. Animals can be 
placed in cages according to their respective doses. However, numbers should be kept small 
enough to ensure that the desired observations are easily seen (OECD 2001). The selection of 
animals is random and marks are placed on them for easy identification. They are placed in cages 
for a minimum of 5 days before commencement of dosing to enable the animals to adjust to the 
laboratory surroundings (OECD 2001). 
Doses should be administered in a constant volume and the maximum volume that can be 
administered is dependent on the size of the animal to be tested. Regulatory authorities state that 
neat or undiluted forms of liquid mixtures should be evaluated for potential risk. Dose 
formulations can be prepared using water or other solvents. However, if water is not used to 
prepare the dose formulations, then the vehicle should be analyzed to determine the toxicological 
properties. Dose formulations should be made up just before they are administered to the animals 
except in situations where preparations have shown to be stable over a period of time (OECD 
2001). 
2.1.2.1.3 Procedure, observations and data reporting 
The test substances are given as a single dose by gavage through a stomach tube or an 
appropriate intubation cannula. Before dosing, animals should not receive any food but can be 
given water (rats should not receive food overnight whereas mice should not receive food for 3-4 
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h). After fasting, the weight of the animals should be recorded followed by the administration of 
the test substance. Food can then be given after 3-4 h and 1-2 h for rats and mice, respectively 
(OECD 2001). Four fixed dose levels of 5, 50, 300 and 2000 mg/kg body weight have been 
outlined from which the initial dose to be used can be chosen. In cases where information 
pertaining to the test substance is not available, it is suggested that an initial dose of 300 mg/kg 
body weight should be used. Before animals can be treated with the next dose, it is imperative to 
ensure that the animals receiving the lower dose survive (OECD 2001). 
Animal observations are conducted on an individual basis at least once in the first 30 min 
following dosing and throughout the first 24 h. Daily observations are then made for a period of 
14 days except when the animals have to be humanely killed. However, observations depend on 
the toxic reactions of the animals to the test substance as well as the duration of time it takes for 
them to recover (OECD 2001). Some toxic reactions tend to appear late (delayed) and hence it is 
essential to note the time at which the signs first appear and when they fade away (Chan and 
Hayes 1994). Once the study is finished, the surviving animals are weighted and then humanely 
killed (OECD 2001). A gross necropsy is conducted on all tested animals including the ones that 
died during the study or those that were taken out of the study on animal welfare grounds. Every 
gross pathological variation observed in each animal must be documented (OECD 2001). 
Data on each animal used in the study should be made available. The summary of the data should 
be presented in a table format which should indicate the test group, number of animals used, 
number of animals exhibiting signs of toxicity, number of animals that died in the course of the 
test or those that were humanely killed, the time that each animal died and the necropsy findings 
(OECD 2001). Furthermore, a test report should be included that consists of information 
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pertaining to the test substance, vehicle, test  animals, test conditions and all results obtained 
after completion of the study (OECD 2001). 
2.1.2.2 Acute Dermal Toxicity 
The guidelines outlined by the OECD for testing chemicals are occasionally being reviewed due 
to advances in the science field as well as animal welfare concerns. Originally, the acute dermal 
toxicity guideline 402 was implemented in 1987. This method is a version of the acute toxic 
class method (OECD 2001) and uses the same number and sex of test animals. The system of 
ranking test substances or chemicals is the same as that used for other acute toxicity testing 
procedures (such as TG 420, 423 and 425) (OECD 2015a).  Before this study can be carried out, 
information on the possible human exposure of the test chemical and the anticipated use should 
be supplied. This information is necessary in validating the need to perform the acute toxicity 
study as well as in selecting a suitable starting dose (OECD 2015a). A widespread assessment of 
mixture products such as pesticides, biocides and other formulations revealed that in 99% of the 
cases, the dermal LD50 was ≥ 2000 mg/kg body weight (OECD 2015a).  
2.1.2.2.1  Animal selection 
The principle is similar to that of the acute oral toxicity study in that the test chemical is 
administered to animals of a single sex in a series of steps using suitable fixed doses (OECD 
2015a). The animals of choice in this study are adult rats. Analysis of acute oral (Lipnick, 
Cotruvo et al. 1995) and acute inhalation toxicity studies (Warbrick, Dearman et al. 2002; Price, 
Stallard et al. 2011) revealed that in most cases the difference between sexes is small, although 
females have shown to be somewhat more sensitive in instances where there are differences. 
Thus, this study also suggests the use of female rats. The rats should be in a healthy state, the 
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strain should be that normally used in laboratory settings, they should not be pregnant and 
nulliparous. The animals must be at least 8-10 weeks old with a weight of between 200-300 g. In 
addition, the skin of the animals should not be damaged (OECD 2015a).  
2.1.2.2.2  Management of animals and preparation 
The housing and feeding conditions of the acute dermal toxicity study are the same as those 
outlined for the acute oral toxicity. The animals are allowed to adjust to the laboratory conditions 
for no less than 5 days before commencement of the study. Animals are placed in study groups in 
a random fashion and marked for easy recognition. About 24 h prior to conducting the study, the 
fur from the animal’s dorsal region of the trunk is removed through clipping or shaving. This 
should be done carefully to prevent bruising of the animal’s skin which might change the 
permeability. About 10% of the dorsal region must be exposed for the application of the test 
chemical and the animal’s weight should be considered when choosing this region (OECD 
2015a). 
2.1.2.2.3 Procedure, observations and data reporting 
The experimental groups consist of 2-3 animals and the test chemical is applied to each animal 
systematically. The three fixed level doses from which the initial dose can be selected are 50, 
200 or 1000 mg/kg body weight which are derived from the GHS Categories for acute dermal 
toxicity. However, if information on the test chemical is lacking, it is advised that the starting 
dose should be 2000 mg/kg body weight on the grounds of animal welfare (OECD 2015a). The 
chemical must be evenly applied on test area (about 10% of the total body surface area). Porous 
gauze dressing and non-irritating tape must be used to ensure that the test chemical remains in 
contact with the skin for the entire 24 h test period. The gauze dressing must be properly secured 
http://etd.uwc.ac.za
 
 
 
 
  Chapter 2Literature review   
25 
 
to make sure that the animals do not remove it and subsequently consume the test chemical. It is 
advisable to keep the animals in separate cages so that they do not end up consuming the 
chemicals on other animals. Liquid test chemicals are normally used without being diluted. Once 
the testing period is over, the animals are taken back to group housing (OECD 2015a). 
Observations of the animals must be conducted for a minimum of 14 days. The criteria for 
conducting observations are similar to those of the acute oral toxicity. However, great care must 
be taken in the first 2-6 h after application of test chemical. The skin, fur, eyes and mucous 
membranes must be observed for any changes. The respiratory, circulatory, autonomic and 
central nervous systems in addition to the somatomotor activity and behavior patterns must also 
be monitored (OECD 2015a). Evaluation of the body weight and necropsy is done in the same 
way as that outlined in the acute oral toxicity. 
Data should be presented in a table form and reported in the same way as that outlined for acute 
oral toxicity. The test report should include the entire aspects outlined in the acute oral toxicity 
testing guideline relating to the test chemical, vehicle, test animals, test conditions and results 
(OECD 2015a). 
2.1.2.3 Skin Sensitization: Local Lymph Node Assay (LLNA) 
The first TG used to establish skin sensitization in mice (LLNA; TG 429) was approved in 2002 
(OECD 2002). The next TG was approved in 2010. The LLNA is an in vivo procedure that 
assesses the immunological processes occurring as a result of chemical stimulation in the initial 
stages of sensitization and can be used to evaluate dose responses (OECD 2010). The principle 
of this test is that chemicals that cause sensitization stimulate the production/proliferation of 
lymphocytes in the lymph nodes located in the area the test chemical is applied. Lymphocyte 
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production is relative to the amount (dose) and strength of the test substance and allows for the 
sensitization to be measured (OECD 2010). 
2.1.2.3.1  Animal selection, management and dose preparation 
The preferred animals for this assay are mice. This assay uses young adult female, nulliparous 
and non-pregnant CBA/Ca or CBA/J mice. During commencement of the study, mice ought to 
be 8-12 weeks old and their weight must not go beyond 20% of the mean weight. Nonetheless, 
additional strains and sex of mice can be used provided the reasons for doing so are justified 
(OECD 2010). The mice should be kept in groups except in situations where mice have to be 
housed separately. The temperature and humidity conditions are similar to those specified in the 
acute oral toxicity study (22 ± 3ºC and 50-60%, respectively). Artificial lighting of 12 h light/day 
cycles should be employed. Animals are fed using the usual laboratory diets and the supply of 
water should be unlimited (OECD 2010).  
The selection of animals is done in a random manner and marks are placed on them to make the 
identification process easier. Before dosing, the animals should be maintained in their cages for 
no less than 5 days for them to acclimatize to the laboratory environment. The skin of all the 
animals must be checked for the presence of any skin lesions before the test substance can be 
applied (OECD 2010). When solid test chemicals are used, dissolving or re-suspending them in 
solvents/vehicles should be done before they are applied to the ear of the mice. Test substances 
that are liquid in nature can either be diluted or applied neat. Fresh preparations of the test 
substance should be made for dosing (OECD 2010). 
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2.1.2.3.2  Procedure and observations 
Doses of test chemicals are chosen from a set of concentrations such as 0.5%, 1%, 2.5%, 5%, 
10%, 25%, 50% and 100%. The measurement of lymphocytes proliferation is done by evaluating 
the mean proliferation values of the test group and vehicle treated control (VC) group and 
comparing them to each other (OECD 2010). The proportion (ratio) of the mean proliferation 
values of the treated group and the VC group are used to calculate the stimulation index (SI), 
which must be ≥ 3 for the test substance to be classified as a skin sensitizer. Radioactive labeling 
is employed in determining the elevation in the number of cells produced in the lymph nodes 
(OECD 2010).  
Positive (several doses) and negative (vehicle of the test substance only) controls are included in 
the assay to assess the proficiency of the assay. This is done by evaluating the reproducibility of 
the results obtained after application of the test substance. However, the vehicle of choice should 
not affect the test results and should be chosen based on its ability to increase the solubility of the 
test substance and improve the concentration yield. The assay must be performed with at least 
four animals in each dose group and at least three concentrations of the test substance (OECD 
2010). A preliminary test can be carried out if information regarding maximum dose levels is 
lacking to determine the most suitable dose. 
Clinical observations should be done for each mouse. Care must be taken when monitoring the 
mice for systemic toxicity or local irritation and observations for each animal must be 
documented. Body weights of each animal must be determined and reported at the beginning of 
testing and at the time the animals are being killed (OECD 2010). 
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2.1.2.3.3 Data reporting 
The compiled data should be presented in a table format showing the proliferation 
(disintegrations per minute, DPM) values for each animal, group mean DPM values, SD or SEM 
values as well as the mean SI values for each dose group in comparison to the VC group (OECD 
2010). The following information should be included: characteristics of the test substance; 
formulation and composition of the test and control substances; justification for vehicle selection; 
information relating to test animals; dose selection criteria for vehicle and test substance; toxicity 
measurement methods and reasons for protocol deviation. The test report can also include any 
statistical analysis carried out (OECD 2010). 
2.1.2.4 In vitro skin irritation: reconstructed human epidermis test method 
The in vitro skin irritation test is used to evaluate the effect of chemicals on the human skin. 
Reconstructed human epidermis (RhE) models are used to assess this effect as its biochemical 
and physiological characteristics are similar to those of the human skin. Non-transformed 
keratinocytes (derived from human skin cells) are used as models for this test. In addition, it 
encompasses the early stages of the inflammatory response that result when cells and tissues are 
damaged due to trauma to specific areas (in vivo irritation responses). This test guideline was 
initially implemented in 2010 but updated in 2013 and 2015 to include extra methods (OECD 
2015b).  
The test chemicals can either be solids (soluble or insoluble in water), liquids (aqueous or non-
aqueous), semi-solids or waxes. However, solids should be ground to a fine powder prior to 
being applied. The use of gases and aerosols has not yet been evaluated in a validation study 
(Welss, Basketter et al. 2004). Test chemicals with the ability to absorb light in the same range 
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as MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and/or capable of 
reducing MTT may impede the cell viability measurements. When these chemicals are assessed, 
the experiments need to employ controls that will be used to correct these factors. In cases where 
classifying a test chemical is clear, one test run consisting of three replicate tissues is adequate 
(OECD 2015b).  
2.1.2.4.1 Principle and procedure of test 
The test chemical is applied to the surface of a three-dimensional RhE model. This model 
consists of human-derived keratinocytes that have undergone differentiation to create a 
multilayer consisting of the basal, spinosum and granular layers as well as a multilayered stratum 
corneum with lipid classes similar to those found in vivo. Chemicals that cause skin irritation 
tend to penetrate the skin and injure the layers underneath such as the keratinocytes and other 
skin cells thus causing an inflammatory response. Inflammatory mediators released during this 
inflammatory response can also exert their action on cells and other structures found in the 
dermis (OECD 2015b). Thus, RhE-based test methods are used to evaluate the initial events that 
occur during skin irritation such as cell/tissue damage through cell viability (Hoffmann 2006; 
Spielmann, Hoffmann et al. 2007).  
Cell viability is assessed or measured by the ability of viable cells, through the use of enzymes, 
to covert the MTT into a blue/purple formazan salt/precipitate (Mosmann 1983). During the 
MTT assay, the tissue sample is placed into a suitable MTT solution (concentration of 0.3 to 1 
mg/ml) for a period of 3 h. Isopropanol (or other solvents with the same characteristics) is then 
used to remove the precipitate from the tissue. The precipitated MTT formazan can be measured 
by standard absorbance measurements (optical density, OD) or an HPLC/UPLC-
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spectrophotometry procedure (OECD 2015b). Negative and positive controls should be included 
and the results generated by these controls must be reproducible (OECD 2015b).  
Each test run must include a minimum of three replicates for every chemical tested as well as 
each control. With regard to both liquid and solid test chemicals, adequate amounts of the test 
chemical must evenly be applied in order to cover the epidermis surface (range of 26-83 µl/cm
2
 
or mg/cm
2
). Nevertheless, solid chemicals require that the epidermis surface be dampened with 
either de-ionized or distilled water prior to the chemical being applied (OECD 2015b). This 
enhances chemical and epidermal surface contact. Once testing is completed, the test chemical 
must be washed off with care using aqueous buffer or 0.9% sodium chloride (NaCl). The 
duration of chemical exposure and incubation temperatures differ depending on the RhE test 
method employed with exposure times ranging between 15 and 60 min and temperatures of 
between 20 and 37°C. Optimization of these parameters can be done based on the fundamental 
properties of the test methods (OECD 2015b). 
The classification of a chemical as being an irritant is done by assessing the potential of the 
chemical to reduce cell viability below the outlined threshold levels (i.e. ≤ 50%, for UN GHS 
Category 2). However, chemicals can also generate cell viabilities that are over the stated 
threshold levels, in this case, they can be regarded as non-irritants (i.e. ˃ 50%, No Category) 
(OECD 2015b). The RhE models must not contain any bacteria, viruses, mycoplasma or fungi 
and should be able to represent in vivo conditions (OECD 2015b).  
2.1.2.4.2  Data reporting 
The following information should be included: OD values; tissue/cell viabilities of the test 
chemical; experiments that were repeated (if any) and mean ± SD for every run. Any 
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observations made must be documented (OECD 2015b). Information on the test chemical and 
control substances must also be included. The information should pertain to physical and 
chemical properties such as chemical identification, purity and physical appearance. The storage 
conditions and type of RhE models should also be indicated (OECD 2015b). 
2.2 Drug resistance in Staphylococcus aureus and use of medicinal plants 
2.2.1 Introduction 
Staphylococcus aureus (S. aureus) is a Gram-positive coccus that belongs to the 
Staphylococcaceae family. It is a normal flora of the skin and mucosa but has the ability to 
colonize other parts of the body through cuts and abrasions causing various illnesses as a result 
of its virulence factors (Stefani, Chung et al. 2012). The various diseases associated with S. 
aureus infections range from mild skin infections to more severe and life-threatening conditions, 
such as osteomyelitis, endocarditis, and sepsis (Azeez-Akande 2010). With the growing trend of 
multi-resistant strains, antimicrobial therapy against S. aureus infections has become an 
increasing challenge (Reiß, Pané-Farré et al. 2012). The ability of bacteria to develop resistance 
to a wide range of antibiotics has led to various studies being carried out to evaluate alternative 
sources of antimicrobial agents (Fischbach and Walsh 2009). These alternative sources include 
natural plant products, which are generating a tremendous amount of interest due to their 
potential to cure a number of diseases and conditions. Numerous studies have been carried out 
that outline these various abilities (Payne, Gwynn et al. 2007; Amenu 2014; Farooqui, Khan et al. 
2015; Haroun and Al-Kayali 2016).  
Drug resistant bacteria contribute to the deaths of millions of people worldwide. Methicillin-
resistant Staphylococcus aureus (MRSA) is one such bacterium that is of major concern. MRSA 
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is the pathogen usually associated with both hospital-acquired (HA-MRSA) and community-
acquired (CA-MRSA) infections (Deleo, Otto et al. 2010). It has been established that MRSA is 
resistant to approximately 23 antibiotics and is one of the leading causes of death in the elderly 
and immunocompromised patients (Dubey, Rath et al. 2012). It causes a wide variety of 
infections which include extensive deep tissue (arthritis, osteomyelitis and renal and breast 
abscesses) and skin and soft tissue (carbuncles and furuncles) infections (Daniyan, Galadima et 
al. 2011).  
Three main mechanisms are responsible for antimicrobial resistance and these are; enzymatic 
inactivation of the drug (Davies 1994) target site modification (Spratt 1994) and drug extrusion 
by efflux which is facilitated by efflux pump genes that code for efflux pump proteins. These 
proteins are responsible for the extrusion of antibiotics, thereby allowing the pathogens to evade  
the effect of the antimicrobial agents (Lomovskaya and Bostian 2006).  
2.2.2 Global prevalence and incidence rates of MRSA  
MRSA strains were initially identified in the United Kingdom (UK) in 1961. This was after they 
developed resistance to methicillin following its introduction (Jevons, 1961). Since then, MRSA 
epidemics and endemics have been reported worldwide (Ayliffe 1997; Chambers 2001; Fridkin, 
Hageman et al. 2003). This eventually led to the assumption that S. aureus epidemiology was 
changing (Boyce 1998; Herold, Immergluck et al. 1998). MRSA infections are causing problems 
for hospitals and healthcare facilities as well as numerous communities worldwide (Bratu, Eramo 
et al. 2005; Kuehnert, Hill et al. 2005; Mulvey, MacDougall et al. 2005). Reports from different 
countries around the world indicated that there was an increase in the prevalence of MRSA 
infections and population risk. Data obtained from North America as well as the Centers for 
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Disease Control and Prevention (CDC), in the United States of America (USA), showed that the 
incidence of MRSA has increased over the years (Hughes 1987; Garner, Jarvis et al. 1988; 
Horan, Culver et al. 1988; Mulvey, MacDougall et al. 2005; Azeez-Akande 2010). Additional 
studies carried out at different hospitals in USA revealed that the prevalence of MRSA rose from 
6% in 1998 to 50% in 2002 (Azeez-Akande 2010). 
Data published from other countries has also shown an increase in the prevalence of MRSA 
infections. In hospital wards in France, for instance, a study carried out revealed that the 
prevalence of MRSA was 33% - 62% (in relation to S. aureus isolates) (Mangeney, Bakkouch et 
al. 1995). Studies carried out in Taiwan indicated a rise in MRSA prevalence from 1981-1986 
(Hsueh, Chen et al. 2002; Hsueh, Liu et al. 2002). Other studies carried out in Japan (Lotus, 
Imamura et al. 1995) and the Republic of Korea (Woojoo and Seunchill 1999) have 
demonstrated MRSA prevalence of 54% and 70%, respectively. However, reports on MRSA 
prevalence in Africa have been very few. Nonetheless, in Sudan, a study conducted at a 
Khartoum hospital revealed a prevalence of 11% (Musa, Shears et al. 1999). Studies carried out 
between 1996 and 1997 in Nigeria, Cameroon, Kenya and Algeria showed MRSA prevalence 
rates of 21 -30% (Nigerian, Cameroon and Kenya) while Algeria had a lower rate of less than 
10% (Kesah, Ben Redjeb et al. 2003).  
Other studies have also reported increased MRSA incidence in Ghana (Odonkor, Newman et al. 
2012), Ethiopia (Geyid and Lemeneh 1991), Kenya (Omari, Malonza et al. 1997), Nigeria 
(Rotimi, Orebamjo et al. 1987; Okesola, Oni et al. 1999), Senegal (Sow, Wade et al. 1998), 
South Africa and Sudan (van den Ende and Rotter 1986; Peddie, Donald et al. 1988; Gardee and 
Kirby 1993; Musa, Shears et al. 1999).  
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2.2.3 Treatment of S. aureus infections 
Penicillin was usually the drug of choice in the treatment of S. aureus infection following its 
discovery. Unfortunately, resistance to penicillin was reported in many countries following its 
introduction as early as 1942. In 1944, Kirby reported penicillinase-producing strains (Kirby 
1944). Oxacillin or flucloxacillin have been used in first-line therapy and are penicillinase-
resistant beta-lactam antibiotics. These drugs were given in combination with gentamicin to treat 
serious infections such as endocarditis (Korzeniowski and Sande 1982; Bayer, Bolger et al. 
1998) . However, the use of gentamicin posed some controversy as its use lead to kidney damage 
(Cosgrove, Vigliani et al. 2009). Antimicrobial susceptibility testing, severity and site of 
infection normally determine the duration and type of treatment administered (Bamberger and 
Boyd 2005). Drugs such as intravenous nafcillin, oxacillin (Bactocill) and oral dicloxacillin 
(Dynapen) have been administered to patients that are not allergic to penicillin (Bamberger and 
Boyd 2005). Cephalosporins such as cephalexin (Keflex) and intravenous cefazolin (Ancef) have 
also been given as substitutes.  
Vancomycin is considered to be the best treatment option in MRSA infections. However, it has 
been shown that the use of vancomycin has a down side. This is because its absorption in the 
gastrointestinal tract is rather poor, it has slow bactericidal activity and also has numerous side 
effects (Levine, Fromm et al. 1991; Gould 2008; Rasmussen, Fowler et al. 2011). Vancomycin is 
administered intravenously due to the low absorption experienced when administered orally. 
Nonetheless, treatment failure has been reported and some studies have actually shown that 
treatment with β-lactams was more beneficial compared to treatment with vancomycin (Chang, 
Peacock et al. 2003; Stryjewski, Szczech et al. 2007).  
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Resistance mechanism of S. aureus Teicoplanin, a glycopeptide, is another drug that has been 
used to treat S. aureus infections and is administered intravenously or intramuscularly. A number 
of studies have revealed that its effectiveness is similar to that of vancomycin (Rolston, Nguyen 
et al. 1994; Yalaz, Cetin et al. 2004). Other drugs such as tigecycline, linezolid (Zyvox), 
daptomycin (Cubicin) and telavancin have also been used in treating S. aureus infections. 
Tigecycline is used in the treatment of complex skin infections and has bacteriostatic properties 
(Rasmussen, Fowler et al. 2011). Linezolid is administered orally or intravenously and has been 
used to treat pneumonia and skin and soft tissue infections caused by S. aureus strains (Lin, 
Zhang et al. 2008; Tascini, Gemignani et al. 2009). In addition, it has demonstrated to have 
bacteriostactic activities (Bamberger and Boyd 2005). Daptomycin has shown bactericidal 
properties in “in vitro” studies and is used to treat complicated skin and soft tissue infections 
(Arbeit, Maki et al. 2004) and is administered intravenously (Bamberger and Boyd 2005). The 
FDA approved the use of telavancin for the treatment of infections of the skin and skin-structures 
(Rasmussen, Fowler et al. 2011). 
2.2.4 Resistance mechanism of S. aureus 
Antimicrobial agents have been used to treat various bacterial infections since their discovery, 
and it was believed that they would contribute to the purge of these infections. Nevertheless, 
diseases considered to have been eradicated or controlled in the past are recurring as a result of 
drug resistance (Levy and Marshall 2004). The emergence of multi-drug resistant bacteria is 
affecting the effectiveness of existing drugs and thus inhibiting the proper and efficient treatment 
of these infections worldwide. This in turn increases both medical and socio-economic expenses 
(Maranan, Moreira et al. 1997; Carbon 1999; Bratu, Eramo et al. 2005). Resistance to new 
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antimicrobial agents is rapid and widespread, indicating that this would be the trend even with 
the new families of antimicrobial agents, thereby limiting their shelf life and effectiveness 
(Coates, Hu et al. 2002). 
Antimicrobial resistance results from three main strategies which include enzymatic inactivation 
of the drug (Davies 1994), target site modification (Spratt 1994), and drug extrusion by efflux 
(Lomovskaya and Bostian 2006). During target site modification, chemical modifications of the 
antibiotic target site decrease the affinity of the antibiotic to its binding site (Lambert 2005). In 
enzymatic inactivation, hydrolytic and transferase enzymes render the antibiotic inactive by 
degrading the antibiotic, as well as modifying it through acetylation, adenylation or 
phosphorylation (Over, Gur et al. 2001). Efflux pump proteins, coded for by efflux pump genes, 
are responsible for the extrusion of antibiotics, thus allowing the pathogens to evade 
antimicrobial effects (Lomovskaya and Bostian 2006).  
2.2.4.1  Methicillin resistance 
Methicillin was introduced in 1961 but methicillin-resistance by some isolates followed shortly 
after its introduction (Jevons 1961). This resulted in limited action and reduced effectiveness of 
therapeutic agents against infections caused by methicillin-resistant isolates (Cosgrove, Sakoulas 
et al. 2003). The mecA gene is responsible for conferring methicillin resistance (Katayama, Ito et 
al. 2000). Methicillin-sensitive Staphylococcus aureus (MSSA) can become methicillin-resistant 
by acquiring the mecA gene, which is the methicillin-resistance determinant (Hiramatsu, Cui et 
al. 2001). The mortality rate from severe MRSA infection was found to be as high as 10-34% 
(Tumbarello, de Gaetano Donati et al. 2002). 
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2.2.4.2 β-lactam resistance 
β-lactams include broad-spectrum penicillins, cephalosporins, monobactams and carbapenems. 
The mechanism of antimicrobial resistance by a large number of bacteria is through the 
degradation of the antibiotics by means of chromosomal-or-plasmid encoded β-lactamases (Bush, 
Calmon et al. 1995). Resistance to carbapenems is achieved by mutations of genes that code for 
porin OprD proteins which are the main route of antibiotic uptake (Trias and Nikaido 1990). 
Resistance to beta- lactam antibiotics is believed to occur in two ways; (i) by the production of 
an enzyme beta- lactamase, which subsequently causes inactivation of the beta- lactam 
antibiotics and (ii) by the expression of transpeptidases, which are resistant to antibiotic activity. 
The mecA gene, which codes for the penicillin-binding protein PBP2a, is responsible for the 
antibiotic resistance exhibited by S. aureus (Archer and Climo 2001; Finan, Archer et al. 2001; 
McKinney, Sharma et al. 2001).  
Penicillin was introduced in the early 1940s. Nevertheless, penicillin-resistant staphylococcal 
strains were detected in both hospitals and communities shortly after its introduction 
(Rammelkamp and Maxon 1942). As the late 1960s approached, over 80% of both hospital-
acquired and community-acquired staphylococcal isolates were penicillin-resistant. This trend of 
resistance, initially appearing in hospitals and then extending to the community, is a pattern now 
evident with new antimicrobial agents (Chambers 2001) 
2.2.4.3  Tetracycline resistance 
Tetracycline has been widely used in the treatment of both Gram-negative and Gram-positive 
bacterial infections, as well as mycoplasma, rickettsiae, and protozoan parasites (Chopra, Lacey 
et al. 1974; Chopra 1975; Markham and Neyfakh 2001). Apart from its therapeutic use in 
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humans and animals, tetracycline has been erratically used in animal husbandry for growth 
promotion, leading to extensive tetracycline resistance in both Gram-negative and Gram-positive 
bacteria (including S. aureus). Tetracycline resistance is achieved by two main mechanisms 
which are active efflux by tetracycline-specific pumps/transporters called Tet-pumps (Markham 
and Neyfakh 2001), and ribosomal protection (Schnappinger and Hillen 1996). Tet-pumps are 
generally spread among Gram-negative and Gram-positive bacteria (Roberts 1994). 
2.2.4.4 Aminoglycoside resistance  
The mode of action of aminoglycosides is the inhibition of protein synthesis by binding to the 
bacterial ribosomes, thereby resulting in their death. This action is mediated by protonated amine 
and/or hydroxyl interactions with the ribosomal RNA of the bacterial 30S ribosomal subunit 
(Lomovskaya and Watkins 2001). Nonetheless, the need to identify other compounds that are 
capable of resisting modification by aminoglycoside modifying enzymes is essential in order to 
improve the action of these therapeutic agents (Miller, Sabatelli et al. 1997). Aminoglycoside 
resistance is believed to be as a result of two main mechanisms which are: specific enzymatic 
inactivation and by modifying enzyme resistance impermeability. These are considered to be the 
most common mechanisms by which resistance occurs (Lomovskaya and Watkins 2001).  
Ribosomal mutations and active efflux of the drug out of the bacteria also contribute to 
aminoglycoside resistance (Macmaster, Zelinskaya et al. 2010). These enzymes exert their 
function by covalently attaching either a phosphate, nucleotide or acetyl moiety to either the 
amine and/or the alcohol key functional group of the antibiotic. This causes a reduction in the 
ribosomal binding affinity due to the change in charge. ANT (4’) IA aminoglycoside 
adenylytransferase 4’ IA is one of the aminoglycoside modifying enzymes found in S. aureus 
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(Porter, Green et al. 2010; Revuelta, Corzana et al. 2010). It attaches an adenyl moiety to 
4’hydroxyl group of a number of aminoglycosides such as kamamycin and gentamicin.  
In staphylococcal species, it has been found that these bacteria tend to possess numerous 
aminoglycoside modifying enzymes that lead to multiple genotypes and complex phenotypes 
(Miller, Sabatelli et al. 1997). Aminoglycosides were some of the very few antimicrobial agents 
that were not affected by the active extrusion brought about by multidrug resistance pumps 
(MDR). Unfortunately, that is currently not the case (Moore, DeShazer et al. 1999). 
2.2.4.5  Quinolone resistance 
When first introduced in the 1980s, the intended use of fluoroquinolones was to treat Gram-
negative bacterial infections. However, because of their ability to treat Gram-positive bacterial 
infections, they were also employed in the treatment of infections brought about by 
staphylococcal species (Gootz and Brighty 1996). Unfortunately, quinolone-resistance rapidly 
emerged especially among methicillin-resistant strains, thus decreasing their use in treatment of 
staphylococcal infections (Hopper 2002).  
Fluoroquinolones exert their antimicrobial effect by inhibiting the activity of type II 
topoisomerases, DNA gyrase (encoded by the gyrA and gyrB genes) and DNA topoisomerase IV 
[encoded by the parC (grlA in S. aureus) and parE (grlB in S. aureus) genes] (Yoon, Lee et al. 
2010). DNA gyrase is responsible for the introduction of negative superhelical twists into 
bacterial DNA, which is essential for the instigation of DNA replication, as well as aid the 
binding of initiation proteins (Hopper 2002). Topoisomerase IV is essential in ensuring the 
separation of daughter cells after DNA replication by removing the interlinking chromosomes 
(Hopper 2002). 
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Resistance to fluoroquinolones is achieved by chromosomal mutations of topoisomerase IV or 
DNA gyrase as well as the action of a multidrug efflux pump (Ng, Trucksis et al. 1996; Hopper 
2002). Alterations in amino acid sequences in vital regions of the enzyme-DNA complex 
(quinolone resistance determining region [QRDR]) consequently result in the reduction of 
quinolone affinity for both targets thus conferring resistance (Ng, Trucksis et al. 1996; Hopper 
2002). Both single and multiple mutations in amino acid sequence play a role fluoroquinolone 
resistance. Nonetheless, complex amino acid mutations are essential for fluoroquinolone-
resistance to occur (Ng, Trucksis et al. 1996; Hopper 2002). 
2.2.4.6  Vancomycin resistance 
Following the increase in MRSA infections, the use of vancomycin to treat these infections 
subsequently increased, thereby influencing the emergence of vancomycin-resistant 
staphylococci (Kirst, Thompson et al. 1998). The first report of vancomycin-resistant 
staphylococci was from a clinical isolate of a Staphylococcus hemolyticus strain (Schwalbe, 
Stapleton et al. 1987) and this was later followed by reports of vancomycin-intermediate-
resistant S. aureus (VISA), in 1997 in Japan (Hiramatsu, Aritaka et al. 1997a). More cases of 
VISA were then reported in other countries (Hiramatsu, Hanaki et al. 1997b; Smith, Pearson et 
al. 1999). Reports of vancomycin-resistant S. aureus infections raised a tremendous amount of 
concern as this demonstrated complete bacterial resistance to vancomycin as well as an unusual 
mode of distribution (Hageman, Pegues et al. 2001; Ward, Johnson et al. 2001). It has been 
established that VISA result from S. aureus parent strains that are susceptible to vancomycin due 
to persistent infection (Sieradzki, Roberts et al. 1999; Smith, Pearson et al. 1999; Moore, 
Perdreau-Remington et al. 2003). Intermediate resistance to vancomycin is thought to occur 
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through sequential point mutations of major staphylococcal regulatory genes (Mwangi, Wu et al. 
2007; Cui, Neoh et al. 2009; Cui, Li et al. 2009). 
Resistance to glycopeptides is mediated via the acquisition of the vanA gene. This gene codes for 
an enzyme that produces an alternative peptidoglycan to which vancomycin will not bind 
(Showsh, De Boever et al. 2001). It has been suggested that alterations in peptidoglycan 
biosynthesis appears to play a role in lowering vancomycin susceptibility (Hiramatsu, Hanaki et 
al. 1997). A change in peptidoglycan biosynthesis also leads to the reduction of cross-linkages 
formed between peptidoglycan strands, consequently leading to more D-Ala-D-Ala residues 
being revealed (Hanaki, Kuwahara-Arai et al. 1998; Hanaki, Labischinski et al. 1998a; Hanaki, 
Labischinski et al. 1998b). The distorted cross-linking is as a result of a reduction in the levels of 
L-glutamine available for amidation of D-glutamate in the pentapeptide bridge (Walsh and Howe 
2002). The increase in the amount of D-Ala-D-Ala residues results in the binding and trapping of 
vancomycin which further prevents drug molecules from reaching their target sites, thus 
rendering the bacteria vancomycin-resistant (Sieradzki, Roberts et al. 1999; Avison, Bennett et 
al. 2002). 
2.2.5 The effect of medicinal plants on S. aureus  
The use of medicinal plants in the treatment of various diseases has been documented and 
several studies have been conducted and are still being conducted on the effect of medicinal 
plants on microbes. Results from a study conducted to evaluate the antimicrobial potential of 
four selected plants namely Aloe secundiflora, Bulbine frutescens, Tagetes minuta and Vernonia 
lasiopus against S. aureus revealed that they all exhibited antimicrobial activity against S. aureus. 
These results further indicated that these plant extracts could be effective against other Gram 
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positive pathogens (Rachuonyo, Ogola et al. 2016). Another study carried out to assess the effect 
of methanolic extracts of 12 medicinal plants traditionally used for medicinal purposes in 
Cameroon against 11 S. aureus clinical isolates demonstrated that 4 out of the 12 plant extracts 
exhibited the greatest antimicrobial activity against the S. aureus isolates. These medicinal plants 
were Dacryodes edulis (showed considerable antimicrobial activity against all the isolates), 
Occimum gratissimum (showed considerable activity against 9 out of 11 isolates), Commelina 
erecta and Spilanthes filicaulis (both showed considerable activity against 6 out of 11 isolates) 
(Sama Fonkeng, Mouokeu et al. 2015). Further evaluation of another set of plant species against 
S. aureus revealed that they possessed antimicrobial activity against this bacterium. The 
medicinal plants that showed the greatest antimicrobial activity were Salvia officinalis, 
Eucalyptus globulus, Coleus forskohlii, Coptis chinensis, Turnera diffusa, and Larrea tridentata 
which had MIC values between 60 to 300 µg/ml. The results also showed that these extracts 
reduced bacterial replication by 10
6
 fold (Snowden, Harrington et al. 2014). 
2.3 Drug resistance in Candida species and use of medicinal plants 
2.3.1 Introduction 
A large number of fungal infections worldwide are caused by yeasts known as Candida 
(Manolakaki, Velmahos et al. 2010). Candida species are usually found as normal flora in 
humans particularly in areas such as the skin, digestive tract and as well as on the genitals. They 
become pathogenic once they enter the bloodstream when the mucosal membrane is injured or 
when the immune system is weakened (Kourkoumpetis, Velmahos et al. 2011). Most of these 
infections are caused by Candida albicans species which cause candidiasis.  It has been observed 
that administrating broad spectrum antibiotics contributes to increased yeast infections, enhances 
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the growth of Candida species in the gastrointestinal tract and enables them to penetrate the 
gastrointestinal mucosa (Kennedy, Volz et al. 1987). In addition to the use of broad spectrum 
antibiotics, using medical devices such as intravenous catheters, undergoing invasive procedures, 
administering cytotoxic chemotherapeutic agents and receiving organ transplants give rise to 
increased Candida infections (Ortega, Marco et al. 2011). The ability of Candida species to 
cause invasive infections is due to specific virulence factors which include evading the host 
immune system and ability to form biofilms on medical devices and on tissue surfaces. Candida 
species also produce hydrolytic enzymes that damage the host tissues and play a role in disease 
causation. Examples of these enzymes include haemolysin, proteases and phospholipases (Silva, 
Negri et al. 2011). 
Candida species form huge, round, white or cream colored colonies when grown on agar 
medium at room temperature. As they grown, they produce a yeast smell. C. albicans has the 
ability to break down glucose and maltose into acids and gases but cannot break down lactose. 
This enables it to be differentiated from other Candida species. The rapid growth of Candida 
species, such as C. albicans, can result in infections like oropharyngeal candidiasis (thrush) as 
well as vulvovaginal candidiasis (vaginal candidiasis). Oral thrush is normally seen in old people 
that wear dentures (Darwazeh, Lamey et al. 1990). In patients with a weakened immune system, 
systemic diseases like abscesses, thrombophlebitis (swelling of the vein walls resulting from 
blood clots) and endocarditis (inflammation of the inner lining of the heart chambers) and 
osteomyelitis may develop (Pappas 2006). Candida species can also cause infections such as nail 
fungus, athlete’s foot, vaginal yeast infections, jock itch (an infection of the groin) and diaper 
rash. Vaginal yeast infections are frequently associated with both healthy individuals and those 
with a weakened immune system whereas oral Candida infections are mostly common in 
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individuals with a weakened immune system. Common symptoms of vulvovaginal candidiasis 
include vaginal itching, white vaginal discharge, pain during sex or when urinating and redness 
and swelling of the vulva (Fidel 2002). C. albicans is usually present in the mouth of adults and 
children. However, infection can result in infants, the elderly and immunocompromised 
individuals. Oral Candida infections cause a burden on the healthcare sector as they are seen in 
both HIV-infected and AIDS patients. It is believed that 90% of people living with AIDS will 
develop oral thrush. Oral thrush present as white sores in the mouth, tongue, cheeks and gums. It 
is also associated with pain when a person attempts to swallow (Saunus, Kazoullis et al. 2008). 
Candida infections are also commonly associated with patients suffering from cancer, renal 
failure, neutropenia and diabetes mellitus. Infection with Candida species can also occur as a 
result of abdominal surgery (Pfaller and Diekema 2007). 
2.3.2 Epidemiology of Candida species 
It has been established that there are over 150 Candida species and approximately 15 are known 
to cause infections in humans. These disease causing Candida species include Candida albicans, 
Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida krusei, Candida 
guilliermondii, Candida lusitaniae, Candida dubliniensis, Candida pelliculosa, Candida kefyr, 
Candida lipolytica, Candida famata, Candida inconspicua, Candida rugosa, and Candida 
norvegensis. However, the frequently isolated pathogens are C. albicans, C. glabrata, C. 
parapsilosis, C. tropicalis, and C. krusei. These have been found in 95% of patients with known 
Candida infections (Diekema, Arbefeville et al. 2012). A large number of bloodstream Candida 
infections are caused by C. albicans which is predominately present in the upper and lower 
respiratory tracts, gastrointestinal tract, genitourinary system and on the skin (Pfaller and 
Diekema 2007). C. albicans infections are associated with increased medical costs, prolonged 
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hospital stay and high death rates which are major health problems (Lai, Wang et al. 2012). 
However, it has been observed that infections arising from other Candida species are on the rise. 
These infections are based on the age of patients, period and state of hospital environment as 
well as other diseases the patient may have (Yapar 2014). These non-albicans species include C. 
glabrata, C. parapsilosis, C. tropicalis and C. krusei. A study conducted in major medical 
facilities in North America revealed that despite C. albicans being the main isolate obtained from 
patients, C. glabrata was the second most commonly isolated non-albicans species. The high 
incidence rates may be attributed to the increased use of broad spectrum antibiotics, weakened 
immune systems and an increase in age (Horn, Neofytos et al. 2009). As such, C. glabrata 
infections are frequent in elderly patients and patients with neoplasm. C. parapsilosis is 
associated with candidemia in newborn babies and adults where it accounts for 30% and 10-15% 
of cases, respectively. Since it is present on the skin, it causes infections in patients using 
catheters which may result in outbreaks. C. tropicalis infections are common in patients with 
leukemia and neutropenia. C. krusei infections are seen in patients receiving hematopoietic stem 
cells as well as leukemia patients with low neutrophil levels (Pappas 2006; Pfaller and Diekema 
2007).  
A study conducted on isolates obtained from South African patients revealed that the percentage 
of Candida species isolated were 81% C. albicans, 10% C. glabrata, 4% C. parapsilosis, 3% C. 
krusei and 1% C. tropicalis (Pfaller and Diekema 2004). Another study carried out in 
Bloemfontein, South Africa demonstrated that the percentage of the isolated Candida species 
were 42% C. albicans, 26% C. tropicalis, 20% C. parapsilosis and 7% C. glabrata (Badenhorst, 
Botha et al. 1991). The two studies collected isolated from both children and adults. Results from 
a third hospital-based study conducted in Soweto, South Africa (between distinct time points) in 
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1990-2007 revealed that in 1990, the percent distribution of Candida species was 62% C. 
albicans and 23% C. tropicalis. Minimal differences in percentage distribution were observed 
between 1998 and 2002. The percent distribution between 2005 and 2007 was 46% C. albicans, 
25% C. parapsilosis and 23% C. glabrata. The incidence rates of these species were attributed to 
a number of factors such as abdominal surgery which accounted for 43% of infections, HIV 
(19%), trauma (16%), diabetes mellitus (12%) and cancer (8%) (Kreusch and Karstaedt 2013). In 
Europe, the Candida species that cause candidemia are C. albicans which accounts for over 50% 
of infections, C. glabrata and C. parapsilosis (14% each), C. tropicalis (7%) and C. krusei (2%) 
(Tortorano, Kibbler et al. 2006). In Chile, the incidence of non-albicans species is on the rise. 
The frequently isolated species was C. parapsilosis with C. tropicalis and C. glabrata being the 
second most isolated species. These species were responsive to amphotericin B treatment 
whereas 50% of C. glabrata species did not respond to fluconazole treatment (Ajenjo, Aquevedo 
et al. 2011). In Brazil, C. albicans caused 40.9% of infections with C. tropicalis causing 20.9%, 
C. parapsilosis causing 20.5% and C. glabrata causing 4.9% of infections (Nucci, Queiroz-
Telles et al. 2010). A study conducted in USA, particularly Atlanta and Baltimore, between 2008 
and 2011 showed that Candida infections occurred in 13.3 per 100 000 people in Atlanta with 
26.2 per 100 000 people in Baltimore (Cleveland, Farley et al. 2012; Lockhart, Iqbal et al. 2012).  
2.3.3 Treatment of Candida infections and classification of antifungal agents 
Fungal infections pose tremendous healthcare challenges worldwide and account for 
approximately 1.5 million deaths annually (Brown, Denning et al. 2012; Pianalto and Alspaugh 
2016).  Candida species are normally associated with infections of the mucosal membrane. 
Developing antifungal drugs is not as easy as developing antibacterial drugs. This is because 
fungi are eukaryotic in nature and therefore possess target sites that are similar to those found in 
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humans. As a result, toxicity may arise which might be an unwanted side effect of antifungal 
treatment (Roemer and Krysan 2014; Denning and Bromley 2015). There are four main groups 
of antifungal drugs that are used to treat fungal infections and these include azoles, polyenes, 
echinocandins and pyrimidine analogs. They can be administered through the oral, topical or 
intravenous route (Denning and Bromley 2015). However, antifungal resistance has prompted 
the development of new antifungal agents that aim at targeting fungal proteins, lipids and cell 
wall synthesis in order for them to exert their action (Perfect 2016). Antifungal agents are 
categorized into various groups based on their mode of action as follows: 
2.3.3.1 Inhibitors of ergosterol biosynthesis 
Ergosterol is the main constituent found in the cell walls of fungi and plays a role in ensuring 
that the fluidity and structure of the cell membrane is maintained. It also enables membrane-
bound enzymes to function properly (Campoy and Adrio 2016). 
2.3.3.1.1  Azoles 
This is the main class of antifungal agents and approximately 20 drugs are available on the 
market. These can either be applied to the skin or administered in the treatment of more serious 
infections. They function by inhibiting the action of a cytochrome P450-dependent enzyme, 14α-
lanosterol demethylase (CYP51), responsible for the biosynthesis of ergosterol from lanosterol 
thereby affecting the growth and replication cycle of fungal cells (Sheehan, Hitchcock et al. 1999; 
Carrillo-Munoz, Giusiano et al. 2006). Azoles can be subdivided into two groups namely 
imidazoles and triazoles. Imidazoles include clotrimazole, miconazole, and ketoconazole. 
Miconazole and clotrimazole were the earliest drugs to be included in this class but oral 
absorption was impossible. For this reason, ketoconazole was developed in 1984 which was 
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easily absorbed when administered orally (Nozawa 1985; Shukla, Singh et al. 2016). 
Nonetheless, the complications associated with this class of azoles such as high toxicity, 
relentless side effects and several drug interactions led to the introduction of triazoles to replace 
the imidazole class (Pardasani 2000; Pappas, Rex et al. 2004).   
Itraconazole and fluconazole were the earliest triazoles to be introduced and were more effective 
options, had reduced toxicity and were effectively absorbed orally when used to treat systemic 
infections in comparison to the imidazoles (Pardasani 2000; Pappas, Rex et al. 2004). 
Unfortunately, more fungal species are increasingly becoming resistant to the azole drugs and 
this is attributed to them being fungistatic as opposed to being fungicidal  (Shukla, Singh et al. 
2016). Voriconazole and posaconazole are also triazoles that are used to treat fungal infections 
and were introduced due to the limitations arising from the use of the other triazole drugs. Their 
use was endorsed by the Food and Drug Administration (FDA) in 2002 for voriconazole and 
2006 for posaconazole (Zaragoza and Pemán 2008; George, Jose et al. 2009). In 2014, the FDA 
approved another drug called Efinaconazole to be applied topically to treat fungal infections 
caused by various fungal species including Candida (Peyton, Gallagher et al. 2015).  
2.3.3.1.2 Allylamines 
Allylamines are antifungal agents that are fungicidal in nature and also function in inhibiting the 
production of ergosterol. They inhibit the action of the enzyme squalene epoxidase (ERG1) 
which facilitates the generation of 2,3-squalene epoxide from squalene leading to the buildup of 
squalene. This buildup enhances permeability thus causing alterations in the integrity of cellular 
components (Vincent 2000; Denning and Hope 2010). This group comprises terbinafine and 
naftifine (Abdel-Kader and Muharram 2017). Terbinafine is extensively used to treat nail 
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infections and is effective against infections caused by Aspergillus, Fusarium as well as other 
filamentous fungi (Ghannoum 1997; Vincent 2000). Naftifine is used in the treatment of 
infections caused by Trichophyton, Epidermophyton, Microsporum and Candida species. It has 
been shown to be fungistatic against Candida species (Ghannoum, Isham et al. 2013). 
2.3.3.2 Fungal cell membrane disruptors 
Disruption of the cell membrane by antifungal agents is achieved by their interaction with 
ergosterol (a steroid present in fungi). Polyenes are antifungal agents with the ability to interact 
with ergosterol. They have an amphiphilic structure which enables them to attach to the lipid 
bilayer and consequently produce complexes with ergosterol thus creating poles in the membrane 
and making it permeable. The structure of ergosterol is similar to that of cholesterol found in 
mammalian cell membranes. Therefore, antifungal agents that target ergosterol may have a 
damaging effect on mammalian cells and tissues as they cause the cellular components to leak 
out subsequently result in cell death (Hossain and Ghannoum 2000; Hossain and Ghannoum 
2001; Andes 2003). Initially, polyenes were the drugs of choice for the treatment of fungal 
infections. They are more effective in the treatment of a large number of fungal infections 
compared to other antifungal drugs and they are fungicidal. Examples of polyenes include 
nystatin, natamycin and amphotericin B (Lalitha, Kumar et al. 2008; Sklenár, Scigel et al. 2013).  
Nystatin and natamycin are used in the treatment of infection caused by Cryptococcus, Candida, 
Aspergillus and Fusarium. Nystatin is administered when treating cutaneous, vaginal and 
esophageal candidiasis. Natamycin is incorporated when treating fungal keratosis or corneal 
infections (Zotchev 2003). Amphotericin B is used in the treatment of the majority of infections 
caused by yeasts and filamentous fungi such as Candida, Aspergillus, Fusarium, Mucor, 
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Scedosporium and Cryptococcus (Laniado-Laborín and Cabrales-Vargas 2009). Polyenes are 
able to bind to cholesterol which results in increased toxicity accompanied by several side effects 
(Lemke, Kiderlen et al. 2005). Nystatin and natamycin are applied topically because they are not 
easily absorbed in the gut and they are associated with high toxicity. Amphotericin B is reserved 
for treating severe infections, such as systemic infections, with the potential to cause death. It is 
administered intravenously because it is not easily absorbed through the gastrointestinal tract and 
this can be harmful to the host cell membrane as it can bind to cholesterol. However, it can cause 
damage to the liver and kidneys resulting in serious side effects  (Odds, Brown et al. 2003).  
2.3.3.3  Inhibitors of fungal cell wall synthesis 
Glucans are polysaccharides made up of D-glucose units that are linked by β-(1,3) or β-(1,6)-
glucan connections. They are normally found in cells walls of yeasts and fungi (Lorand and 
Kocsis 2007). The cell wall is predominately made up of β-(1,3)-D-Glucan and is the attachment 
point or structure for chitins and glycoproteins. It also plays an important role in ensuring that 
the cell wall is strong and stable. Echinocandins are antifungal agents that target the cell wall by 
inhibiting the synthesis of β-glucan. The drugs that belong to this group include caspofungin, 
micafungin and anidulafungin (Sucher, Chahine et al. 2009; Mukherjee, Sheehan et al. 2011). 
These drugs exert their function by inhibiting the action of β -(1,3)-D-glucan synthase leading to 
the an alteration in the structure of the cell wall which results in cell death (Eschenauer, DePestel 
et al. 2007).  Absorption of these drugs in the gastrointestinal tract is quite poor due to the fact 
that they have high molecular weights. They exhibit minimal toxicity as they target components 
that are not found in mammalian cells and they also do not normally interact with other drugs. 
Unfortunately, their half-life is short and this affects their use in the hospital environment as they 
have to be given to patients once every day through intravenous injections (Petrikkos and Skiada 
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2007; Pfaller, Messer et al. 2016). Caspofungin, micafungin and anidulafungin have been shown 
to be effective in the treatment of Candida, demonstrating fungicidal activities, as well as in the 
treatment of infections caused by Aspergillus, where they demonstrate fungistatic activities. 
Micafungin is given through intravenous injection and is administered to patients with 
candidemia, acute disseminated candidiasis, Candida peritonitis, abscesses and esophageal 
candidiasis. Anidulafungin is also administered intravenously to patients with fungal infections 
in the abdomen or stomach, blood and esophagus. It is very efficient in the treatment of Candida 
infections that have become resistant to fluconazole. Caspofungin is administered as a parenteral 
injection and is used to treat invasive candidiasis and invasive aspergillosis (Arevalo, Carillo-
Munoz et al. 2003; Akins 2005; Gershkovich, Wasan et al. 2009).  
2.3.3.4 Inhibitors of sphingolipids biosynthesis 
Sphingolipids are found in large numbers in the cell membranes of eukaryotes. They have 
numerous functions in fungal cells and they also aid in enabling the fungi become pathogenic. 
Sphingolipids play a role in maintaining the structural integrity of the fungal cell membrane as 
well as the cell signaling pathway (Rollin-Pinheiro, Singh et al. 2016). Studies have shown that 
inhibiting enzymes responsible for the synthesis of sphingolipids makes the fungi less virulent. 
Aureobasidin A is an example of a sphingolipid biosynthesis inhibitor and can be used in the 
treatment of Saccharomyces cerevisiae, Schizosaccharomyces pombe, C. albicans, C. glabrata, 
A. nidulans, A. niger and C. neoformans (Zhong, Jeffries et al. 2000). 
2.3.3.5 Nucleic acid synthesis inhibitors 
Flucytosine (5FC) is an example of an antifungal agent that inhibits the synthesis of nucleic acids 
by hindering the metabolism of pyrimidines and prevents the synthesis of DNA, RNA and 
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proteins. For instance, fungal cells contain ATPases that facilitate the entry of pyrimidines into 
the cell by active transport. As a result, because flucytosine is a pyrimidine, it gets into the cell 
via these ATPases. Inside the cell, it is converted to 5-fluorouracil (5-FU) by a fungal enzyme 
called cytosine deaminase. 5-FU is then integrated into RNA resulting in defective RNA 
synthesis (Onishi, Meinz et al. 2000).  DNA synthesis in fungi can be inhibited when 5-FU is 
converted to 5-FdUMP (5-fluorodeoxyuridine monophosphate) which prevents the action of 
thymidylate synthase (Onishi, Meinz et al. 2000; Arevalo, Carillo-Munoz et al. 2003). 5-FU is 
administered orally and is effective in the treatment of fungal urinary tract infections (UTIs) and 
can be used to treat certain strains of Candida and Cryptococcus. However, fungal cells are able 
to develop resistance to this drug. Resistance occurs either at the point at which the drug is 
transported into the cell or at the cytosine deaminase step. This is the reason why 5-FU is given 
in combination with amphotericin B, itraconazole or fluconazole. These combinations can be 
used for the treatment of Candida infections (Zhanel, Karlowsky et al. 1997). 
2.3.3.6 Protein biosynthesis inhibitors 
Drugs that target protein synthesis include cispentacin and icofungipen. Cispentacin exerts its 
function by inhibiting the action of isoleucyl tRNA synthetase. Icofungipen is a synthetic 
derivative of cispentacin. These drugs have demonstrated high antifungal activity when used to 
treat infections caused by C. albicans (Konishi, Nishio et al. 1989; Petraitis, Petraitiene et al. 
2004). Another drug that is classified as a protein synthesis inhibitor is sordarin. This drug 
functions by inhibiting the action of the fungal translation elongation factor 2 (EF2). EF2 is a 
protein that plays a role in protein synthesis by facilitating the ribosomal translocation process 
(Herreros, Martinez et al. 1998).  Sordarin is highly specific and studies are being conducted so 
as to develop derivatives of this compound (Campoy and Adrio 2016). 
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2.3.4 Mechanisms involved in antifungal resistance 
Despite the potent nature of some antifungal agents, resistance can still occur due to the ability of 
fungi to evade the mechanisms of action of these antifungal agents. This is due to their natural 
ability to develop features and strategies that allow them to thrive and grow despite drug 
availability. Most of the resistance mechanisms occur at a molecular level (Peman, Canton et al. 
2009; Sanglard 2016). In order for microorganisms to evade the action of the antifungal agents, 
three main resistance methods are employed (Sanglard 2016). The first method employed is 
reducing the concentration of the drug required to effectively treat the infection and eradicate the 
fungi. The second method is modifying the target sites to which the drug binds and the last 
method is altering the metabolic processes in order to redirect the actions of the antifungal drug 
(Campoy and Adrio 2016). 
2.3.4.1 Reduction of effective drug concentration 
2.3.4.1.1  Drug efflux pumps 
Drug concentrations within the cells are reduced by means of efflux pumps. This method relies 
on the enhanced activity of these efflux pumps to reduce drug concentrations. These efflux 
pumps are transporters that confer resistance to a number of fungi and belong to the ATP-
binding cassette (ABC) and major facilitator superfamily (MFS) families. Examples of drug 
efflux transporters include CDR1 and CDR2 which are responsible for the azole resistance 
observed in C. albicans. An increase in the regulation of these transporters increases drug efflux 
thereby decreasing the amount of the drug within the cells (Mishra, Prasad et al. 2007; Sardi, 
Almeida et al. 2011). Additional ABC transporters that confer resistance to other fungi are 
CgCDR1, CgCDR2, CgSNQ2 that enable C. glabrata to become resistant to azoles. A MFS 
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transporter called MDR1 plays a role in the resistance seen in clinical isolates of C. albicans and 
C. dubliniensis to azoles. Increased expression of MDR1 causes an increase in the removal of 
azoles from the cells (Mogavero, Tavanti et al. 2011). Fluconazole resistance seen in C. albicans 
is due to a MFS transporter called FLU1 (Calabrese, Bille et al. 2000). An increase in the 
regulation of either ABC or MFS transporters is attributed to specific mechanisms employed by 
the drug resistant fungi. One such mechanism is the presence of point mutations in the regulators 
of the expression of drug efflux transporters. These point mutations are referred to as gain-of-
function mutations (GOF) and they lead to up-regulation of transporters in drug resistant fungi 
(Vandeputte, Ferrari et al. 2012). This can be seen in the case of C. albicans where fluconazole 
resistance arises from GOF mutations in a transcription factor called Upc2p (Dunkel, Liu et al. 
2008). In addition to point mutations, up-regulation of genes such as, ERG1, ERG3, ERG7, 
ERG9, ERG11 or ERG25, that code for enzymes involved in sterol biosynthesis, can also cause a 
reduction in drug concentration and are responsible for conferring azole resistance to fungal 
species (Henry and al. 2000; Romani 2004). 
2.3.4.1.2  Biofilm formation 
Drug concentrations can further be reduced due to the ability of some fungal species to produce 
biofilms. Fungi such as Candida, Aspergillus, Cryptococcus, Trichosporon, Coccidioides and 
Pneumocystis form biofilms that enable them to become resistant to drugs such as azoles, 
polyenes and pyrimidine analogs (Sardi, Scorzoni et al. 2013; Desai, Mitchell et al. 2014). 
Biofilms are complex structures that consist of polysaccharides, carbohydrates, proteins and are 
formed by cells to prevent drugs from reaching the cells and exerting their effects. The biofilms 
also contain signaling molecules (Bonhomme and d’Enfert 2013; Mitchell, Zarnowski et al. 
2015). The ability of fungal species to form biofilms enables them to become pathogenic and 
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studies have shown that most of the infections caused by C. albicans are as a result of the 
production of biofilms (Ramage, Saville et al. 2005; Martinez and Fries 2010). Furthermore, 
other studies have indicated that C. glabrata, C. parapsilosis, and C. tropicalis have the ability to 
also produce biofilms (Silva, Henriques et al. 2009). Biofilms can grow and thrive on both living 
and non-living surfaces, such as medical devices, making this a major healthcare problem 
(Hawser and Douglas 1994). Biofilm formation on medical devices, particularly vascular and 
urinary catheters, is the main cause of infections and deaths among patients in hospitals 
accounting for 90% of infections. Catheter-related biofilms can result in bloodstream infections 
which can occur in one out of every 100 patients admitted (DiDone, Oga et al. 2011). Other 
medical devices on which fungi, such as Candida, can grow include joint prostheses, cardiac 
valves, artificial vascular bypass devices, pacemakers, ventricular assist devices and central 
nervous system shunts. This can lead to life threatening conditions (Byers, Chapman et al. 1992). 
Death rates associated with device-related infections can reach 30%. Infections associated with 
Candida species that are able to form biofilms are difficult to treat as they do not respond to most 
of the antifungal agents. Unfortunately, surgical procedures are employed to remove infected 
devices which are then replaced (Viudes, Peman et al. 2002; Finkel and Mitchell 2011). 
Amphotericin B and echinocandins are the only antifungal agents that have been used in the 
treatment of infections caused by C. albicans biofilms (Kuhn, George et al. 2002). Nonetheless, 
despite treatment with these antifungal agents, the Candida biofilms are tremendously difficult to 
completely eliminate from the body (Montejo 2011). 
2.3.4.2   Modification of target sites 
Drug resistance can also develop through modifications of target sites. Resistance to azoles and 
echinocandins can occur through this type of mechanism. For instance, mutations in the ERG11 
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gene (a gene that codes for 14-α sterol demethylase) found in C. albicans reduces its sensitivity 
to azole drugs resulting in resistance. A large number of point mutations result in a reduction in 
the sensitivity of fungi to fluconazole and posaconazole (Sanglard and Coste 2015). Fungal 
species become resistant to echinocandins due to point mutations in either FSK1 or FSK2 genes 
which code for the enzyme (1,3)-β-D-glucan synthase enzyme (Vandeputte, Ferrari et al. 2012; 
Sanglard 2016). These mutations lead to decreased effectiveness of these drugs against (1,3)-β-D-
glucan synthase (Wiederhold 2016). Point mutations in the FUR1 gene are the main causes of 
resistance seen in pyrimidine analogs such as fluzytosine (5FC). Mutations in this gene result in 
fungi becoming completely resistant to 5FC and 5FU (Vandeputte, Ferrari et al. 2012). Point 
mutations in genes coding for the enzyme cytosine deaminase are the main causes of 5FC 
resistance in a large number of Candida species (Vandeputte, Pineau et al. 2011). 
2.3.4.3  Modification of metabolic processes or pathways 
Modifications in the metabolic processes or pathways are another way in which fungal species 
become resistant to antifungal agents. These modifications lead to a reduction in function. This 
can be seen in cases where inhibition of the ERG3 gene results in the modification of the final 
step of ergosterol biosynthesis. This modification prevents the generation of toxic methylated 
sterols from 5FU thus facilitating azole resistance (Sanglard 2016). In addition, mutations in 
genes such as ERG3, ERG6, ERG24 and ERG2 also result in a reduction in the presence of 
ergosterol in the plasma membrane. In some cases, ergosterol can be completely absent due to 
these mutations (Vincent, Lancaster et al. 2013). Reduced expression of FUR1 results in fungal 
strains being less susceptible to 5FC. In C. glabrata strains, down-regulation of this gene makes 
them completely resistant to 5FC (Vandeputte, Ferrari et al. 2012). Currently, fungal species are 
becoming resistant to more than one class of antifungal agents. This creates problems in the 
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healthcare sector as treating these multidrug resistant pathogens becomes increasingly difficult 
(Sanglard 2016). The resistance profiles observed in Candida species are as a result of point or 
simultaneous mutations in genes such as ERG2, ERG3, ERG5 and ERG11 which lead to azole 
and amphotericin B resistance (Vincent, Lancaster et al. 2013; Sanglard 2016). Reports have also 
indicated multidrug resistance to echinocandins and azoles resulting from mutations in the FSK2 
gene and changes in the regulation of ABC transporters (Sanglard 2016). Multidrug resistance 
has been observed in species such as C. albicans, C. glabrata and C. lusitaniae, with C. glabrata 
showing the greatest amount of resistance especially to drugs such as fluconazole, voriconazole 
and echinocandins (Denning and Bromley 2015; Jensen, Astvad et al. 2015). 
2.3.5 The effect of medicinal plants on Candida species  
Numerous studies have been carried out on medicinal plants to evaluate their effect on fungal 
species including Candida. Evaluation of the effect of Euphorbia hirta L. leaf extract on C. 
albicans revealed that it resulted in lysis as well as disintegration of the yeast cells after 
treatment as seen using transmission electron microscopy (TEM). Furthermore, this extract also 
showed a fungicidal effect against C. albicans (Rajeh, Zuraini et al. 2010; Basma, Zuraini et al. 
2011). Another study carried out to assess the effect of Pogostemon parviflorus Benth. 
methanolic leaf extracts against C. albicans, C. glabrata, C. tropicalis and C. dubliensis 
demonstrated that this extract inhibited the growth of these Candida species (Najafi and Sadeghi-
Nejad 2011). Evaluation of the in vitro and in vivo antifungal activities of Sapindus saponaria L. 
extracts against C. albicans and C. glabrata isolates also showed some promising results. Results 
of the evaluation of the in vitro activities of the extracts revealed that they had inhibitory and 
fungicidal effects against the Candida strains. Evaluation of the in vivo activities revealed that 
the extracts were effective against C. albicans and C. glabrata isolates that were either 
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susceptible or resistant to azole drugs (Dota, Faria et al. 2010). The study of the anti-Candida 
activity of Zataria multiflora Boiss aqueous, ethanolic and methanolic extracts revealed that the 
ethanolic and methanolic extracts exhibited greater activity against the Candida species whereas 
the aqueous extract was not as effective as the other two extracts (Saleem, Nazli et al. 2004). 
Synergistic effects of plant species and antifungal drugs against Candida species have also been 
shown. A study conducted to assess the effect of Ficus lyrata L. extract and nystatin on C. 
albicans isolates showed that the extract had a greater effect at lower concentrations compared to 
nystatin. In addition, the MIC of nystatin alone was 36 mg/ml but reduced to 0.05 mg/ml when 
combined with the extract thus showing a synergistic effect (Bidarigh, Khoshkholgh Pahlaviani 
et al. 2011). 
2.4 Drug resistance in cancer and use of medicinal plants 
2.4.1 Introduction 
Cancer is defined as a set of diseases associated with irregular or uncontrolled cell growth. The 
cells can either form tumors within tissues or they can result in what is termed as liquid cancer 
when the affected area is blood or the bone marrow (Nussbaumera, Bonnabrya et al. 2011). 
These abnormal cells have the potential of spreading to other parts of the body causing major 
complications and high mortality rates. According to the International Agency on Cancer (IAC), 
12.4 million cancer cases and 7.6 million deaths were reported worldwide in 2008. It is projected 
that cancer incidence rates are expected to rise to 27 million with more than 11 million cancer 
related deaths by 2030 worldwide (Li, Chen et al. 2012). In 2012, about 14 million new cancer 
cases were reported with 8.2 million cancer associated deaths. These numbers increased slightly 
in 2013 with 14.9 million new cases being reported while the cancer-related deaths remained the 
http://etd.uwc.ac.za
 
 
 
 
  Chapter 2Literature review   
59 
 
same at 8.2 million (Fitzmaurice, Dicker et al. 2015). Unfortunately, these numbers are 
anticipated to increase over time (Wang, Yang et al. 2015). The high incidence and mortality 
rates create a problem for the healthcare systems worldwide (Li, Chen et al. 2012).  
The main type of cancer associated with women worldwide is breast cancer. It has been reported 
that 23% of cancer cases are as a result of breast cancer and it accounts for 14% of cancer-
associated deaths (Jemal, Bray et al. 2011). Breast cancer incidence is higher in Western 
countries compared to Asia. However, approximately 50% of breast cancer cases and 60% of 
deaths are linked to developing countries (Jemal, Bray et al. 2011). Breast cancer is detected in 
over 1.2 million women worldwide each year. Women between the ages of 14-30 and those over 
the age of 40 have an increased risk of developing breast cancer as a result of environmental 
factors or late menopause (Singha, Ngcoyaa et al. 2016). The major forms of cancer treatment 
are surgery, chemotherapy, and/or radiotherapy (Shewach and Kuchta 2009). However, these 
treatment options have some disadvantages. For example, even though chemotherapeutic agents 
target tumor cells and minimize their proliferation, they are associated with numerous unwanted 
side effects (Nussbaumera, Bonnabrya et al. 2011). These side effects include gastrointestinal 
tract lesions, hair loss, and bone marrow suppression. The side effects normally arise due to the 
action of the chemotherapeutic agents on both healthy and cancerous cells (Nussbaumera, 
Bonnabrya et al. 2011).  
Apart from the numerous side effects, resistance to the chemotherapeutic agents can also develop.  
Even though chemotherapy is essential in cancer treatment, resistance develops as a result of 
dose-limiting toxicities (Wang, Yang et al. 2015). This drug resistance can either be inherited or 
acquired. Inherited drug resistance occurs when specific drugs fail to treat the cancer and 
acquired drug resistance occurs when the cancer cells becomes unresponsive to 
http://etd.uwc.ac.za
 
 
 
 
  Chapter 2Literature review   
60 
 
chemotherapeutic agents that initially worked in the treatment of that specific type of cancer 
(Wang, Yang et al. 2015). The need to find ways to combat cancer resistance has caused 
researchers to find alternative treatment options in the fight against cancer. The use of natural 
compounds is one way in which drug resistance can be alleviated. Drugs developed from natural 
compounds, such as plants, are believed to be more effective because they have an effect on 
several target sites, are associated with fewer side effects and can be used to treat multiple types 
of cancer (Newman, Cragg et al. 2003).   
2.4.2 Global breast cancer incidence rates 
The high mortality rates seen in females worldwide are as a result of breast cancer. According to 
GLOBOCAN 2012, approximately 1.7 million breast cancer cases and 521 900 deaths were 
reported in 2012 (Ferlay, Soerjomataram et al. 2012). Breast cancer prevalence is high in 
Western Europe and the United States whereas the prevalence is much lower in African and Asia. 
In Africa, breast cancer is the major type of cancer frequently detected in women (Ferlay, Shin et 
al. 2010) and has an age standardized rate (ASR) of 28.0 cases per 100 000. This ASR is less 
than that seen in more developed countries which is 66.4 cases per 100 000 (Ferlay, Shin et al. 
2010). The prevalence of breast cancer in African women is higher among younger women that 
have not yet reached menopause. This trend is different from that seen in developed countries 
(Holcombe, Weedon et al. 1999). This variation in ASR rates is due to the fact that African 
women possess characteristics that protect them from developing breast cancer compared to their 
counterparts in developed countries. Furthermore, the lower ASR rates are attributed to African 
women beginning their menstruation at a later age, giving birth to their first child at a much 
lower age and them normally having more than four children who are allowed to breastfeed for 
more than 6 months (Huo, Adebamowo et al. 2008; Awatef, Olfa et al. 2010). 
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It has been shown that there are differences in mortality rates among countries. It is reported that 
the Unites States has the highest number of breast cancer associated deaths especially among 
black women. The increase in the prevalence of breast cancer in HICs reveals that facilities to 
screen breast are easily accessible and that there are increased chances of developing breast 
cancer in HIC probably due to the lifestyle and environments factors (Althuis, Dozier et al. 
2005).  The risk factors that increase the chances of developing breast cancer include increase in 
weight over the age of 18, excess body weight, the use of menopausal hormone therapy (MHT), 
lack of exercise, alcohol intake and reproductive and hormone problems (Colditz, Baer et al. 
2006; Chlebowski, Manson et al. 2013). However, it has been shown that breastfeeding reduces 
the chances of developing breast cancer (Colditz, Baer et al. 2006). Breast cancer prevalence in 
LMICs is rising and is believed to be attributed to the changes in reproductive health and 
advances in breast cancer knowledge and screening facilities (Althuis, Dozier et al. 2005; 
Colditz, Sellers et al. 2006). Despite the incidence rates being high in HICs, the number of breast 
cancer related deaths have been reducing in these countries mainly due to early diagnosis of 
breast cancer and enhanced treatment options (Althuis, Dozier et al. 2005). However, the same 
trend is not seen in LMIC like Latin America, the Caribbean and parts of Asia. The mortality 
rates in these countries continue to rise. This is attributed to the various risk factors and the 
unavailability of facilities that can easily detect and treat breast cancer (Bray, Jemal et al. 2012; 
Chatenoud, Bertuccio et al. 2014; Youlden, Cramb et al. 2014). 
2.4.3 Breast cancer in South Africa 
Breast cancer is a disease that is acknowledged as being cause by mutations to various genes or 
alleles. The different subtypes have been identified using a number of techniques such as 
histology, immuno- histochemical markers and geno-transcriptomics (Curtis, Shah et al. 2012; 
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Anderson, Rosenberg et al. 2014). These techniques have revealed significant diverse subtypes 
that contribute to variations in aetiology, prognosis and treatment. In order to determine sub-
groups that are more susceptible to breast cancer as well as the specific disease causation 
patterns, it is vital to analyze the profile of the age-specific incidence rate curves and also assess 
the age at which women are normally diagnosed with breast cancer (Armitage and Doll 1954).  
Breast cancer statistics obtained from studies conducted in USA showed that there are two 
distinct categories with regard to age distribution and onset of disease. Some women develop 
breast cancer close to 50 years of age while others develop breast cancer when they are close to 
70 years (Anderson, Rosenberg et al. 2014). Data pertaining to the age at which breast cancer is 
commonly diagnosed in sub-Saharan Africa populations is lacking (Dickens, Pfeiffer et al. 2016). 
As a result, studies have to be conducted to assess the age-frequency of breast cancer diagnosis. 
South Africa affords an exclusive location for analyzing the age-frequency of breast cancer 
diagnosis. This is due to the fact that South Africa is multi-racial and contains a national cancer 
registry with electronic data on the hormonal and human epidermal growth factor receptor 2 
(HER2) receptors that are normally assessed when diagnosing women with breast cancer all over 
the country (Herd, Francies et al. 2015).  
In South Africa, there is no well-structured program intended for the screening of breast cancer 
in the general population. Breast cancer screening is limited to a small population group with the 
money to access private health care. A study was carried out to determine the receptor 
distribution in more than 10 000 women in South Africa (Dickens, Duarte et al. 2014). The 
findings of this study were incorporated in another study to investigate the breast cancer sub-
populations in black and white South African women and the age at which breast cancer 
develops (Dickens, Pfeiffer et al. 2016). The study conducted in 2016 revealed that there was a 
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constant trend in the age at which women developed (early and late onset) breast cancer in the 
breast cancer sub-population of black and white women in South Africa. These distinct groups 
were similar to those seen in Europe and the US (Anderson and Matsuno 2006; Anderson, 
Rosenberg et al. 2013). Furthermore, results of the analysis of the age-frequency distribution of 
breast cancer development showed that South African black women are diagnosed with breast 
cancer at a mean age of 53 years whilst South African white women are diagnosed at a mean age 
of 58 years (Dickens, Pfeiffer et al. 2016).  
Another study carried out to investigate breast and cervical cancer screening and associated 
factors among older adult women in South Africa revealed that of the entire sample of women, 
only 24.3% had previously had a PAP smear test done and only 15.5% had previously gone for a 
mammogram. This study also revealed that women that went for breast cancer screening were 
younger, highly educated, were from a White, Colored or Indian/Asian background, wealthy and 
had health insurance. A similar trend was observed for those women that went for cervical 
cancer screening (Peltzer and Phaswana-Mafuya 2014). Without proper cancer screening 
methods, detection of breast cancer in elderly women will be delayed which will subsequently 
increase mortality rates as the cancer would have reached an advanced stage by the time it is 
diagnosed (Peltzer and Phaswana-Mafuya 2014).  
2.4.4 Classification of anticancer drugs for the treatment of breast and other types of 
cancer  
One way in which various forms of cancer can be treated is by the use of single or multiple 
chemotherapeutic agents. Treatment is given to either get rid of the cancer cells or prevent cancer 
cell growth. However, cytotoxic agents cause a wide range of side effects which include 
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gastrointestinal tract lesions, hair loss, nausea, and bone marrow suppression. In addition, cancer 
cells can become resistant to these chemotherapeutic agents. Side effects arise due to the fact that 
these anticancer agents are not specific as they destroy both cancerous cells and normal cells 
(Nussbaumera, Bonnabrya et al. 2011). Chemotherapeutic agents have been used since 1940 
with the first being nitrogen mustards (very potent alkylating agents) and antimetabolites. As a 
result, more chemotherapeutic drugs have been developed since then (Shewach and Kuchta 
2009). Classification of anticancer agents is done based on their mode of action. Anticancer 
agents can be classified as DNA-interactive agents, antimetabolites, antitubulin agents, 
molecular targeting agents, hormones and monoclonal antibodies. Biological agents can also be 
used in the treatment of cancer (Nussbaumera, Bonnabrya et al. 2011). 
2.4.4.1 DNA interactive agents 
DNA interactive agents are the major group of anticancer agents and use a wide range of modes 
of action. Classes of drugs found in this group include alkylating agents, cross-linking agents, 
intercalating agents, topoisomerase inhibitors and DNA cleaving agents (Nussbaumera, 
Bonnabrya et al. 2011). 
2.4.4.1.1 Alkylating agents  
These have been used to treat cancer for many years and are capable of alkylating numerous 
molecules such as proteins, RNA and DNA. Alkylating drugs possesses an alkyl group that 
covalently binds to DNA thereby preventing accurate and proper DNA replication. This 
capability is what enables them to have anti-cancer properties (Lind 2008). Since DNA is 
composed of two strands, the alkylating drugs can either form intra-strand cross-links by binding 
twice to one DNA strand or form inter-strand cross-links by binding once to both strands. These 
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cross-links interfere with DNA replication causing breaks in the DNA strands as the cell attempts 
to replicate the DNA. This then ultimately results in programmed cell death referred to as 
apoptosis (Damia and D'Incalci 1998; Siddik 2005). These chemotherapeutic drugs are not 
dependent on particular stages of the cell cycle and are therefore referred to as cell-cycle 
independent drugs. Therefore, the outcome of treatment depends on the dosage of drug used 
(Malhotra and Perry 2003). Examples of alkylating agents include dacarbazine, temozolomide, 
procarbazine and ecteinascidin-743 (Nussbaumera, Bonnabrya et al. 2011).  
2.4.4.1.2 Cross-linking agents 
Cross-linking agents also exert their action by attaching to the DNA strands forming either intra-
strand or inter-strand DNA cross-links. The main types of drugs that belong to this group include 
platinum complexes (such as cisplatin, carboplatin, oxaliplatin) (Crombag, Joerger et al. 2016), 
nitrogen mustards (e.g., cyclophosphamide, ifosfamide) (Salman, Swinden et al. 2016) and 
nitrosurea compounds (Nussbaumera, Bonnabrya et al. 2011).  
2.4.4.1.3 Intercalating agents 
2.4.4.1.3.1  Anthracyclines  
This group comprises antitumor antibiotics that have a structure made up of a planar 
anthraquinone nucleus linked to an amino-containing sugar. Examples of drugs that belong to 
this group include doxorubicin, daunorubicin, and aclarubicin which are isolated from 
Streptomyces peucetiusor or Streptomyces galilaeus (Volkova and Russell 2011). Epirubicin and 
idarubicin also belong to this class and are regarded as semisynthetic analogues (Nussbaumera, 
Bonnabrya et al. 2011). Doxorubicin is extensively administered to treat various forms of cancer 
which include lymphomas, leukemia as well as numerous solid tumours such as breast cancer. 
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Side effects associated with the use of doxorubicin are vomiting, nausea, myelosuppression, 
mucositis, cardiotoxicity caused by dose buildup and alopecia (Nussbaumera, Bonnabrya et al. 
2011; Volkova and Russell 2011)..  
2.4.4.1.3.2  Mitoxantrone and actinomycin-D 
These drugs also exert their effect by DNA intercalation (introducing molecules between the 
DNA strands), producing extremely reactive free radicals that damage cellular components as 
well as inhibit the action of topoisomerases (Minotti, Menna et al. 2004). Mitoxantrone is used to 
treat cancers such as adult nonlymphocytic leukaemia, non-Hodgkin’s lymphoma and breast 
whereas actinomycin-D is employed in the treatment of AIDS-related Kaposi’s sarcoma, certain 
testicular sarcomas and paediatric cancers (Nussbaumera, Bonnabrya et al. 2011). 
2.4.4.1.4  Topoisomerase inhibitors 
This class of chemotherapeutic agents has an effect on topoisomerase I and topoisomerase II 
enzymes thereby interfering with their function. For DNA replication or transcription to occur, 
unwinding of the DNA double-strand helix has to take place. However, as DNA begins to 
unwind, the adjoining wound DNA coils up tightly forming supercoils. Topoisomerase enzymes 
function to alleviate the tension created by this supercoiling. Topoisomerase inhibitors prevent 
the action of topoisomerase I and II thus impeding the replication and transcription processes 
(Lodish, Berk et al. 2000; Goodsell 2002). Examples of topoisomerase I inhibitors include 
irinotecan and topotecan. These are semi-synthetic drugs derived from camptothecin (a natural 
product obtained from the bark of a Chinese ornamental tree called Camptotheca acuminata) 
(Malhotra and Perry 2003). Examples of topoisomerase II inhibitors include etoposide, 
doxorubicin, mitoxantrone, teniposide novobiocin, merbarone, and aclarubicin (Nitiss 2009). 
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2.4.4.1.5 DNA cleaving agents  
Bleomycin is a glycopeptide obtained from Streptomyces verticillus. Its mode of action also 
includes intercalating DNA and production of free radicals. This is facilitated by the ability of 
bleomycin to bind to a metal ion and is subsequently chemically reduced which leads to it 
reacting with oxygen (Dorr 1992; Airley 2009). The ability of bleomycin to accumulate in 
squamous cells makes it appropriate for use in the treatment of head and neck tumours as well as 
testicular carcinomas and Hodgkin’s disease (Nussbaumera, Bonnabrya et al. 2011). 
2.4.4.2  Antimetabolites 
This group consists of purine and pyrimidine analogues. Examples of purine analogues include 
azathioprine, mercaptopurine, thioguanine, cladribine, clofarabine and fludarabine (Grem and 
Keith 2005). Examples of pyrimidine analogues consist of drugs such as 5-Fluorouracil (5-FU), 
tegafur, capecitabine, cytarabine, gemcitabine and azacitidine (Grem and Keith 2005). 5-FU is 
extensively used to treat breast tumours as well as cancers that are confined to the 
gastrointestinal tract such as advanced colorectal cancer (Nussbaumera, Bonnabrya et al. 2011). 
2.4.4.3 Antitubulin agents 
These chemotherapeutic drugs are obtained from plants and inhibit cell division by interfering 
with microtubule function. Microtubules (comprising α-tubulin and β-tubulin proteins) are 
essential for cell division (Rowinsky and Donehower 1991) and are constantly being assembled 
and disassembled. Anti-microtubule drugs can be classified into two major groups, vinca 
alkaloids and taxanes. Vinca alkaloids disrupt microtubule formation while taxanes inhibit the 
disassembly of microtubules, consequently preventing completion of mitosis. Apoptosis occurs 
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as a result of the cancer cells not being able to complete mitosis which leads to cell cycle arrest 
(Lind 2008; Yue, Liu et al. 2010).  
Vincristine and vinblastine are naturally occurring vinca alkaloids. When these drugs proved 
effective in the treatment of lung and breast solid tumors, acute leukemia and lymphomas 
(Nussbaumera, Bonnabrya et al. 2011), semi-synthetic vinca alkaloids such as vinorelbine, 
vindesine, and vinflunine were manufactured (Yue, Liu et al. 2010). Taxanes consist of drugs 
that are both natural and semi-synthetic. Examples include paclitaxel and docetaxel (Yue, Liu et 
al. 2010). Paclitaxel and docetaxel are employed in the treatment of advanced or metastatic non-
small-cell lung cancer as well as metastatic breast cancer when first-line treatment fails 
(Nussbaumera, Bonnabrya et al. 2011). 
Podophyllotoxin is another drug in this class that is mainly obtained from American mayapple 
(Podophyllum peltatum) and Himalayan mayapple (Podophyllum hexandrum or Podophyllum 
emodi). The mode of action of this drug is the same as that of vinca alkaloids. It prevents 
microtubules from forming by attaching to tubulin. Two additional drugs manufactured from 
podophyllotoxin include etoposide and teniposide (Damayanthi and Lown 1998).  
2.4.4.4 Adjuvant hormonal therapy  
Close to 60-70% of breast cancers are sensitive to hormone therapy and classification is based on 
them being either estrogen receptor positive (ER+) or progesterone receptor positive (PR+). 
Women with ER+ or PR+ breast cancer are normally treated using either tamoxifen or an 
aromatase inhibitor (for post-menopausal women) and treatment can last up to 10 years (Burstein, 
Temin et al. 2014).  However, it has been shown that prolonged tamoxifen can lead to stroke, 
pulmonary embolism and incidence of uterine cancer (Ribnikar, Sousa et al. 2017).  
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2.4.4.5  Immunotherapy (targeted therapy) 
Immunotherapy is one of many cancer treatment options that aid the immune system combat 
cancer.  This type of therapy is used in the management of cancer by incorporating therapeutic 
agents synthesized from living organisms (Spellman and Tang 2016). Immunotherapy has 
proved to be effective in the treatment of cancers such as breast, melanoma and non-small cell 
lung cancer. It utilizes therapies such as monoclonal antibodies, bispecific antibodies, immune 
checkpoint inhibition, vaccinations and antibody-drug conjugates (Spellman and Tang 2016). 
Unlike other types of solid tumors such as melanomas which are considered to be immunogenic, 
breast cancer was believed not to cause an immune response. Nevertheless, it has been shown 
that enhancing the activity of the immune system in patients with breasts cancer decreased tumor 
growth (Spellman and Tang 2016). A number of therapies incorporating immune system 
components have been developed that target breast cancer cells which include targeted 
monoclonal antibodies to tumor receptors (HER-2). These types of therapies can be used with 
chemotherapy, endocrine therapy or antibody-drug conjugates. However, obtaining the most 
effective combination of these treatment options for individual patients and subtypes of cancers 
is a problem (Spellman and Tang 2016). 
2.4.4.5.1 Targeted monoclonal antibodies  
This type of cancer treatment relies on monoclonal antibodies to inhibit the function of tumor-
specific proteins as well pathways that play a role in the growth and development of tumors. 
They exert their functions by inhibiting angiogenesis, initiating apoptosis and blocking growth 
factor receptors (Mimeault and Batra 2010). The FDA recommended the use of monoclonal 
antibodies (MABs) such as cetuximab, trastuzumab and bevacizumab to treat different types of 
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cancers (Hurvitz, Hu et al. 2013). Cetuximab and trastuzumab function by binding to growth 
factors such as epidermal growth factor receptor (EGFR) and HER2/neu proteins which leads to 
hampering of cancer cell growth (Markovic and Chung 2012). In addition to hampering cell 
growth, these two drugs can also prevent the cancer from spreading particularly in colon and 
head and neck cancers. It has been shown that when EGFR is highly expressed, the condition of 
the patient becomes worse (Hirsch, Varella-Garcia et al. 2009).  
Trastuzumab is used to treat invasive HER2/neu positive breast cancer and its mechanism of 
action is the same as that of cetuximab. It enhances immune response by activating natural killer 
(NK) cells which have the ability to cause cell lysis. Trastuzumab is also able to reduce the 
ability of the cancer cells to carry out angiogenesis (Hubalek, Brunner et al. 2010). Regrettably, 
patients receiving trastuzumab develop either primary or secondary resistance following its use 
(Spellman and Tang 2016). The use of more than one MAB (bispecific antibodies) has proved to 
be effective in the treatment of cancer. One such example is the use of a combination of 
trastuzumab and pertuzumab in the treatment of treat breast cancer (McDonagh, Huhalov et al. 
2012). Clinical trials conducted to incorporate pertuzumab, a new HER2 MAB capable of 
enhancing the mode of action of trastuzumab, in the treatment of trastuzumab-resistant breast 
cancer showed that the activity of trastuzumab was improved when combined with pertuzumab 
(Gianni, Pienkowski et al. 2012; Swain, Kim et al. 2013). 
Bevacizumab is employed in the treatment of a wide range of cancers such as some forms of 
lung cancers, renal cancers, ovarian cancers, and glioblastoma multiforme of the brain. Its mode 
of action is the inhibition of angiogenesis through its attachment to vascular endothelial growth 
factor A (VEGF-A) (Ellis 2006; Hudis 2007; Lambrechts, Lenz et al. 2013). These types of 
targeted treatment options are considered to be more effective in treating cancers that have 
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developed resistance to conventional chemotherapeutic agents. In addition, they are not as toxic 
as the standard chemotherapeutic agents (Ong, Das et al. 2012). Unfortunately, the use of 
immunotherapy has its challenges which are attributed to the differences in the immune system 
profile of patients and varieties in the types of tumor encountered. Immune system profiles differ 
among patients because of genetics, lifestyle, epigenetics, nutrition and the environment (Agur 
and Vuk-Pavlovic 2012). In addition to this, some forms of immunotherapy can only treat a 
small number of patients. Thus for the treatment to be effective, immunotherapy has to be 
tailored to cater for individual patients (Wayteck, Breckpot et al. 2014).  
Antibodies can also be conjugated to chemotherapeutic drugs and used in the treatment of cancer. 
An example of this is T-DM1 which is an antibody-drug conjugate comprising trastuzumab and 
emtansine. Once this drug reaches the target site, which is the tumor location, emtansine exerts 
its function by damaging the microtubules leading to cell death and can be used in the treatment 
of breast cancer (Arteaga, Sliwkowski et al. 2012; Verma, Miles et al. 2012). Another antibody-
drug conjugate that is employed in the treatment of breast cancer is MM-302. The antibody is 
conjugated to liposomal doxorubicin (Spellman and Tang 2016). 
2.4.4.6 Small molecule drugs (targeted therapy) 
 Apart from the use of MABs, small molecule drugs are also employed in the treatment of 
various forms of cancer because they are small enough to enter inside the cancer cells. A large 
number of these small-molecule drugs inhibit the action of tyrosine kinase (Sutandyo 2016). 
Tyrosine kinase is an enzyme that plays a role in the transfer of a phosphate group from 
adenosine 3/tri phosphates (ATP) to a specific protein. Once activated, this enzyme can lead to 
increased cell proliferation, initiation of apoptosis, initiation of angiogenesis and metastasis and 
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well as resistance to other forms of treatment (Krause and Van Etten 2005). In cancer cells, 
disruptions of the regulation of tyrosine kinase as well as mutations of specific genes enable the 
tyrosine receptor to be highly expressed. This increased expression can be seen in HER2 positive 
breast cancer (Krause and Van Etten 2005). Small molecule drugs inhibit the action of tyrosine 
kinase and can be classified as epidermal growth factor receptor (EGFR) or vascular endothelial 
growth factor (VEGF) (Sutandyo 2016). 
2.4.4.6.1 EGFR inhibitors 
The small molecules that target the EGFR and hence regarded as EGFR inhibitors include 
gefitinib, erlotinib, lapatinib, neratinib, afatinib and canertinib. Their mode of action is to block 
EGFR from being phosphorylated thus leading to an inhibition of protein signaling. Gefitinib is 
incorporated in the treatment of non-small cell lung cancer in the Unites States. It targets the 
cyclin-dependent kinases and causes an inhibition of their activities (Haber, Bell et al. 2005) 
Erlotinib (known as Tarceva on the market) is a drug that has the same mode of action as 
gefitinib (Katzel, Fanucchi et al. 2009). Lapatinib causes an inhibition of pathways such as 
EGFR, HER2, and Akt. It can be used for the treatment of a wide range of cancers and the rate of 
resistance is lower that other anti-EGFR agents (Verma, Miles et al. 2012). Neratinib is a drug 
with the same mode of action as lapatinib and targets EGFR- HER4 or EGFR- HER2 (Hubalek, 
Brunner et al. 2010). Afatinib is another drug that is classified as an EGFR inhibitor which 
targets HER2 and EGFR kinases. Not only is afatinib effective against EGFR mutations, it can 
also be used to treat cancers resistant to erlotinib or gefitinib treatment (Minkovsky and Berezov 
2009). Results obtained from clinical trials indicate that it is capable of preventing the growth of 
a wide range of cancers such as metastatic breast cancer, metastatic gastric carcinoma and 
advanced hepatocellular carcinoma (Li, Zhao et al. 2010). Canertinib is used in the treatment of a 
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number of cancers because of its extensive effects on cancer cells. Nonetheless, some EGFR 
mutations do not respond to treatment with EGFR inhibitors (Kancha, von Bubnoff et al. 2009). 
Furthermore, EGFRs are also found on normal epithelial cells of the skin and mucosa and 
inhibiting them could result in side effects affecting the skin and gastrointestinal tract (Agero, 
Dusza et al. 2006). 
2.4.5 VEGF inhibitors 
Members of the VEGF family include VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and 
placenta growth factor (PlGF). Three receptors are also included in this family and these are 
VEGF receptor (VEGFR) 1, 2 and 3 (Hicklin and Ellis 2005). All malignant tumors express 
VEGF-A and VEGFR-2. VEGFs exert their effects on endothelial cells and stimulate vascular 
permeability which leads to fibrin being deposited into the extracellular matrix. This then leads 
to cell proliferation and migration. In vitro studies demonstrated that in addition to the 
production of endothelial cells, new blood vessels were also formed once VEGF interacted with 
the specific receptors (Agero, Dusza et al. 2006; Sitohy, Nagy et al. 2012). An example of a drug 
found in this class is sorafenib which functions by inhibiting targets such as VEGFR 1-3, PDGF-
h receptor serine threonine kinase and Raf-1. The action of sorafenib on these pathways prevents 
cell proliferation and tumorigenesis and has shown to be effective in the treatment of 
hepatocellular and renal cell carcinomas (Rini 2007).    
2.4.6 Mechanisms of drug resistance in cancer 
Drug resistance develops when cancer cells no longer respond to the effects of chemotherapeutic 
agents. Initially, drug resistance was thought to occur when bacteria were no longer susceptible 
to particular antibiotics. However, it has been found that the same principle applies to diseases 
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such as cancer. Drug resistance in cancers occurs through various processes such as drug 
inactivation, DNA mutations, drug inhibition and degradation, drug efflux, DNA damage repair, 
drug target alteration, cell death inhibition and the epithelial-mesenchymal transition (EMT) 
(Housman, Byler et al. 2014). Figure 2.1 outlines the different drug resistance mechanisms.    
 
 
Figure 2.1: Categories of cancer drug resistance mechanisms. These mechanisms can enable or 
promote direct or indirect drug resistance in human cancer cells. They can act independently or 
in combination and through various signal transduction pathways. 
 
2.4.6.1 Drug inactivation 
For most anticancer drugs to effectively function in the body, they have to be activated. This 
activation process requires the interaction of drug compounds with molecules and proteins in the 
body. This interaction subsequently causes alteration, breakdown or intercalation of the drug 
with molecules and proteins thus resulting in drug activation. Nonetheless, drug resistance can 
arise when cancer cells inhibit the drugs from effectively being activated (Housman, Byler et al. 
2014).  
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2.4.6.2 Alteration of drug targets 
The effectiveness of a drug is determined by the target site to which it binds. If these targets are 
modified or changed in any way, as seen in mutations or when there are changes to their 
expression levels, then the effectiveness of the drug is affected. Drug resistance in cancers 
develops when the drug targets are modified. This can be seen in the case where cancer cells 
develop resistance to topoisomerase II inhibitors as a result of mutated topoisomerase II genes 
(Zwelling, Hinds et al. 1989; Hinds, Deisseroth et al. 1991; Stavrovskaya 2000). Drug resistance 
can also develop to drugs that target the human epidermal growth factor receptor 2 (HER2). This 
is a type of receptor tyrosine kinase that plays a role in the normal growth of cells. The 
expression levels of HER2 are very high in about 30% breast cancer patients (Holohan, Van 
Schaeybroeck et al. 2013). Cancer cells become resistant to HER2 inhibitors following 
prolonged use of these drugs (Slamon, Godolphin et al. 1989; Slamon, Leyland-Jones et al. 
2001).  
Furthermore, drug resistance can develop as a result of disruptions in the drug activation 
processes. This is evident in cases where HER2-positive breast cancer tumors are treated with 
trastuzumab. Trastuzumab has been shown to be effective against breast cancer when 
administered with chemotherapy. Unfortunately, trastuzumab resistance occurs in patients that 
originally respond to treatment despite continued treatment. In other cases, it has been observed 
that trastuzumab is less effective when administered on its own (Berns, Horlings et al. 2007; 
Dieras, Vincent-Salomon et al. 2007). Tomoxifen resistance has been shown in breast cancer 
cells. Tomoxifen resistance occurs when ER signaling interacts with other signaling pathways 
involved in the growth of breast cancer cells. For instance, when the growth factor receptor 
signaling activity (such as HER2) is high in tumors, tamoxifen administration will cause an 
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increase in tumor growth due to an alteration in its normal function (Shou, Massarweh et al. 
2004). 
2.4.6.3  Drug efflux 
The majority of research conducted on cancer resistance focuses on drug efflux. Drug efflux is 
made possible through the action of ATP-binding cassette (ABC) transporter family proteins. 
These proteins are located on the membrane (transmembrane proteins) of cells and enable the 
movement of a wide range of substances into and out of the cell. Despite the ABC transporters 
being numerous (approximately 49 known members), they are categorized based on the presence 
of the transmembrane domain (Chang and Roth 2001). The transmembrane domain facilitates the 
expulsion of substances from inside the cell via the alteration in structure that occurs once the 
substance binds to this domain. This ensures that toxins do not build up within the cell (Sauna 
and Ambudkar 2001). The expression levels of these proteins are high in the epithelium found in 
the liver and intestines where they prevent the accumulation of drugs and other dangerous 
compounds (Borst and Elferink 2002; Housman, Byler et al. 2014). Cancer drug resistance is 
made possible through the action of three ABC transport proteins namely multidrug resistance 
protein 1 (MDR1), multidrug resistance-associated protein 1 (MRP1), and breast cancer 
resistance protein (BCRP). The transporters are able to remove xenobiotics, including vinca 
alkaloids, epipodophyllotoxins, anthracyclines, taxanes, and kinase inhibitors from inside the 
cancer cell (Housman, Byler et al. 2014). MDR1 is not usually expressed in tissues such as 
breast, lung and prostate and drug resistance in these tissues is attributed to MRP1 and BCRP 
expression. 
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2.4.6.4   DNA damage repair 
Repairing damage done to DNA is essential in the development of drug resistance. When 
chemotherapeutic agents cause damage to DNA, DNA damage response (DDR) processes enable 
this damage to be repaired. In platinum resistance, drugs like cisplatin bring about DNA damage 
by forming cross-links which result in apoptosis. Nevertheless, this damage can be repaired by 
removing the damaged DNA and through homologous recombination (Selvakumaran, Pisarcik et 
al. 2003; Olaussen, Dunant et al. 2006; Bonanno, Favaretto et al. 2014). As a result, for a drug to 
be effective, this DNA damage repair system must malfunction in some way to prevent the 
damaged DNA from being repaired. Disrupting the regulation and function of DDR genes and 
the processes involved in DNA damage repair through mutations and epigenetic silencing are 
implemented in numerous cancers (Esteller 2000; Goode, Ulrich et al. 2002; Curtin 2012). 
2.4.6.5 Cell death inhibition 
Apoptosis and autophagy are two processes that play a vital role in cell death. Apoptosis is 
carried out by two well known pathways: the intrinsic pathway in the mitochondria facilitated by 
B-cell lymphoma 2 (BCL-2) family proteins (i.e. caspase-9 and Akt) as well as the extrinsic 
pathway facilitated by receptors on the surface of cells that are involved in death (Housman, 
Byler et al. 2014). The merging of these two pathways occurs once caspase-3 is activated thus 
resulting in apoptosis. In numerous types of cancers, the expression levels of Akt (BCL-2 family 
protein) as well as other antiapoptotic proteins are high. Drug trials being carried out on drugs 
such as BCL-2 family inhibitors, histone deacetylase inhibitors (HDACi), protease inhibitors and 
kinase inhibitors demonstrate that they can be effectively utilized in cancer treatment (Housman, 
Byler et al. 2014). However, long term use of current BCL-2 family protein inhibitors results in 
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resistance despite them being able to induce apoptosis in cancerous cells (Mataga, Rosenthal et 
al. 2012; Holohan, Van Schaeybroeck et al. 2013; Sarkar and Faller 2013). 
2.4.6.6 Epithelial-Mesenchymal Transition and Metastasis 
Solid tumors have the ability to spread (become metastatic) as a result of processes that enable 
them to transition from epithelial cells to mesenchymal cells which is referred to as epithelial to 
mesenchymal transition (EMT). As the tumor spreads, new blood vessels form around it in a 
process known as angiogenesis. EMT is also incorporated in cancer drug resistance and studies 
are being conducted to target this mechanism in drug development (Shang, Cai et al. 2013). 
Current studies show that cancer stem cells, also called progenitor cells, are involved in the 
development of metastatic cancer cells. This may give an explanation as to why cancer may 
reappear in different areas of the body despite the cancer being successfully treated (Chaffer, 
Brueckmann et al. 2011; Byler, Goldgar et al. 2014a; Byler and Sarkar 2014b). A number of 
aspects are utilized in EMT for drug resistance to occur. Nonetheless, they rely on the metastatic 
grade of the tumor (degree of differentiation and EMT). This can be seen in ERBB2 (HER2) 
positive breast cancer, where β1 integrins levels are highly expressed in tumors leading to 
increased resistant traits to antibody inhibitors like transtuzumab (Lenisak, Xu et al. 2009). 
2.4.6.7 Epigenetics and cancer resistance 
Epigenetic alterations play an essential role in the development of cancer resistance. The two 
major kinds of epigenetic modifications are DNA methylation as well as histone modification 
through acetylation or methylation. DNA methylation involves the attachment of methyl groups 
to cytosines at CG-dinucleotides located on CpG islands, mainly found in upstream gene 
promoter regions but methylation may take place anywhere on the genome. On the other hand, 
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histone alterations change chromatin structure and arrangement. Current studies indicate that 
epigenetic modifications like histone methylation and acetylation contribute to drug resistance 
(Housman, Byler et al. 2014). Furthermore, it is believed that DNA methylation is linked to the 
ability of cancer cells to acquire multidrug resistance. Experiments carried out indicated that 
when the MDR1 promoter in cancer cell lines was demethylated, the cancer cells attained 
multidrug resistant traits (Kantharidis, El-Osta et al. 1997). Epigenetic modifications also play a 
role in repairing damaged DNA (Plumb, Strathdee et al. 2000). Epigenetic modifications have 
also been shown to enable human breast cells become resistant to drugs. For instance, MDA-
MB-231 breast cancer cells become resistant to methotrexate by means of a natural flaw in drug 
uptake and their inability to express reduced folate carriers (RFC) (Housman, Byler et al. 2014). 
2.4.7 Effect of medicinal plants on cancer cell lines 
A number of studies have been conducted to assess the potential anticancer properties of 
medicinal plants. A study carried out to evaluate the anticancer activity of Eclipta alba against 
human breast cancer cell lines (MCF-7 and MDA-MB-231) demonstrated that the extract caused 
apoptosis and the disruption of the mitochondrial membrane potential in addition to DNA 
damage. The results also revealed that the extract inhibited the growth of both cell lines in a 
dose-dependent fashion (Yadav, Arya et al. 2017). Another study that assessed the anticancer 
activity of a medicinal plant, Chamerion angustifolium L., against breast cancer cell lines (MCF-
7, MDA-MB-468 and MDA-MB-231) revealed that the extract inhibited the growth of all the 
cell lines. The results also showed that the extract caused cell death as seen by the lack of 
proliferation at high concentrations particularly with the MCF-7 cells (Maruška, Ugenskienė et 
al. 2017). A study evaluating the effect of the crude extract of Piper cubeba on breast cancer 
(MCF-7, MDA-MB-468 and MDA-MB-231) and normal breast (MCF-12A) cell lines revealed 
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that its fractions had a cytotoxic effect on the breast cancer cell lines resulting in apoptosis and 
DNA fragmentation. However, this was not the case with the normal breast cells as the fractions 
did not cause apoptosis or DNA fragmentation (Graidist, Martla et al. 2015). Another medicinal 
plant, Mangifera indica L., has also been evaluated for its potential anticancer properties. Its 
ethanolic extract was tested on breast cancer (MCF-7 and MDA-MB-231) and normal breast 
(MCF-10A) cells. The results showed that it was very toxic to the MCF-7 and MDA-MB-
231cells with minimal toxicity to the MCF-10A cells. Furthermore, the extract seemed to 
demonstrate cytotoxicity against both estrogen positive and estrogen negative breast cancer cells 
(Abdullah, Mohammed et al. 2014). 
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3 CHAPTER 3: Evaluation of the potential toxicity of Galenia 
africana using acute oral, acute dermal, skin sensitization and 
skin irritation studies 
3.1 Abstract 
Background: Medicinal plants are used by a large proportion of the global population as 
complementary and alternative medicines. However, little is known about their toxicity. 
Sensitization to chemicals is a severe condition that arises as a result of reactive molecules. G. 
africana has been used to treat wounds, coughs and skin diseases and is used in cosmetic 
formulations such as lotions and shampoos.  
Objective/Purpose: To assess the toxicity profile of G. africana in animal and reconstructed 
human epidermis models using the acute oral, acute dermal, dermal sensitization and skin 
irritation toxicity studies. 
Methods: The acute oral and acute dermal toxicity potential of G. africana was analyzed after a 
single administration of 300 mg/kg and 2000 mg/kg for acute oral toxicity and 2000 mg/kg for 
acute dermal toxicity. Sprague-Dawley rats were used for both the acute oral and acute dermal 
toxicity studies. In the dermal sensitization study, CBA/Ca mice were treated with G. africana 
concentrations of 25% (50 mg/ml), 50% (100 mg/ml) and 100% (200 mg/ml) respectively. The 
vehicle of choice was dimethylformamide which was also included as a control. The in vitro skin 
irritation potential of G. africana was assessed using the EpiSkin® irritation test. The irritation 
potential of G. africana (concentrate) and G. africana (in-use dilution) extracts were assessed 
using the EpiSkin® reconstituted human epidermis models.  
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Results: The results of the acute oral and acute dermal toxicity studies revealed that the median 
lethal dosage (LD50) for G. africana extract in Sprague-Dawley rats was considered to exceed 
2000 mg/kg. In the dermal sensitization study, the stimulation index (SI) values for the mice 
treated with the G. africana extract at concentrations of 25% (50 mg/ml), 50% (100 mg/ml) and 
100% (200 mg/ml), when compared to the control group, were 1.3, 0.9 and 1.3, respectively. The 
open application of the extract at the various concentrations did not result in a SI of ≥ 3 in any 
group. Hence, it did not elicit a hypersensitivity response. Results from the EpiSkin® irritation 
test showed that both the G. africana (concentrate) and G. africana (in-use dilution) extracts 
were non-irritant to the EpiSkin® reconstituted human epidermis models.  
Conclusion: These findings demonstrate that the toxicity profile of G. africana is acceptable for 
its intended use and can subsequently be used in the pharmacology and cosmetic industries.   
3.2 Introduction 
Medicinal plants have been used over the years in the treatment of various ailments (Lee 2013). 
Evidence has shown that the use of these medicinal plants and plant-derived medicine dates back 
to prehistoric times (Aboelsoud 2010). They have been used in the Indian, Chinese, Greek and 
African cultures, and are still being used (Ifeoma and Oluwakanyinsola 2013). Medicinal plants 
possess a wide range of beneficial properties that enable them to be used for the treatment of 
illnesses (Fankam, Kuiate et al. 2014). They are potential sources of vitamins, dietary fiber and 
minerals. They also contain various phytochemicals such as flavonoids that have numerous 
health benefits (Sarker and Nahar 2004; Radji, Kurniati et al. 2015). Herbal medicine research 
and its market have increased over the years. This can be attributed to the advent of drug 
resistance, and the need for alternative treatment methods (Oluwatuyi, Kaatz et al. 2004).  
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Galenia africana (G. africana), commonly known as “kraalbos”, is predominantly found in the 
Namaqualand region as well as the Western and Southern Karoo. Ethnobotanical surveys have 
shown that it has been used in the treatment of various ailments such as coughs, wounds, skin 
infections, eye infections and venereal sores (Watt and Breyer-Brandwijk 1962; Mativandlela, 
Muthivhi et al. 2009). G. africana plant extract is being commercialized for use as a synergistic 
adjuvant in pesticide formulations and plant growth stimulant in agrochemical applications 
(Klaasen and Vries 2009; Klaasen 2014). Additional interest in the commercialization of this 
indigenous South African plant is the invasive nature of this pioneer shrub that could provide 
income for small-holder farmers that have access to the G. africana biomass. Watt and Breyer-
Brandwijk also noted that G. africana was used by indigenous tribes of South Africa as a 
component of various cosmetic products such as lotions, decoctions and wound dressings (Watt 
and Breyer-Brandwijk 1962). It is for this reason that G. africana is currently being incorporated 
in shampoo, lotion, soap and hand wash formulations. The antifungal and antimycobacterial 
activity of G. africana extracts and flavonoid fractions have also been reported (Vries, El Bitar et 
al. 2005; Mativandlela, Meyer et al. 2008; Ticha, Klaasen et al. 2015). Toxicity data for G. 
africana extracts was identified as a requirement for the registration of agrochemical products. 
Environmental toxicity (Pool, Klaasen et al. 2009a) and in vitro immunotoxicity (Pool, Klaasen 
et al. 2009b) of G. africana have been reported. Regulatory bodies such as the Organization for 
Economic Co-operation and Development (OECD) published guidelines that help govern the 
toxicological assessment of botanical products. These guidelines are aimed at establishing the 
safety and toxicity levels of various botanical and chemical products (OECD 2010). One of the 
first tests assesses the potential of compounds to stimulate skin sensitization, thus causing 
allergic contact dermatitis (ACD) (Goebel, Aeby et al. 2012; OECD 2012). The principle of skin 
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sensitization tests is based on the utilization of animal model studies, which rely on the 
penetration of the test compound into the upper layer of the skin and subsequent interaction with 
underlying cells (Reisinger, Hoffmann et al. 2015). The effect of the sensitizing compound on 
the skin is evaluated based on events occurring in the animal models as a result of their immune 
response mechanisms (Ainscough, Frank Gerberick et al. 2013). With the potential commercial 
product applications of G. africana extract, it was essential to carry out skin sensitization tests. 
Toxicity studies can be classified in three groups based on the extent of drug exposure, namely 
acute, sub-acute and chronic toxicological studies. Initial exposure/contact to a single quantity of 
a substance is referred to as acute toxicity. In addition, corrosion, irritancy and sensitization 
(topical or local toxicity) tests are incorporated to assess the effect of substances on the skin or 
eyes (Rajalakshmi, Jayachitra et al. 2014). Toxicological studies are essential in evaluating the 
safety and potential side effects of medicinal plants. This is important because it has been shown 
that they are capable of causing severe side effects when consumed or used (Menegati, de Lima 
et al. 2016).  
With the potential application of G. africana in the agricultural and medical sectors, its safety 
had to be established. The aim of this study was to evaluate the toxicological profile of G. 
africana ethanolic extract in animal and reconstructed human skin models. 
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3.3 Materials and Methods 
3.3.1 Preparation of G. africana extract 
The G. africana extract (Batch No. Ga-1-1 (06/06/08) was commercially prepared by Afriplex 
Pty (Ltd), South Africa, for The University of the Western Cape (UWC), Bellville, Cape Town. 
The plant material was collected from Komaggas farmers, Komaggas (29.7987 S, 17.4825 E), 
Namaqua District, Northern Cape Province. The plant was dried for several weeks to maintain 
the bioactivity and then passed through a hammer mill to produce a powdery material 
(approximately 2-3 mm). The milled plant material was mixed with 80% ethanol, in the 
maceration process, to produce a yellow-green to brown-green 20% (w/v) extract with a pH of 
6.9. This was then used as a stock solution. The identity, strength, purity and composition, or 
other characteristics which appropriately defined the batch from which the test item for this study 
was drawn, were determined by UWC, South Africa. Stability of the test item and method of 
fabrication were documented by Afriplex Pty (Ltd) and the certificate of analysis supplied (see 
Appendix I). The certificate of analysis outlined the composition and physical and chemical 
properties of the extract. After the data was reviewed by the Study Director at Charles River 
Laboratory, Edinburgh, United Kingdom (UK) on 27
th
 February 2009, the G. africana extract 
was approved for use in the study. Two containers, each holding approximately 1 L of the extract, 
were received under ambient conditions at Charles River. 
This stock solution was used either undiluted or diluted in an appropriate vehicle for the studies 
described in the following sections. G. africana doses and concentrations used in these studies 
were expressed as the ammonium salt and adjusted for the strength of the stock solution. 
Chemical analysis of G. africana revealed that it contained total solids of 1.7% m/m and a 
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specific gravity of 0.8611. The stock solution was demonstrated to be stable for at least 48 
months at ambient room temperature in the dark. Dose formulations were generally prepared on 
the day of use. A DMA 38 Density Meter (No. 005260) was used to record the G. africana 
density of 0.883 g/ml and this value was used in preparing the dose formulations. Formulation 
analysis with regard to concentration, homogeneity and stability was done by Charles River 
Laboratories. Furthermore, the plant name has been checked with http://www.theplantlist.org. 
3.3.2 Testing facilities and regulatory compliance  
The studies described in the following sections were performed by Charles River Laboratories. 
All animal experiments were conducted in the P39 room of the toxicology accommodation at 
Charles River. Chemical analysis of the extract was performed at Afriplex (Pty) Ltd. All the 
studies were performed according to OECD Guidelines for the Testing of Chemicals and Good 
Laboratory Practices (see Appendix II).  Study protocols were approved by the testing facilities’ 
Institutional Animal Care and Use Committees. Animal husbandry and use were in accordance 
with applicable local and international regulations and guidelines. All animals were supplied by 
Charles River UK Limited, Test Facility Study No. 515938 (Kent, UK). The animals were 
allowed to acclimatize to the toxicology housing at these laboratories for at least 7-8 days before 
dosing.  
3.3.3 Acute oral toxicity study 
The acute oral toxicity test of G. africana extract was evaluated in mice according to the 
procedures outlined by the OECD guideline No. 423 (OECD 2001). It was conducted to assess 
the adverse effects which may result within a short time period following a single oral 
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administration of G. africana extract. Oral administration was selected as it is a potential route of 
accidental human exposure and it allows for hazard classification. 
3.3.3.1 Animals and management 
Nine female (nulliparous and non-pregnant) rats of the Sprague-Dawley Crl:CD (SD) strain were 
used. The animals were supplied by Charles River UK Limited (Kent, UK).  They were received 
in a batch that was 6-7 weeks old and that weighed 165-177 g at dispatch. 
3.3.3.2 Acclimatization, dose group allocation and animal identification 
Animals were allowed to acclimatize to the toxicology accommodation at these laboratories for 
at least 14 days before dosing. No formal randomization protocol was followed when allocating 
the animals to the groups. On the day of arrival, the animals were removed from their transport 
box in a random fashion and assigned to dose groups by placing them in cages labeled with at 
least the study number, animal number and group number. Each animal received a unique ear 
mark, through manual punch, which identified it individually within the study and which 
corresponded to that particular animal’s number. 
3.3.3.3 Room environment 
The animals were housed in groups of three in polypropylene cages (dimensions 61 x 43.5 x 24 
cm) with stainless steel grid tops and solid bottoms. Wood shavings were provided by Datesand 
(Manchester, UK) and used as bedding. Wooden chew sticks were placed in each cage and they 
were supplied by Estap OÜ, Harjumaa, Estonia). The environment was also monitored 
throughout the day and recordings made every 15 min. Standard conditions were maintained 
from the time the animals arrived until the end of the observation period. These included an 
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average of temperature 21°C, average daily humidity of 36% and 83% (minimum and maximum 
respectively), a 12 h light/dark cycle (7:00-19:00) and minimum ventilation of 15 air changes per 
h. Each cage was also provided with a water bottle and food hopper. 
3.3.3.4 Room sanitation, diet and water 
Cages, cage racks and water bottles were changed weekly during the study period. In addition, 
the floor was cleaned daily with 0.5% Tego 2000 disinfectant solution (Th. Goldschmidt and 
Company Limited, Middlesex, UK). The walls and ceiling were cleaned weekly. Rat and Mouse 
No. 1 Maintenance Diet (Special Diets Services Limited, Essex, UK) and water taken from the 
public supply (Scottish Water, Edinburgh, Midlothian, UK) were available ad libitum, except for 
a period of overnight food deprivation before dosing. Ad libitum feeding was resumed as soon as 
possible after dosing. Each batch of the diet was analyzed routinely by the supplier for numerous 
nutritional components as well as chemical and microbiological contaminants. Water quality was 
assessed and certificate of analysis for dissolved materials, heavy metals, pesticide residues, pH, 
nitrates and nitrites were periodically supplied.  
3.3.3.5 Experimental design 
Dose groups 
Nine female rats were identified, allocated to dose groups and treated as follows (Table 3.1): 
Table 3.1: Dosage and dose volume of G. africana administered to animals in different groups. 
Group Dosage (mg/kg) Dose volume (ml/kg) Animals 
1 300 0.34 1-3 
2 2000 2.27 4-6 
3 2000 2.27 7-9 
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Justification of route and dosage 
Oral administration was selected for this study as it a potential route that humans can be 
accidentally exposed to test substances. It also allows for hazard classification of test substances. 
Due to the fact that the study director’s review of G. africana revealed that low toxicity was 
likely, a starting dose of 300 mg/kg was thought to be appropriate and it was administered to 
three female rats (Group 1). Following the administration of 300 mg/kg, no adverse signs were 
observed after 48 h, hence, another group of three female rats (Group 2) was included that 
received a dosage of 2000 mg/kg, which is the next dosage stated in the regulatory guideline for 
this study (OECD No. 423). There were no adverse signs in these animals either and so to 
complete the study a further three females (Group 3) received a dosage of 2000 mg/kg. 
Route and duration of treatment 
Each animal received a single oral administration by means of a gavage tube fitted to a graduated 
syringe. Treatment was followed by a 14 day observation period. The groups were dosed at least 
2 days apart. The dose was calculated on the basis of the animals’ body weights on the day of 
dosing. 
3.3.3.6 Observations 
All animals were checked for viability early in the morning and again as late as possible on each 
day. Animals were also observed for reaction to treatment at least 5 times on the day of dosing 
(Day 1) and once daily thereafter, until Day 15. The body weights of each individual animal 
were recorded on Day 1 as well as on Days 8 and 15. 
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3.3.3.7  Terminal studies 
All animals were subjected to a gross necropsy at the end of the observation period on Day 15. 
Animals were euthanized by exposure to an increasing concentration of carbon dioxide and 
major blood vessels were cut to exsanguinate. The necropsy consisted of an examination of the 
cranial, thoracic and abdominal organs and tissues in situ. Carcasses were discarded after this 
procedure. 
3.3.3.8 Statistical analysis and electronic data capture software used 
No formal statistical analysis was carried out. Test item/control formulation: Dispense version 
7.0.3.7 was used to electronically capture the data. 
3.3.4 Acute dermal toxicity study  
The acute dermal toxicity test was conducted in accordance with the OECD guideline No. 402 
for chemical testing (OECD 1987; OECD 2015a). It was conducted to assess the adverse effects 
that may occur within a short time period following a single dermal administration of G. africana 
extract. Dermal administration was chosen as it is a potential route of accidental human exposure 
and allows hazard classification to be evaluated. 
3.3.4.1 Animals and management 
All animal experiments were conducted in the P39 room of the toxicology accommodation at 
Charles River. Five male and five female (nulliparous and non-pregnant) rats of the Sprague 
Dawley Crl:CD(SD) strain, obtained in a batch, were used. All animals were supplied by Charles 
River UK Limited, Test Facility Study No. 515938 (Kent, UK). They were approximately 8 
weeks old and weighed 291-301 g (males) and 182-190 g (female) on dispatch. 
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3.3.4.2 Acclimatization, dose group allocation and animal identification 
Animals were allowed to acclimatize to the toxicology housing at these laboratories for at least 7 
days before dosing. No formal randomization procedure was utilized. On arrival the animals 
were removed from their transport box in a random fashion and assigned to dose groups by 
placing them in cages labeled with at least study number, animal number and group number. 
Each animal received a unique ear mark, by manual punch, which identified it individually 
within the study and which corresponded to that animal's number. 
3.3.4.3 Room environment 
The animals were housed individually in cages (dimensions 61 x 43.5 x 24 cm) with steel grid 
tops and solid bottoms. Wood shavings were provided by Datesand (Manchester, UK) and used 
as bedding. Wood shavings and wooden chew sticks were placed in the cages and supplied by 
the same companies outlined in the acute oral toxicity study. The bedding and chew sticks did 
not contain any extra substances in adequate amounts to influence the outcome of the study. 
Every cage contained a water bottle and food hopper. The environment was monitored 
throughout the day and recordings made every 15 min. The animals were maintained under the 
same standard conditions outlined in the acute oral toxicity study. Each cage was also provided 
with a water bottle and food hopper. 
3.3.4.4  Room sanitation, diet and water 
Cages, cage racks and water bottles were changed weekly during the study.  The floor was 
cleaned everyday with 05% ‘Tego 200’disinfectant solution. The walls and ceiling were cleaned 
weekly. Diet and water was supplied as outlined in the acute oral toxicity study ad libitum. Each 
batch of the diet was analyzed routinely by the supplier for numerous nutritional components as 
 
 
 
 
  Chapter 3Toxicity studies 
137 
 
well as chemical and microbiological contaminants. Water quality was assessed and certificate of 
analysis for dissolved materials, heavy metals, pesticide residues, pH, nitrates and nitrites were 
periodically supplied. 
3.3.4.5 Experimental design 
Dose group, justification of route and dosage 
Five animals per sex were identified and allocated to the dose group. The treatment was as 
follows: Group number 1, dosage of 2000 mg/mg and dosage volume of 2.3 mg/kg. Five animals 
per sex (n=5) were identified and allocated to the dose group, i.e. males (1-5) and females (6-10). 
Dermal administration was selected for this study due to the possibility of accidental human 
exposure via this route. The dosage applied was 2000 mg/kg based on OECD guideline 402 
which states that a limited test at one dose level should be 2000 mg/kg body weight for this type 
of study. 
3.3.4.6 Route and duration of treatment 
G. africana was applied topically in a single 24 h application under occlusion. 24 h prior to 
applying G. africana, the hair was clipped from the dorsal area of the trunk of each rat 
(approximately 6 cm x 7 cm). Care was taken to prevent grazing the skin. On the day of 
treatment, the appropriate amount of G. africana was applied topically onto the dorsal skin and 
spread uniformly over as much of the clipped area of the trunk as possible. G. africana was then 
covered by a gauze patch (approximately 5 cm x 6 cm) and semi-occlusive tape (‘Micropore’, 
3M Medical-Surgical Division, USA) and secured in place with a strip of non-irritating occlusive 
tape (‘Sleek’, Smith and Nephew Medical Limited, USA) wound around the trunk.  
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The administered doses were calculated on the basis of the body weights of the animals on the 
day of dosing and the dose volume was based on the density of the test item (0.883 g/ml). The 
males were treated first and the females were treated one week later. On the basis that the test 
item covered approximately 80% of the patch and that the mean surface areas of the rats were 
approximately 425 cm
2
 (males) and 338 cm
2
 (females), the following calculations were made: 
Table 3.2: Mean dose volumes of G. africana application based on body surface areas. 
Sex Mean dose (ml) Body surface covered 
(%) 
Dosage (mg/ cm
2
) 
Males 0.78 6 29 
Females 0.55 7 20 
 
Table 3.2 outlines the mean does volumes applied to the body surface of the animals. After a 
contact period of approximately 24 h, the patches were removed, the dosing sites were 
demarcated and the skin was wiped with water. This was followed by a 14 day observation 
period.  
3.3.4.7 Observations 
All animals were checked daily for viability early in the morning and again as late as possible. 
The animals were also inspected for reaction to treatment six times on the day of dosing (Day 1) 
and everyday afterwards until they were killed on Day 15. Each animal’s body weight was 
assessed and recorded on Day 1 and again on Days 8 and 15. 
3.3.4.8 Terminal studies 
All animals were subjected to a gross necropsy at the end of the observation period on Day 15. 
Animals were euthanized by exposure to increasing concentrations of carbon dioxide and major 
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blood vessels were severed to exsanguinate them. The necropsy consisted of examination of the 
cranial, thoracic and abdominal organs and tissues in situ. Lesions were recorded in descriptive 
terms. Abnormal tissues were collected and preserved in 10% neutral buffered formalin. 
Carcasses were discarded following this process. 
3.3.4.9 Statistical analysis and electronic data capture software used 
No formal statistical analysis was carried out. Dose formulation: Dispense version 7.0.3.7 was 
used to electronically capture the data. 
3.3.5 Skin sensitization test using the local lymph node assay (LLNA) 
The local lymph node assay was conducted in accordance with the OECD test guideline No. 429 
(OECD 2010). This study examined the delayed contact hypersensitivity potential of G. africana 
in CBA/Ca mice. 
3.3.5.1 G. africana and control formulations 
A pre-dose formulation trial was carried out that revealed that the preferred vehicle, acetone: 
olive oil (4:1 v/v) did not produce a formulation that was appropriate for dosing. However, 
results from the trial showed that dimethylformamide was a more suitable vehicle and was thus 
selected to be used in this study. 
G. africana dose formulations were prepared volumetrically on the day of dosing. The required 
amount of G. africana was weighed and the necessary quantity of dimethylformamide was added 
until the graduated mark was reached (this was only done for Group 2 and 3 formulations). The 
G. africana/dimethylformamide mixture was then manually mixed using a spatula until a visibly 
homogenous formulation was obtained. A suitable amount of G. africana extract was 
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administered to animals in Group 4 as supplied (100% undiluted state). Group 1 (control group) 
animals were administered with an appropriate amount of dimethylformamide. On Day 1 of the 
main phase, the formulations that were prepared had pH values ranging from 4.5 to 5.5. 
3.3.5.2 Radioisotope 
The radioisotope used was [methyl-3H] thymidine (batch No. 335) obtained from GE Healthcare 
UK Limited (Buckinghamshire, England, UK). This was stored in the refrigerator, away from 
light, in the radiochemistry laboratory at Charles River. The supplier indicated that the purity of 
this chemical was 98.7%. 
3.3.5.3 Animals and management 
Twenty-two female (nulliparous and non-pregnant) mice of the CBA/Ca strain were used for this 
assay. All animals were supplied by Charles River UK Limited (Kent, UK) to Charles River 
International Laboratory (Edinburgh, UK). They were 7-8 weeks old and weighed 16-20 g on 
dispatch. 
3.3.5.4 Acclimatization, dose group allocation and animal identification 
The animals were allowed to acclimatize to the toxicology housing at these laboratories for at 
least 8 days prior to the start of dosing. There was no formal randomization procedure carried out 
when allocating the animals to the dose groups. On arrival, the animals were randomly removed 
from their transport box and allocated to dose groups by placing them in cages labeled with at 
least study number, animal number and group number. Each animal received a subcutaneous 
implant which individually identified it within the study and which corresponded to that animal's 
number. 
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3.3.5.5 Room environment 
The animals were accommodated in cages (dimensions 36.5 x 20.7 x 14 cm) and were placed in 
them in groups of 2 or 3. The cages had a stainless steel grid top, a water bottle and were 
incorporated with a food hopper. The cages were provided with wood shavings, used as bedding, 
and nesting material (‘Nestlets’) both supplied by Datesand Limited (Manchester, UK). In 
addition, wooden chew sticks were placed in every cage (Estap OÜ, Harjumaa, Estonia). 
Analysis of the bedding, nesting material and chew sticks was done and it revealed that there was 
no contamination. The environment in which the animals were housed was monitored throughout 
the day and recordings were made every 15 min. The standard conditions were; average daily 
temperatures of 19-21°C, average daily relative humidity 54-70%, lighting 12 h light/dark cycle 
(7:00-19:00) and ventilation minimum of 15 air changes per h. 
3.3.5.6 Room sanitation, diet and water 
Cages, cage racks and water bottles were changed weekly during the study period. The floor was 
cleaned daily with same disinfectant used in the other studies (0.5% Tego 2000). The wall and 
the ceiling were cleaned weekly. Diet and water were available ad libitum throughout the study 
as outlined in the acute oral and dermal toxicity studies. The supplier conducted routine analysis 
of each diet batch to assess the nutritional components as well as any chemical and 
microbiological contaminants. The water was analyzed for dissolved materials, heavy metals, 
pesticide residues, pH, nitrates and nitrites. The analysis of the diet and water revealed that there 
was no contamination. 
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3.3.5.7 Experimental design 
Dose groups 
In order to determine whether G. africana extract had any toxic effects, the preliminary and main 
phases were conducted. 
Preliminary phase 
In this phase of the study, two female mice were identified, allocated to the dose group and 
treated. This group (Group 5) consisted of animals 21 and 22 that received a G. africana 
treatment of 100% (undiluted extract). 
Main phase 
Following the preliminary phase, test concentrations were selected for the main phase and five 
animals per group were identified, allocated to dose groups and treated as follows as outlined in 
Table 3.3: Group 1 received dimethylformamide, Group 2 received 25% (50 mg/ml) extract, 
Group 3 received 50% (100 mg/ml) extract and Group 4 received 100% (200 mg/ml) extract. 
Table 3.3: Treatment of animals with the vehicle and formulations of G. africana. 
Group Treatment Formulation 
concentration (%) 
Animal 
1 Dimethylformamide 0 1-5 
2 G. africana extract 25 6-10 
3 G. africana extract 50 11-15 
4 G. africana extract 100 16-20 
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Positive control 
The local lymph node assay was regularly checked, at the laboratories, in order to validate this 
test method. Hexyl cinnamicaldehyde was used as a positive control at concentrations of 5%, 
10% and 25% because it was considered to be a sensitizer in CBA/Ca mice. 
Justification of dose group 
At the time of the study, there was no data relating to the potential of G. africana components to 
cause local irritation. Investigations conducted by the study director showed that ethanol had an 
oral LD50 value of 3450 mg/kg in mice. A preliminary study was conducted in order to find out 
whether the undiluted extract could result in local irritation or systemic toxicity.  
Results from the preliminary study revealed that there were no signs of local irritation or 
systemic toxicity and the body weight of the animals was not affected. As a result, dose 
concentrations of 25%, 50% and 100% were selected as suitable non-toxic doses to be 
administered in the main phase. This concentration series is outlined in the OECD guideline No. 
49. 
Route and duration of treatment and collection of lymph nodes 
Preliminary phase 
For 3 consecutive days (Days 1-3), an open application of 25 µl of undiluted G. africana extract 
was administered to the dorsum of each ear of the animals. The animals did not receive treatment 
on Days 4 and 5. 
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Main phase 
In this phase, for 3 consecutive days (Day 1-3), animals received an open application of 25 μl of 
the appropriate formulation onto the dorsum of each ear. Similar to the preliminary phase, there 
was no treatment on days 4 and 5. On day 6, each animal received an intravenous injection (250 
μl) of phosphate buffered saline (PBS) containing approximately 20 μCi of [methyl-3H] 
thymidine (GE Healthcare UK Limited, England, UK) into the lateral tail vein. Approximately 5 
h following intravenous administration, all animals were killed by exposure to increasing 
concentrations of carbon dioxide and the major blood vessels were severed to exsanguinate the 
animals. Each pair of draining auricular lymph nodes was collected from each animal and the 
animals were then discarded. A single cell suspension of lymph node cells from each paired 
sample was prepared by gentle disaggregation through 200 μm mesh stainless steel gauze. The 
lymph nodes cells were then washed twice in excess of PBS and precipitated with 5% 
trichloroacetic acid at 2-8°C for approximately 19 h. The pellets were re-suspended in 200 μl 
‘Solvable’ and transferred to vials containing 10 ml scintillation fluid (Aquasafe 500 plus liquid, 
Zinsser Analytic, Maidenhead, UK). Incorporation of titrated thymidine was measured by β-
scintillation counting and was expressed as disintegrations per minute (DPM). 
3.3.5.8 Observations 
All animals were checked for viability early in the morning and again as late as possible daily. 
For both the preliminary and main phases, the body weight of each individual animal was 
recorded on Day 1 (before the first dose) and on Day 6 (before the thymidine injection). 
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Daily observations 
Preliminary phase 
Animals were inspected for any signs of reaction to treatment on each day of dosing. 
Observations were performed pre-dose, immediately post dose and then a minimum of 3 more 
times within 4 h of dosing. Thereafter observations were performed once daily until Day 6. The 
animals were killed by cervical dislocation on Day 14 and then later discarded. 
Main phase 
Just like the preliminary phase, animals in this phase were also examined for reaction to 
treatment.  On each day of dosing, the observations were performed prior to dosing, immediately 
after dosing and approximately 1, 2, 3 and 4 h after dosing. From then on, animals were 
monitored once daily until they were killed on Day 6 (day of thymidine injection). 
3.3.5.9 Calculation of results  
The results were corrected for background radiation and expressed as stimulation index (SI). The 
SI was obtained by dividing the mean DPM obtained from each group by the mean DPM of the 
control group. 
SI   Mean group DPM   Mean control DPM  
The SI for the control group would consequently be 1. A positive response was indicated by an 
SI value of ≥ 3 accompanied by consideration of dose-response and, where applicable, statistical 
significance. Since none of the groups produced SI values ≥ 3, it was not possible to calculate the 
estimated concentration of G. africana that would produce a 3-fold increase in draining lymph 
node cell proliferation (i.e. the EC3 value). No formal statistical analysis was performed. 
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3.3.6 SkinEthic EpiSkin® skin irritation assay 
The SkinEthic EpiSkin® irritation assay was conducted in accordance with OECD 439 (OECD 
2015b). This skin irritation assay measures the skin irritation potential of a test item by assessing 
the cytotoxic effects after a specific exposure period and recovery time. The endpoint of this 
assay is the estimation of the cell viability by evaluating the cell viability by means of the cells’ 
ability to reduce the MTT to its formazan metabolite via mitochondrial reductase. Irritant 
materials are classified as those that are able to reduce cell viability below a threshold of 50% of 
the negative control value. 
3.3.6.1 Chemicals and reagents 
EpiSkin® kits containing tissue culture units and assay medium/maintenance medium were 
supplied by Episkin SNC (Lyon, France). Eugenol was supplied by Sigma Aldrich, Germany. 
Dulbecco’s phosphate buffered saline (PBS), sodium dodecyl sulphate, methylthiazoldiphenyl-
tetrazolium bromide (MTT), isopropanol and hydrochloric acid (fuming) were obtained from 
Sigma-Aldrich Inc. (St Louis, MO, USA). All other materials were provided by Charles River 
(Edinburg) and were of analytical grade where possible. 
3.3.6.2 Justification of the Episkin® skin irritation test system 
Evaluation of skin irritation potential of test items normally involves the use of laboratory 
animals as outlined by the OECD guidelines for toxicity studies. However, there is concern 
pertaining to pain and suffering experienced by the animals when these studies are conducted 
and this issue has been addressed in animal protection legislation (Louhimies 2002). Article 23 
of Council Directive 86/609/EEC states that: 
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“The Commission and Member States should encourage research into the development and 
validation of alternative techniques which could provide the same level of information as that 
obtained in experiments using animals but which involve fewer animals or which entail painful 
procedures, and shall take other steps as they consider appropriate to encourage research in this 
field. The Commission and Member States shall monitor trends in experimental methods” 
(Louhimies 2002). 
This is the reason why this skin irritation study was conducted in order to replace, reduce and 
refine animal use while ensuring that this assay does not affect the integrity of the test or the 
results produced (Louhimies 2002). Furthermore, the European Centre for the Validation of 
Alternative Methods (ECVAM) sanctioned the used of the Episkin® skin irritation assay in a 
validation statement released in April 2007. ECVAM describes the test as demonstrating 
evidence of being a reliable and relevant standalone test for predicting skin irritation through the 
assessment of MTT reduction. The skin irritation tests can also be used, according to ECVAM, 
to categorize test substances as being irritants or non-irritants to the skin (Hartung 2007).  
3.3.6.3 Episkin® Reconstructed Human Epidermis 
The EpiSkin® reconstituted human epidermis (RhE) models were obtained from Episkin SNC, 
Lyon, France. EpiSkin® technical data, safety sheet and certificate of analysis were provided 
(see Appendix III). The RhE models were generated by culturing adult human keratinocytes on a 
collagen base in conditions that allow their terminal differentiation and the reconstruction of an 
epidermis containing a functional horny layer (stratum corneum). The human keratinocytes are 
collected from mammary or abdominal samples obtained from healthy consenting donors during 
plastic surgery. HIV 1 and 2, HEP B and HEP C tests are conducted on the donors. The 
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bacteriological and fungal sterility of the cells is also verified. During the emersion process (10 
days), the epidermis differentiates and a horny layer is produced. The reproducibility of each 
batch is assessed by means of histological analysis taking into consideration the general 
organization, the stratification of the epidermis, the nucleation of the basal layer and the size of 
the intercellular spaces, adhesion of the basal layer to the support and the quality of the granular 
cells and horny layer. Every single criterion is scored out of 4 with a maximum score of 28. The 
minimum score for the criterion to be accepted as a model is 19.5. The reproducibility of the 
response of each EpiSkin® batch is tested against a reference irritant which is SDS. The IC50 of 
the surfactant is measured by the MTT assay after 18 h of contact. The minimum score for the 
acceptability of the model is 1.5 mg/ml. 
3.3.6.4 Episkin® units and pre-incubation 
Upon arrival of the EpiSkin® kits at Charles River, examination of their quality was done. The 
pH and temperature indicators were both in acceptable ranges. The units were placed in a 12 well 
microtitre plate with each individual unit being transferred to a single well containing 2 ml 
maintenance medium pre-warmed in a 37C water bath. Before dosing, all units were incubated 
for 24 h at 37ºC in a humidified atmosphere with 5% CO2. 
3.3.6.5 Formulation of In-Use Dilution 
To prepare the in-use dilution (1%, v/v), the concentrate G. africana extract (0.1 ml) was added 
to water (9.9 ml) and mixed by vortexing. The concentrated extract contains plant extract in 
ethanol at a concentration of 20% (w/v). Therefore, the concentration of the plant extract in the 
in-use dilution was 0.2% (w/v). 
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3.3.6.6 MTT direct reduction by G. africana 
Prior to conducting the irritation assay, G. africana was tested to determine if it was capable of 
reducing MTT to its formazan metabolite. Since the assay depends on the ability of viable skin 
cells to reduce MTT to formazan, any reduction by G. africana would interfere with the integrity 
of the results. 10 µl of G. africana was added to 2 ml MTT (approximately 0.3 mg/ml) in PBS in 
a glass universal vial (three replicates) and incubated at 37C in a humidified atmosphere with 
5% CO2 for approximately 3 h. Formazan production was assessed by visual inspection. Three 
replicates of the positive control (eugenol, 10 µl) and negative control (sterile, ultra-pure water, 
10 µl) were tested in parallel to demonstrate the efficacy of the MTT solution. 
3.3.6.7 G. africana application and terminal exposure procedures (15 min post-dose) 
Concentrated G. africana extract and the in-use dilution were each applied onto the exposed 
surface of three viable EpiSkin® reconstructed human epidermis units using a Gilson positive 
displacement pipette set to deliver 10 µl.  The test item was gently spread over the entire exposed 
skin surface using the tip of the pipette, taking care to avoid damaging the epidermis. The surface 
area of the EpiSkin® was 0.38 cm
2
, therefore, the application rate was 26.3 µl/cm
2
. After 
exposure to the G. africana or positive and negative controls for 15 min, the EpiSkin® units 
were washed by rinsing with Dulbecco’s phosphate buffered saline (25 ml). After washing, all 
skin units were blotted dry with tissue paper, transferred to fresh maintenance medium and 
incubated for 42 h at 37C in a humidified atmosphere with 5% CO2. 
3.3.6.8 MTT test  
After the recovery period, all EpiSkin® units were transferred to a new 12 well microtiter plate 
containing MTT solution (2 ml per well, 0.3 mg/ml) in assay medium. Each unit was tapped 
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gently on tissue paper to remove residual moisture before transferring to the MTT solution. The 
skin units were then incubated for 3h at 37C in a humidified atmosphere with 5% CO2. After 
incubation, each skin unit was removed from the MTT solution and gently tapped dry on tissue 
paper to remove any excess moisture. The exposed skin was then completely removed from the 
unit using a specially designed biopsy punch. The epidermis was separated from the collagen 
matrix and both layers added to an appropriately labeled microfuge tube containing acidic 
isopropanol (500 µl).  The tubes were capped and the contents mixed by vortexing. The biopsies 
were completely immersed in the solvent. Samples were then stored at about 4C protected from 
light. 
3.3.6.9 Absorbance Measurement and calculation of results 
After 69 h storage, the samples were removed from the refrigerator and mixed by vortexing to 
ensure a homogenous mixture. Two aliquots (200 µl) were then added to a 96 well flat bottom 
microtiter plate for each sample, ensuring that no solid material was removed from the sample 
tube.  Plates were analyzed using an MRX plate reader at a wavelength measurement of 550 nm. 
Absorbance values were calculated against the background acidified isopropanol sample 
contained on the plate. 
Optical Density (OD) 
OD Treated Tissue (TT) = OD TT raw – OD blank mean 
OD Negative Control (NC) = OD NC raw – OD blank mean 
The corrected mean OD Negative Control corresponds to 100% viability 
OD Positive Control (PC) = OD PC raw – OD blank mean 
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Individual Viabilities (%) 
% Positive Control 1  = [OD PC1 / Mean OD NC] x 100 
% Positive Control 2  = [OD PC2 / Mean OD NC] x 100 
% Positive Control 3  = [OD PC3 / Mean OD NC] x 100 
% Treated Tissue 1  = [OD TT1 / Mean OD NC] x 100 
% Treated Tissue 2  = [OD TT2 / Mean OD NC] x 100 
% Treated Tissue 3  = [OD TT3 / Mean OD NC] x 100 
Mean Viabilities (%) and Relative viability (%) 
Mean Positive Control % = (%PC1 + %PC2+ %PC3) / 3 
Mean Treated Tissue % = (%TT1 + %TT2 + %TT3) / 3 
% Viability = [ODTT / ODNC] x 100 
Acceptance Criteria  
The assay was deemed acceptable if the following occurred: 
The mean OD value of the 3 negative control tissues was ≥ 0.6 and the standard deviation value 
(SD) of the % viability was ≤ 18. The mean % viability of the 3 positive control tissues was ≤ 
30% and the SD was ≤ 18. The mean % viability SD of the 3 treated tissues was ≤ 18. 
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Interpretation of skin irritancy 
According to the GHS category 2, a test chemical is considered to be irritant if the tissue viability 
after exposure and post-treatment incubation is less than or equal (≤) to 50%. However, 
classification can differ depending on country/regional regulatory requirements. In this case, the 
test chemical can be considered as “no category” if the tissue viability after exposure and post-
treatment incubation is greater than (˃) 50%.  
3.4 Results 
3.4.1 Acute oral toxicity study 
There were no unscheduled deaths among animals receiving G. africana extract at either the 300 
mg/kg or 2000 mg/kg dosage. There were no adverse signs of reaction to treatment recorded at 
either the 300 mg/kg or 2000 mg/kg dosage (Table 3.4). Body weight gain was considered to be 
acceptable for rats of this age and strain (Figure 3.1). Macroscopic examination on Day 15 
revealed no abnormalities in any animal (Table 3.5). 
Table 3.4: Individual daily observations of the effect of G. africana on the animals in Group 1 
(300 mg/kg) and Groups 2 and 3 (2000 mg/kg). 
                        Time after dosing on day 1 (h) 
Group Sign At dosing ¼-1 ¼  2-2 ½    3-4 4¼ -5 ½  Day 2-15 
1-3 No 
abnormalities 
detected 
(NAD) 
1-9 1-9 1-9 1-9 1-9 1-9 
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Figure 3.1: Trends in mean body weight gain of animals treated with G. africana extract at 
concentrations of 300 mg/kg (Group 1) and 2000 mg/kg (Groups 2 and 3) within a 15 day period. 
 
Table 3.5: Individual necropsy findings of the effect of G. africana on the animals in Group 1 
(300 mg/kg) and Groups 2 and 3 (2000 mg/kg). 
Group Animal Individual finding Day of death 
1 1 No abnormalities 
detected (NAD) 
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3.4.2 Acute dermal toxicity study 
There were no unscheduled deaths during the observation period. There were no systemic signs 
of toxicity recorded in any animal at any observation time-point (Table 3.6). Body weight gain 
was considered to be acceptable for rats of this age and strain (Figure 3.2).  
Table 3.6: Individual daily observations of the effect of G. africana (2000 mg/kg) on the 
animals. 
Group/Sex Sign Day(s) of Study 
  1-7 8-15 
Male No abnormalities 
detected (NAD) 
1-5 1-5 
Female NAD 6-10 6-10 
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Figure 3.2: Trends in mean body weight gain of male and female rats after a single dose 
application of G. africana extract (2000 mg/kg) within a 15 day period. 
 
Necropsy of the females on Day 15 revealed no macroscopic abnormalities. Among males, 
enlargement of the mandibular lymph nodes was recorded in 4 of the 5 animals. Other 
macroscopic abnormalities included dark and/or pale foci in the lungs, which affected 3 males, 
and intestinal abnormalities such as pale appearance and/or abnormal contents of the jejunum, 
which was recorded in 2 males. In addition there were single instances of reddening of the lungs, 
prominence of Peyer’s patch, speckling of the thymus and distension of the ileum. The necropsy 
findings seen in males are commonly observed background findings in rats of this strain and are 
not considered to be a result of dermal application of G. africana extract (Table 3.7). 
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Table 3.7: Individual necropsy findings of the effect of G. africana (200 mg/kg) on the animals. 
Sex Animal Individual Finding 
Male 1 Mandibular lymph nodes: enlarged (14x8x2 mm) 
Lungs: reddened, all lobes 
             many dark foci, all lobes (red, pinpoint appearance) 
             many pale loci, all lobes (cream, ≤3 mm diameter) 
 
 
 
 
2 Mandibular lymph nodes: enlarged (11x7x2 mm) 
Intestines: jejunum- pale 
                 Peyer’s patch- prominent 
Thymus: specked, right lobe 
Lungs: dark focus, left lobe (red, 3 mm diameter) 
 3 Mandibular lymph nodes: enlarged (14x8x2 mm) 
 4 Intestines: jejunum- pale, with abnormal (white) contents 
Lungs: 3 dark foci, left lobe (red, 1 mm diameter) 
 5 Mandibular lymph nodes: enlarged (11x6x2 mm) 
Intestines: ileum-distended by contents (6 mm) 
Female 6-10 No abnormalities detected 
 
3.4.3 Local lymph node assay 
Results were corrected for background radiation and expressed as SI. This was obtained by 
dividing the mean DPM obtained from each group by the mean DPM of the control group. The 
SI for the control group, therefore, is one. A positive response is indicated by an SI ≥ 3, together 
with consideration of dose-response and, where appropriate, statistical significance. As there was 
no stimulation index ≥ 3 recorded for any group it was not possible to calculate the estimated 
concentration of test item that would produce a 3-fold increase in draining lymph node cell 
proliferation (the EC3 value). No systemic signs and no signs of local irritation were noted in 
either animal receiving undiluted G. africana extract. Body weight gain was considered to be 
acceptable for mice of this age and strain. Based on these findings, concentrations of 25% (50 
mg/ml), 50% (100 mg/ml) and 100% (200 mg/ml) (i.e. undiluted) G. africana extract were 
selected for testing in the main phase. No systemic signs were noted in any animal during the 
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observation period. There was no effect of treatment on body weight (Figure 3.3). Although 
body weight losses were recorded in 4 of the 20 mice, they were restricted to animals treated 
with either the 25% (50 mg/ml) or 50% (100 mg/ml) concentrations. There were no body weight 
losses among control mice or among mice treated with undiluted G. africana extract. The 
stimulation indices for mice treated with the G. africana extract at concentrations of 25% (50 
mg/ml), 50% (100 mg/ml) and 100% (200 mg/ml) were 1.3, 0.9 and 1.3, respectively (Table 3.8). 
 
 
Figure 3.3: Trends in mean body weight gain of female mice after an open application of G. 
africana extract (25, 50 and 100%) and vehicle (dimethylformamide) within a 6 day period. 
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Table 3.8: Overall assessment of individual and group mean disintegration per minute counts 
(DPM) and SI values obtained after treatment with dimethylformamide (vehicle) and G. africana 
concentrations. 
a
Suspensions for lymph node cells from animals 1, 12 and 13 were spilled during processing. 
Therefore, DPM counts from these animals are not presented in the Table. 
 
 
 
 
 
 
 
Group Concentration 
(%) 
Animal DPM Group Mean 
DPM 
Stimulation 
Index 
1 vehicle 1 -
a 
1456 1 
  2 1760   
  3 1906   
  4 338   
  5 1821   
2 25 6 4269 1922 1.3 
  7 653   
  8 1169   
  9 681   
  10 2840   
3 50 11 1235 1240 0.9 
  12 -
a 
  
  13 -
a 
  
  14 1783   
  15 703   
4 100 16 1095 1829 1.3 
  17 1542   
  18 2318   
  19 2260   
  20 1932   
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3.4.4 SkinEthic EpiSkin® irritation assay 
A graphical representation of the SkinEthic EpiSkin® irritation assay results are shown in 
Figures 3.4 and 3.5. 
 
Figure 3.4: Optical density of EpiSkin® MTT test samples (mean and SD, n=6). However, mean 
and SD were calculated from n=4 test samples for positive and G. africana extract (concentrate). 
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Figure 3.5: Relative cell viability of EpiSkin ® cultures treated with G. africana extract after 42 
h recovery time (mean and SD, n=6). However, mean and SD were calculated from n=4 samples 
for positive and G. africana extract (concentrate).  
-----------Threshold value for positive response (50% of the negative control viability). 
 
The results of the direct reduction test are shown in Table 3.9. The test was scored by visual 
assessment of the formation of the purple-colored formazan. The positive control (eugenol) 
reduced the MTT solution to formazan almost immediately, generating a dark purple color 
before incubation. The negative control (sterile ultra-pure water) and test items (G. africana 
concentrated extract and in-use dilution) did not reduce MTT to formazan after approximately 3 
h incubation. 
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Table 3.9: Evaluation of direct reduction of MTT by G. africana extract. 
Test Item Replicate ID Volume  MTT Solution 
Volume 
Color change observed 
G. africana extract 
Concentrate 
Rep 1 10 µl 2 ml No color change after 3 h 
incubation 
 Rep 2 10 µl  No color change after 3 h 
incubation 
 Rep 3 10 µl  No color change after 3 h 
incubation 
G. africana extract 
Dilution (1%, v/v) 
Rep 1 10 µl 2 ml No color change after 3 h 
incubation 
 Rep 2 10 µl  No color change after 3 h 
incubation 
 Rep 3 10 µl  No color change after 3 h 
incubation 
Sterile Water 
(Negative Control) 
Rep 1 10 µl 2 ml No color change after 3 h 
incubation 
 Rep 2 10 µl  No color change after 3 h 
incubation 
 Rep 3 10 µl  No color change after 3 h 
incubation 
Eugenol 
(Positive Control) 
Rep 1 10 µl 2 ml Immediate dark blue/purple color 
change 
 
 Rep 2 10 µl  Immediate dark blue/purple color 
change 
 Rep 3 10 µl  Immediate dark blue/purple color 
change 
 
The results of the EpiSkin® irritation assay with G. africana concentrated extract and in-use 
dilution are shown in Tables 3.10 and 3.11. Table 3.10 shows the mean corrected absorbance 
(OD) values for the positive and negative controls and for the test item. Table 3.11 shows the 
relative viabilities of the EpiSkin® cultures as a percentage of the mean negative control value.  
The negative control results were within the acceptance criteria defined in the ECVAM 
validation SOP. The positive control results were within the acceptance criteria defined in the 
ECVAM validation SOP. The results of the assay were similar for both viable EpiSkin® units 
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dosed with concentrated G. africana extract. Exposure to concentrated G. africana extract 
resulted in a mean EpiSkin® viability of 84.75%  11.26% of the negative control value. The 
results of the assay were similar for all viable EpiSkin® units dosed with G. africana extract 
(in-use dilution). Exposure to G. africana extract (in-use dilution) resulted in a mean EpiSkin® 
viability of 92.97%  14.63% of the negative control value. 
Table 3.10: Optical density (OD) of EpiSkin® MTT test samples. 
Test Item Replicate ID Corrected OD 
(550 nm) 
Mean SD CV (%) 
G. africana 
extract 
Concentrate 
Rep 1 0.798 0.757 0.101 13.28 
  0.880    
 Rep 2 0.664    
  0.687    
 Rep 3 0.117
*
    
  0.121
*
    
G. africana 
extract 
Dilution 
(1%, v/v) 
Rep 1 0.688 0.831 0.131 15.73 
  0.747    
 Rep 2 0.960    
  1.019    
 Rep 3 0.756    
  0.814    
5% SDS 
Solution 
(Positive 
Control) 
Rep 1 0.321
*
 0.126 0.064 55.02 
  0.278
*
    
 Rep 2 0.185    
  0.187    
 Rep 3 0.069    
  0.063    
PBS Solution 
(Negative 
Control) 
Rep 1 0.840 0.894 0.033 3.70 
  0.904    
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 Rep 2 0.900    
  0.941    
 Rep 3 0.880    
  0.896    
*Data was rejected from the mean and SD calculations. See section 3.4.4.1. 
 
Table 3.11: Percentage viability of EpiSkin® cultures treated with G. africana extract after 42 h 
recovery time. 
Test Item Replicate ID Viability after 42 h 
(%) 
Mean (%) SD (%) CV (%) 
G. africana extract 
Concentrate 
Rep 1 89.31 84.75 11.26 13.28 
  98.49    
 Rep 2 74.31    
  76.89    
 Rep 3 13.09
*
    
  15.54
*
    
G. africana extract 
Dilution (1%, v/v) 
Rep 1 77.00 92.97 14.63 15.73 
  83.60    
 Rep 2 107.44    
  114.05    
 Rep 3 84.61    
  91.10    
5% SDS Solution 
(Positive Control) 
Rep 1 35.93
*
 14.10 7.76 55.02 
  31.11
*
    
 Rep 2 20.71    
  20.93    
 Rep 3 7.72    
  7.05    
PBS Solution 
(Negative Control) 
Rep 1 94.01 100.00 3.70 3.70 
  101.18    
 Rep 2 100.73    
  105.32    
 Rep 3 98.49    
  100.28    
*Data was rejected from the mean and SD calculations. See section 3.4.4.1. 
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3.4.4.1 Sample Rejection 
Due to inadvertent excision of the reconstructed skin tissue from the collagen matrix, it was 
necessary to reject the results from one of the EpiSkin® units dosed with G. africana extract 
(concentrate).  The optical density and cell viability were therefore calculated from 2 EpiSkin® 
units. It was also necessary to reject the results from one of the EpiSkin® units dosed with the 
positive control. This was due to incomplete spreading of the SDS over the surface of the 
EpiSkin®. 
3.5 Discussion 
Botanicals are attractive alternatives to synthetic agrochemicals because they are said to pose 
little threat to human health and to the environment (Isman 2006). In spite of the scale of 
scientific data documenting the activity of plant extracts, only a handful, such as neem oil, 
essential oils, pyrethrum and rotenone are used commercially on agricultural products because of 
increasingly stringent regulatory requirements (Isman 2006). Toxicity testing is vital as it 
facilitates the evaluation of the possible harmful side effects attributed to these products. Because 
a number of substances provoke allergic contact dermatitis in humans, assessment of safety by 
carrying out skin sensitization tests is crucial. Furthermore, it is imperative to evaluate the short 
or long term effects these products might have as well as the potential course of human exposure 
(Bras, Gumilar et al. 2011). For this reason, this study evaluated the effects of acute exposure of 
the ethanolic extract of G. africana in mice, rats and EpiSkin® reconstituted human epidermis. 
The local lymph node assay (LLNA) was utilized to assess skin sensitivity of G. africana. At the 
time of the study, no data pertaining to the potential of G. africana components to cause local 
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irritation in mice, rats or skin was available. This study was performed in accordance with the 
OECD guidelines and Principles of Good Laboratory Practice. 
This study showed that at the highest (undiluted) concentration (2000 mg/ml) the extract had no 
toxic effects as demonstrated by the local lymph node assay. In addition, it did not elicit a 
hypersensitivity reaction in the mice. No concentration resulted in a stimulation index of ≥ 3 in 
any group. Consequently, it was considered that the test item does not have the potential to cause 
sensitization. In the acute oral and acute dermal toxicity studies, the median lethal oral dosage 
(LD50) of G. africana extract was considered to exceed 2000 mg/kg. Evaluation of the effect of 
the extract on EpiSkin® reconstituted human epidermis revealed that the G. africana extract 
(concentrate) G. africana extract (in-use dilution) were non-irritants. These findings will be 
included in the documentation for a toxicological review to register G. africana extracts as 
pesticidal adjuvants and plant growth stimulants. 
Environmental toxicology studies of G. africana extracts have been found to have a variety of 
inhibitory effects (EC50) against Vibrio fischeri (0.7 µg/ml, 30 min), Selenastrum capricornatum 
(100 µg/ml, 72 h), Daphnia pulex (30 µg/ml, 48 h) and Poecilia reticulata (20 µg/ml 96 h) (Pool 
et al., 2009 a). The minimum inhibitory concentrations (MIC) of plants against various fungal 
pathogens (Alternaria, Botrytis, Cylindrocarpon, Eutypa, Fusarium) ranged from 25 to 100 
mg/ml (Vries et al., 2005). The MIC value for Mycobacterium smegmatis was 0.78 mg/ml 
(Mativandlela, Meyer et al. 2008). An immune toxicity study of G. africana extract found that 
concentrations of 19 to 500 µg/ml modulate pro-inflammatory cytokines of BALB/c mouse 
spleenocytes (Pool, Klaasen et al. 2009b). 
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A number of toxicity studies have been carried out on plant compounds in the hope of assessing 
their skin sensitization potential. A study on the essential oils of western juniper oil and Port-
Orford-cedar oil evaluated their potential to cause dermal toxic effects on mice and rabbits 
(Craig, Karchesy et al. 2004). Data collected in the Port-Orford-cedar oil study showed that 
concentrations of 0.5%, 5% and 50% did not induce a hypersensitivity reaction and hence, was 
not considered to be a sensitizer. However, western juniper oil extract at 50% concentration 
demonstrated a positive reaction of 3.33 SI (with 3.0 or greater representing a positive response). 
This result classified western juniper oil as a potential sensitizer (Craig, Karchesy et al. 2004). A 
study of the skin irritancy potential of Angelica keiskei leaf aqueous and ethanol fractions (100 
mg/dose), demonstrated that these fractions did not induce acute toxicity in the skin of the 
animals as assessed by anatomical and pathological observations (Lee 2013). Toxicity studies on 
different root extracts of Anacyclus pyrethrum DC showed that this medicinal plant was safe to 
use at known dosages (Kumar and Lalitha 2013). All these studies were carried out in 
accordance with OECD guidelines. Acute oral toxicity studies of the methanol extract of Mentha 
spicata, a medicinal plant used for the alleviation of different classes of pain, revealed that this 
plant extract can be classified as non-toxic (Naidu, Ismail et al. 2014). 
The abundance of medicinal plants and their use in traditional medicine makes them ideal 
choices as agrochemicals and/or pesticides (Manjula and Mamidala 2013). With the cost of 
conventional chemicals being high, agrochemicals can be used and made available even in rural 
areas. Furthermore, agrochemicals help protect the environment and preserve wildlife (Nnamonu 
and Ali 2013). Toxicity and safety assessment of medicinal plants already in use, including the 
ones not commercialized, is therefore important. 
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3.6 Conclusion 
From this study, it can be concluded that the median lethal oral dosage (LD50) of G. africana 
extract was considered to exceed 2000 mg/kg in both the acute oral and acute dermal toxicity 
studies. Evaluation of the effect of the extract on EpiSkin® reconstructed human epidermis 
revealed that the G. africana extract (concentrate) G. africana extract (in-use dilution) were non-
irritants. Furthermore, open application of the extract at various concentrations did not result in a 
SI ≥ 3 in any group. Hence, it did not elicit a hypersensitivity response. These findings will be 
included in the documentation for a toxicological review to register G. africana extracts as 
pesticidal adjuvants and plant growth stimulants. G. africana has been shown to have bio-
stimulating properties. Studies carried out on this medicinal plant revealed that it increased the 
levels and concentrations of polyphenolics, flavonoids and chlorophyll when applied. G. 
africana is applied directly (foliar application) onto filed crops, fruit trees and grass at a 
concentration of 0.15% (750 ml/100 L). For cosmetic formulations, G. africana is used at a 
concentration of 1% or lower (10 ml/ 250 ml).  
The outcomes of this study demonstrated that the ethanolic extract of G. africana did not result 
in any in vivo danger. Pharmacological and biochemical investigations will be essential in 
elucidating the mechanism of action and will be beneficial in utilizing this plant as a therapeutic 
agent. Furthermore, a detailed experimental analysis of the chronic toxicities and genotoxicity 
are important to support these findings. Toxicity assessment of medicinal plants already in use, 
including the ones not yet commercialized, is important in evaluating their safety and sensitizing 
potential at dosages for which these formulations are being used. Clinical trials have not yet been 
performed on this medicinal plant. 
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4 CHAPTER 4: Antimicrobial activity of Galenia africana alone 
and in combination with antimicrobial drugs against 
Staphylococcus aureus 
4.1 Abstract 
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for causing 
severe hospital and community acquired infections. Globally, MRSA infection rates have 
continued to rise due to its ability to develop resistance to commonly used drugs. It is for this 
reason that medicinal plants are being considered as alternative sources of treatment. G. africana 
is a medicinal plant known to have antifungal and antimycobacterial properties. It has also been 
used in the treatment of skin infections, eye inflammations and wounds. 
Objective/Purpose: The purpose of this study was to evaluate the antimicrobial activity of G. 
africana alone as well as its interaction with antimicrobial drugs against methicillin-sensitive 
(MSSA) and methicillin-resistant (MRSA) Staphylococcus aureus. 
Methods: The antimicrobial activity of G. africana extracts and the interactions between the 
ethanolic extract and various antibacterial agents were investigated by the broth microdilution, 
checkerboard assay and the Sensititre susceptibility testing method. The minimum bactericidal 
concentrations (MBCs) of the extracts were also determined. 
Results: The MIC of the dried extract against both MSSA and MRSA was 25 mg/ml while that 
of the ethanolic extract was 3.12 mg/ml for both strains. The MIC results indicated that the 
growth inhibitory effect of the ethanolic extract was more than that of the dried extract. In the 
checkerboard assay, the fractional inhibitory concentration (FIC) indices showed the ethanolic 
and ampicillin combination was additive (FICI of 0.64) against MSSA but indifference (FICI of 
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1.002) against MRSA. The results of the Sensititre susceptibility test showed that the extract 
increased the activity of some of the antibacterial agents. The MBC results showed that the dried 
extract was bacteriostatic against both MSSA and MRSA strains. The ethanolic extract was 
bactericidal against the MSSA and MRSA strains with MBCs of 3.125 and 6.25 mg/m,l 
respectively. 
Conclusion: The results of this study suggest that G. africana could be employed for use as a 
natural antimicrobial agent in the treatment of MRSA. The results of the combination studies 
also suggest the potential use of G. africana extract and antibacterial drug combinations for the 
treatment of bacterial infections. 
4.2 Introduction 
Staphylococcus aureus causes a wide range of both hospital and community associated infections 
which include pneumonia, meningitis, bacterial arthritis, endocarditis and septicemia (Cha, Lee 
et al. 2014). In addition, S. aureus has been shown to cause severe and complex infections of the 
skin and skin-structures (Gould, David et al. 2012). Methicillin-resistant Staphylococcus aureus 
(MRSA) is a growing concern as it affects the global healthcare system. Not only is MRSA 
related to human infections, but it has been reported to be present in animals as well, thus 
increasing the risk of people being infected through zoonotic spread (Malm, Biernasiuk et al. 
2005; Defres, Marwick et al. 2009). The increase in MRSA associated infections has resulted in 
extensive use of antibiotics, particularly vancomycin (Levine 2008; Moravvej, Estaji et al. 2013). 
The extensive and inappropriate use of these antibiotics has led to the development of drug 
resistance (Usha, Jose et al. 2010).  
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It has been reported that S. aureus isolates are resistant to over 20 diverse groups of antibacterial 
drugs (Aqil, Khan et al. 2005; Maltezou and Giamarellou 2006). The advent of antibiotic 
resistant microorganisms is a worldwide problem due to the fact that drug resistance increases 
mortality rates and puts a strain on the expenditure of the healthcare system (Abd El-Kalek and 
Eman A. Mohamed 2012). The increase in drug resistance and the increased risk of 
microorganisms being resistant to newly developed antimicrobial agents has prompted the need 
to explore the use of natural products and medicinal plants as potential therapeutic agents 
(Konate, Mavoungou et al. 2012).  
Medicinal plants are used across the world for the treatment of various diseases as they possess 
numerous health beneficial compounds such as alkaloids, tannins, terpenoids and flavonoids 
(Cha, Lee et al. 2014). G. africana is a South African medicinal plant reported to have numerous 
health benefits. Studies have shown that it has been used for the treatment of various conditions 
such as skin infections, eye infections and wounds (Watt and Breyer-Brandwijk 1962). 
Evaluation of the antimycobacterial activity of G. africana revealed that it exhibited significant 
antimycobacterial activity against Mycobacterium smegmatis and Mycobacterium tuberculosis 
with MICs of 0.78 and 1.2 mg/ml, respectively (Mativandlela, Meyer et al. 2008). 
In this study, the antimicrobial activity of G. africana extract against methicillin-sensitive and 
methicillin-resistant Staphylococcus aureus isolates was assessed using the broth microdilution 
assay. The bacteriostatic and bactericidal concentrations of the extract were also determined.   
The synergistic effect of the extract and several antimicrobial agents was evaluated using the 
checkerboard assay and Sensititre susceptibility testing method.      
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4.3 Materials and Methods 
4.3.1 Bacterial cultures and growth conditions 
The bacterial cultures used for the study were S. aureus strains ATCC 25923 and ATCC 33591, 
representing methicillin-sensitive (MSSA) and -resistant (MRSA) strains, respectively. These 
were obtained from the American Type Culture Collection (ATCC). Prior to sub-culturing, the 
isolates were maintained on Müller Hinton agar (MHA) (Sigma Aldrich, USA) and checked for 
contamination throughout the experiments. The bacterial strains were sub-cultured on MHA 
plates for 18-24 h at 37ºC. The nephelometer was used in the standardization process of the 
culture suspensions. Prior to standardizing the culture suspensions, the nephelometer was 
calibrated with the 0.5 McFarland standard (which was gently mixed, by inverting the tube 
containing the standard, a couple of times). 3-5 colonies were picked to prepare a suspension in 5 
ml of de-ionized water and homogenized by vortexing. The suspension was then adjusted to 0.5 
McFarland standard which corresponded to 1-2 x 10
8
 CFU/ml. This was used for subsequent 
experiments. Cation Adjusted Müller Hinton broth (CAMHB) (Trek Diagnostics Systems, UK) 
was used in the broth microdilution assay, checkerboard assay and Sensititre susceptibility 
testing method. 
4.3.2 Preparation of G. africana and ampicillin 
In this study, two different types of G. africana extracts were incorporated to assess its effect 
against S. aureus strains. The first was a 20% (w/v) extract of air dried leaves and shoots of G. 
africana (Kraalbos) commercially prepared in 60% ethanol and then oven dried under negative 
pressure to form crystals (Brenn-O-Kem (Pty) Ltd, Wolseley, South Africa). In order to make up 
the stock solution, the dried extract was weighed out and crushed in a tube containing CAMHB 
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(TREK Diagnostics System, UK) in order to emulsify it. Once this was done, the tube was 
centrifuged and the supernatant filter sterilized into another sterile 50 ml greiner tube. This was 
appropriately labeled and stored at 4ºC for subsequent use. The second was a 20% (w/v) extract 
in 60% ethanol with a pH of about 6.9. This extract was not dried. The desired concentrations of 
both G. africana extracts were made up in CAMHB. Samples of the dried extract and neat 
ethanolic extract were sent to Cape Peninsula University of Technology (CPUT) (Bellville, 
South Africa) for analysis in order to determine their chemical composition. Once analysis was 
done, a certificate of analysis was supplied (see Appendix IV). Ampicillin was purchased from 
Sigma-Aldrich (USA) and dissolved in sterile distilled water to make the appropriate stock 
solution from which the desired concentrations were made. De-ionized water was purchased 
from TREK Diagnostics Systems, UK. 
4.3.3 MIC determination using the broth microdilution assay 
The MIC (minimum inhibitory concentration) of G. africana was determined by the broth 
microdilution method performed in sterile 96-well flat-bottom microtitre plates as outlined by the 
CLSI (CLSI 2012). Antimicrobial susceptibility testing was performed using 5 replicates for 
both MSSA (ATCC 25923) and MRSA (33591) strains. Culture suspensions adjusted to 0.5 
McFarland standard (in de-ionized water) were used in this assay. A 1:100 dilution cell 
suspension was prepared, from the 0.5 McFarland standard cell suspension, that contained a final 
number of 5 x 10
5
 bacterial cells per well. 100 µl of broth was then added to columns 2-11 (rows 
A-E) and 100 µl of the extract was added to column 2 and serially diluted (two-fold serial 
dilutions) until column 11 and 100 µl discarded from the wells in this column. Care was taken to 
ensure that no broth was added to column 12. Column 1 contained the extract at double the 
required concentration so as to obtain the desired concentration once the cell suspension was 
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added to the wells. Column 12 contained the following controls: positive control (100 µl of cell 
suspension and 100 µl of broth in 12 A&B); ampicillin control at a final concentration of 0.25 
µg/mg (100 µl of ampicillin and 100 µl of cell suspension in 12 C); de-ionized water control 
(200 µl of de-ionized water in 12 D) and a broth control (200 µl of broth in 12 E). The broth and 
de-ionized controls were included as sterility controls. 100 µl of the cell suspension was then 
added to each well except the broth and de-ionized control wells. The plates were then covered 
with a plastic film and incubated for 24 h at 37ºC and observed for microbial growth. After the 
incubation period, the MIC was determined by adding 40 µl of 0.2 mg/ml p-iodonitrotetrazolium 
chloride (INT) (Sigma-Aldrich, USA) and incubating for a further 30 min at 37ºC (Eloff 1998; 
Mativandlela, Lall et al. 2006). This was used as an indicator for microbial growth. The MIC 
was selected as the lowest concentration that did not show any bacterial growth as indicated by a 
lack of color change after the incubation period (changing of color from yellow to pink if wells 
contained viable cells and no color change if growth was inhibited). This broth microdilution 
assay was performed for both the dried and ethanolic G. africana extracts. 
4.3.4 Minimum Bactericidal Concentration (MBC) determination 
The MBC was evaluated by sub-culturing aliquots from wells whose concentrations were ≥ MIC 
(Rabe, Mullholland et al. 2002). This was determined by sub-culturing a 10 µl aliquot from each 
negative well (wells that did not produce any color change) and from a positive well (cell 
suspension control well) onto drug-free MHA. The plates were incubated for 18-24 h at 37ºC. 
The concentration that yielded no single bacterial colony on the solid medium was taken as the 
MBC (Costa, Endo et al. 2015). 
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4.3.5 Checkerboard assay 
The synergistic interaction between G. africana and ampicillin was evaluated using the 
checkerboard assay as previously described (Hsieh, Yu et al. 1993; Petersen, Labthavikul et al. 
2006), with some modifications. This assay was employed to establish the effect that 
combinations of G. africana extract and ampicillin would have on the bacterial cell growth. In 
this method, the extract-ampicillin combination effect was assessed using only the ethanolic 
extract of G. africana, as it exhibited the greatest antibacterial effect in the broth microdilution 
assay. This method allowed for the evaluation of various combinations ranging from 4 x MIC to 
     x MIC for G. africana and ampicillin. This broad range allowed for the evaluation of 
antagonism and synergism. Both G. africana and ampicillin were tested on their own, on the 
same 96-well plate, for easy comparison. Two-fold serial dilutions of ampicillin were made 
across the X-axis (Row A: 2-10) and two-fold serial dilutions of G. africana extract were made 
across the Y-axis (Column 1: B-H). Ampicillin concentrations ranged from 0.62-16 µg/ml and G. 
africana concentrations ranged from 0.39 to 25 mg/ml. Both the extract and ampicillin were 
made up at double their concentrations so as to acquire the desired concentrations once the cell 
suspensions were added to the wells. This was done in order to ensure that the appropriate 
concentration was obtained once all the components were added to the wells. For example, since 
the starting concentration for ampicillin was 16 µg/ml and that of G. africana was 25 mg/ml, the 
necessary starting concentrations were, therefore, 32 µg/ml and 50 mg/ml for ampicillin and G. 
africana, respectively. In order to carry out the checkerboard assay, two plate panels were used 
for both strains. Panel 1 was used for the extract-ampicillin combination and panel 2 was used 
for the preparation of the ampicillin dilutions.  For panel 1, 50 µl of CAMHB was added to all 
the wells except the wells in rows A (1-11) and B (1-11) and column 1 (A-H). Once the broth 
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was added, 50 µl of G. africana extract at a concentration of 100 mg/ml was then added to row C 
(2-10). Two fold serial dilutions were made, down the Y-axis, from each well in row C (2-10) 
down to row H (2-10). 50 µl was discarded from these last wells. 50 µl of the extract at a 
concentration of 100 mg/ml was the added to row B (2-10). For panel 2, 100 µl of CAMHB was 
added to wells in columns 3-10. 64 µg/ml of ampicillin was then added to column 3 (B-H) and 
two-fold serial dilutions made until column 10 (B-H). Care was taken to ensure that 100 µl of 
ampicillin was discarded from column 10 and not added to column 11 as this column contained 
the control wells. Column 2 contained only 100 µl of ampicillin (64 µg/ml) with no CAMHB 
added. This was done to make sure that the final concentration of ampicillin and G. africana in 
the combination assay would be the appropriate range. In addition, this plate layout also ensured 
that the ampicillin would be added to panel 1 (plate containing the extract) in the same way that 
it appeared in panel 2, as the wells were corresponding to each other in both plate panels. Once 
the concentration panels were established, 50 µl of ampicillin in column 2 (in panel 2) was added 
to column 2 (in panel 1), and the same applied to all the other concentrations. Once this was done, 
panel 1 now had both ampicillin and G. africana at double their desired starting concentration 
(32 µg/ml and 50 mg/ml for ampicillin and G. africana, respectively). 100 µl of bacterial cell 
suspension was then added to the wells and this resulted in starting concentrations of 16 µg/ml 
for ampicillin and 25 mg/ml for G. africana. Control wells were also included in column 11 that 
contained the following controls: positive control (cell suspension and broth only, wells A&B); 
negative control (broth only; wells C&D) and de-ionized water control (water only; wells E&F). 
Well A1 was also used as a positive control well. The plates were then covered with a plastic 
film and incubated at 37ºC for 24 h. After the incubation period, 40 µl of 0.2 mg/ml of p-
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iodonitrotetrazolium chloride (INT) was then added and the plates incubated for another 30 min 
at 37ºC.  
4.3.5.1 Calculating the Fractional Inhibitory Concentration Index (FICI) 
The FICI was used to evaluate the interaction between ampicillin and G. africana in the 
checkerboard assy. It was determined using the fractional inhibitory concentrations (FICs) of 
ampicillin and G. africana. The FIC for both ampicillin and G. africana was calculated using the 
negative wells (wells that exhibited no growth) in the growth-no-growth interface. The FIC for a 
particular drug in a given well is established by dividing the concentration of that drug in that 
well by the control MIC of the test organism to that same drug. The FIC index of a well is 
obtained by adding the FICs of each of the drugs present in the well. The FICI is calculated as 
follows:  
FIC index   FICx   FICy   
( )
(MICx)
   
 Y 
(MICy)
 
The (X) is the MIC of drug X in combination; (MICx) is the MIC of drug X alone; FICx is the 
fractional inhibitory concentration of drug X; and (Y), (MICy) and FICy are established in the 
same way for Y as they are for X  (Krogstad and Moellering 1986). The results were interpreted 
as follows: FICI ≤ 0.5 was defined as synergy, 0.5 ˂ FICI ˂ 1 as additive, 1 ˂ FICI ˂ 4 as 
indifference and antagonism as FICI ˃ 4 (Olajuyigbe and Afolayan 2013). 
4.3.6 Sensititre susceptibility testing 
The Sensititre susceptibility testing system is a type of broth microdilution method that provides 
qualitative and quantitative data as outlined by the manufacturer (TREK Diagnostic Systems, 
UK). This data establishes whether an organism is either susceptible or resistant to antimicrobial 
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drugs (qualitative data) and also provides the MIC (quantitative data) results. This method was 
performed using plates that contained different concentrations of antimicrobial agents. This 
particular assay allowed for the interpretation of results by either reading them manually 
(through visual reading of growth) or using plate readers such as the Sensititre ARIS or Sensititre 
Auto reader that rely on fluorescence. The Sensititre susceptibility system was performed 
according to the method outlined by TREK Diagnostic Systems and is normally used to select 
drugs of choice for the treatment of microbial infections. The format of the Sensititre Gram 
positive plate is shown in Figure 4.1. The Sensititre GPN3F plates (for evaluating Gram-positive 
bacteria) were used for this assay and they were obtained from TREK Diagnostics Systems (UK). 
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Figure 4.1: Sensititre Gram positive plate format. 
 
However, in this study, this method was used to analyze the effect of the combination of G. 
africana with the various antimicrobial agents contained on the plates. For this analysis, three G. 
africana concentrations were chosen and these were 3.12 mg/ml, 6.25 mg/ml and 12.50 mg/ml 
(as they showed the best antimicrobial effect). 3-5 colonies of both MSSA (ATCC 25923) and 
MRSA (ATCC 33591) were picked from primary cultures on agar plates and emulsified in 5 ml 
of de-ionized water. After being emulsified, the cell suspensions were adjusted to 0.5 McFarland 
standard using a nephelometer. According to the protocol, in order to obtain a cell suspension of 
1 x 10
5
 CFU/ml (the recommended number of cells for this method), 10 µl of the cell suspension, 
adjusted to 0.5 McFarland standard, should be added to the tube containing 11 ml of CAMHB. 
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However, since G. africana was to be added to this tube, calculations were made to ensure that 
the required final G. africana concentrations were obtained while ensuring that the appropriate 
number of cells was maintained and used. Prior to adding the cell suspension to the tube 
containing the CAMHB, G. africana was added to the tube. This was done by removing an 
appropriated volume of broth from the tube and replacing it with the same volume of the G. 
africana extract in order to have the desired G. africana concentration. For example, to have a 
final concentration of 3.12 mg/ml, 172 µl of broth was removed and replaced with 172 µl of G. 
africana extract. Once the extract was added to the broth, 10 µl of the cell suspension was 
transferred into the tube containing the extract-broth mixture using a calibrated pipette. This was 
done for all the G. africana concentrations used in this method. Plates that did not contain the 
extract were also included in order to assess the effect of the antimicrobial agents on their own 
against both MSSA (ATCC 25923) and MRSA (ATCC 33591) strains. The tubes were then 
vortexed for 15-30 s (or inverted 8-10 times) to ensure that a homogenized mixture was obtained. 
50 µl of the broth-extract suspension was then poured into a sterile seed trough and added to the 
plates using a multichannel pipette. The plates were then covered with an adhesive seal provided 
and care was taken to ensure that all wells were covered and sealed properly. The plates were 
then placed in a 37ºC incubator for 24 h. After the incubation period, the plates were read 
manually by visual reading of growth. Growth appeared as turbidity or as a deposit of cells at the 
bottom of the well. The MIC was recorded as the lowest concentration of antimicrobial agent 
alone as well as the antimicrobial-extract combination that inhibited visible growth.  
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4.4 Results  
4.4.1 Broth microdilution 
The broth microdilution method was performed using both the dried G. africana extract as well 
as the ethanolic extract. Figures 4.2 and 4.3 represent the antibacterial activity of the dried 
extract against MSSA (ATCC 25923) and MRSA (ATCC 33591), respectively. Figures 4.4 and 
4.5 represent the antibacterial activity of the ethanolic extract. Ampicillin, at a concentration of 
0.25 µg/ml, was also included as a control. The breakpoints for ampicillin, as outlined by the 
CLSI, are that if an organism is sensitive to ampicillin, then the MIC would be ≤ 0.25 µg/ml and 
if the organism was resistant to ampicillin, then the MIC would be ≥ 0.5 µg/ml. 
 
 
Figure 4.2: Broth microdilution results of MSSA treated with the dried G. africana extract 
(0.024 to 25 mg/ml). Columns 1-11 (A-E) represent the extract concentrations from highest to 
lowest. Concentrations were from highest to lowest. Column 12 contained control wells as 
follows: 12A&B: Positive control; 12C: Ampicillin control; 12D: De-ionized water control and 
12E: Broth control.  
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Figure 4.2 shows the effect of the dried G. africana extract against MSSA (ATCC 25923). The 
MIC obtained after the stipulated incubation period was 25 mg/ml. The ampicillin control 
demonstrated that MSSA was sensitive to it as there was no visible bacterial growth in the well 
(well C12). 
 
 
Figure 4.3: Broth microdilution results of MRSA treated with the dried G. africana extract 
(0.024 to 25 mg/ml). Columns 1-11 (A-E) represent the extract concentrations from highest to 
lowest. Concentrations were from highest to lowest. Column 12 contained control wells as 
follows: 12A&B: Positive control; 12C:  Ampicillin control; 12D: De-ionized water control and 
12E: Broth control.  
 
Figure 4.3 shows the effect of the dried G. africana extract against MRSA (ATCC 33591). The 
MIC obtained after the stipulated incubation period was also 25 mg/ml, revealing that G. 
africana had the same effect on both MSSA and MRSA strains. However, the ampicillin control 
demonstrated that MRSA was resistant to it as there was visible growth in the well (well C12). 
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Figure 4.4: Broth microdilution results of MSSA treated with the G. africana ethanolic extract 
(0.098 to 100 mg/ml). Columns 1-11 (A-E) represent the extract concentrations from highest to 
lowest. Column 12 contained control wells as follows: 12A&B: Positive control; 12C: 
Ampicillin control; 12D: De-ionized water control and 12E: Broth control.  
 
Figure 4.4 represents the results obtained after treating the MSSA bacterial cells with the 
ethanolic G. africana extract. It was clear to see that the antibacterial activity of the ethanolic 
extract was greater than that of the dried extract. The MIC obtained with the ethanolic extract 
was 3.12 mg/ml (which was much lower than the MIC of the dried extract). The ethanol 
concentration in these well was 0.94%, which was low and did not influence the outcome of the 
results.  
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Figure 4.5: Broth microdilution results of MRSA treated with the G. africana ethanolic extract 
(0.098 to 100 mg/ml). Columns 1-11 (A-E) represent the extract concentrations from highest to 
lowest. Column 12 contained control wells as follows: 12A&B: Positive control; 12C:  
Ampicillin control; 12D: De-ionized water control and 12E: Broth control. Concentrations were 
from highest to lowest. 
 
Figure 4.5 also represents the results obtained after the treatment of bacterial cells with the 
ethanolic G. africana extract, except in this case, the effect on MRSA (ATCC 33591) was 
evaluated. In the same way, it was clear to see that the antibacterial activity of the ethanolic 
extract was greater than that of the dried extract. The MIC obtained with the ethanolic extract 
was also 3.12 mg/ml (column 6: A-E), demonstrating that both the dried extract and ethanolic 
extract had the same effect on both bacterial strains. The ethanol concentration in these well was 
also 0.94%, which was low and did not influence the outcome of the results.  
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4.4.2 Minimum Bactericidal Concentration (MBC) determination 
This was done in order to evaluate the effect of the dried and ethanolic extracts on the bacterial 
cells. Sub-culturing the negative wells (wells with no visible growth) onto MHA enabled the 
antibacterial effect to be evaluated.   
 
Figure 4.6: Results of the MFC of MSSA and MRSA treated with the dried G. africana extract. 
A1 represents a G. africana concentration of 25 mg/ml. 
 
The results obtained in Figure 4.6 showed that the dried extract did not kill the bacterial but 
instead just inhibited their growth as seen by the presence of colonies on the MHA plates for 
both MSSA (ATCC 25923) and MRSA (ATCC 33591). This demonstrated that the dried extract 
was bacteriostatic and not bactericidal.  
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Figure 4.7: Results of the MFC of MSSA (A) and MRSA (B) treated with the G. africana 
ethanolic extract. A1-A6 represent the different G. africana concentrations as follows: A1: 100 
mg/ml; A2: 50 mg/ml; A3: 25 mg/ml; A4: 12.5 mg/ml; A5: 6.25 mg/ml and A6: 3.12 mg/ml. 
 
On the other hand, the ethanolic extract showed considerable killing potential (bactericidal 
ability) than the dried extract against both MSSA (ATCC 25923) and MRSA (ATCC 33591) 
(Figure 4.7). The MBC of the extract against MSSA (ATCC 25923) was 6.25 mg/ml while that 
of the MRSA (ATCC 33591) was 12.5 mg/ml. 
4.4.3 Checkerboard assay 
The checkerboard assay was used to assess the effect of the interaction between ampicillin and G. 
africana against MSSA (ATCC 25923) and MRSA (ATCC 33591). Since the ethanolic extract 
exhibited the greatest antibacterial activity against both strains, as seen by the lower MIC, it was 
selected to be used in this assay.  
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Figure 4.8: Checkerboard assay results of MSSA treated with the G. africana ethanolic extract 
(0.039 to 25 mg/ml) and ampicillin (0.062 to 16 µg/ml). Row A (A2-A10) represents ampicillin 
and Column 1 (B-H) represent G. africana concentrations. Concentrations were from highest to 
lowest. The remaining wells represent combinations of ampicillin and G. africana. 
 
Figure 4.8 represents the checkerboard assay results obtained after the treatment of MSSA 
(ATCC 25923) with the ethanolic extract. Column 1 (B-H) represents the G. africana ethanolic 
extract at concentrations of 25 to 0.039 mg/ml, respectively. Row A (2-10) represents ampicillin 
at concentrations of 16 to 0.062 µg/ml, respectively. The MIC of ampicillin alone was 0.12 
µg/ml and the MIC of ampicillin in the combination was 0.062 µg/ml. The MIC of G. africana 
alone was 3.12 mg/ml and the MIC in the combination was 0.39 mg/ml. Hence, the FIC index 
was calculated as follows: 
FIC index   
0.062 µg/ml
0.12 µg/ml
    
0.3  mg/ml
3.12 mg/ml
   0.52   0.12   0.64 
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Since the FICI obtained was 0.64, it meant that the interaction between ampicillin and G. 
africana was additive when tested against MSSA (ATCC 25923). 
 
Figure 4.9: Checkerboard assay results of MRSA treated with the G. africana ethanolic extract 
(0.039 to 25 mg/ml) and ampicillin (0.062 to 16 µg/ml). Row A (A2-A10) represents ampicillin 
and Column 1 (B-H) represent G. africana concentrations. Concentrations were from highest to 
lowest. The remaining wells represent combinations of ampicillin and G. africana. 
 
The plate layout of Figure 4.9 was similar to that of the MSSA (ATCC 25923). Column 1 (B-H) 
represented G. africana ethanolic extract at concentrations of 25 to 0.039 mg/ml, respectively 
and row A (2-10) represented ampicillin at concentrations of 16 to 0.062 µg/ml, respectively. 
However, the results obtained were different from those of MSSA (ATCC 25923). There was no 
MIC established for ampicillin using the range of concentrations and so for calculation sake, the 
next concentration in the sequence, 32 µg/ml, was used as the MIC of ampicillin alone. The MIC 
of ampicillin in the combination was 0.062 µg/ml. The MIC of the extract alone was 3.12 mg/ml 
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and the MIC of the extract in the combination was still 3.12 mg/ml. Hence, the FIC index was 
calculated as follows: 
FIC index   
0.062 µg/ml
32 µg/ml
    
3.12 mg/ml
3.12 mg/ml
   0.002   1   1.002 
The FICI value indicated that the interaction between ampicillin and G. africana was classified 
as indifference (meaning that the result obtained was due to the effect of the most active 
therapeutic agent, in this case G. africana).  
4.4.4 Sensititre susceptibility testing 
The effect of the interaction between ampicillin and G. africana was also assessed using this 
susceptibility testing method. It is generally used to evaluate the susceptibility of 
microorganisms to various drugs. The MIC interpretive criteria used to interpret the results 
obtained in this testing method are summarized in Table 4.1 according to the CLSI (CLSI 2012). 
Table 4.1: MIC Interpretive Criteria for Staphylococcus aureus species as outlined by the CLSI. 
                                                      MIC (µg/ml) 
Antibacterial drugs Dilution range S I R 
Erythromycin 0.25-4 ≤ 0.5 1-4 ≥ 8 
Clindamycin 0.12-2 ≤ 0.5 1-2 ≥ 4 
Quinupristin/ 
dalfopristin 
0.12-4 ≤ 1 2 ≥ 4 
Daptomycin 0.25-8 ≤ 1 ─ ─ 
Vancomycin 1-128 ≤ 2 4-8 ≥ 16 
Tetracycline 2-16 ≤ 4 8 ≥ 16 
Ampicillin 0.12-16 ≤ 0.25 ─ ≥ 0.5 
Gentamicin 2-16 ≤ 4 8 ≥ 16 
Levofloxacin 0.25-8 ≤ 1 2 ≥ 4 
Linezolid 0.5-8 ≤ 4 ─ ≥ 8 
Ceftriaxone 8-64 ≤ 8 16-32 ≥ 64 
Penicillin 0.06-8 ≤ 0.12 ─ ≥ 0.25 
Rifampicin 0.5-4 ≤ 1 2 ≥ 4 
Gatifloxacin 1-8 ≤ 0.5 1 ≥ 2 
Ciprofloxacin 0.5-2 ≤ ─ ≥ 
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Trimethoprim/ 
sulfamethoxazole 
 ≤ 2/38 
 
─ ≥ 4/76 
Oxacillin + 2% NaCl 0.25-8      ≤ 2            ─           ≥ 4 
S: Susceptible; I: intermediate and R: resistant 
Table 4.2: Results of the Sensititre susceptibility testing method for the different G. africana and 
antibiotic combinations against MSSA (ATCC 25923) and MRSA (ATCC 33591). 
                                MIC of antibacterial drug (µg/ml) 
                                                    MSSA                MRSA 
Antibacterial drugs Drugs 
alone 
Drugs 
+ GA
a 
Drugs 
+ GA
b 
Drugs 
+ GA
c 
Drugs 
alone 
Drugs 
+ GA
a
 
Drugs 
+ GA
b
 
Drugs 
+ GA
c
 
Erythromycin ≤ 0.25 ≤ 0.25 ≤ 0.25 ≤ 0.25 ˃ 4 ˃ 4 ˃ 4 = 2 
Clindamycin = 0.25 ≤ 0.12 ≤ 0.12 ≤ 0.12 > 2 > 2 = 0.5 = 0.5 
Quinupristin/ 
dalfopristin 
= 0.5 = 0.25 = 0.25 ≤ 0.12 = 1 = 0.5 = 0.5 ˃ 4 
Daptomycin ≤ 0.25 ≤ 0.25 ≤ 0.25 ≤ 0.25 = 0.5 = 1 =0.5 =0.5 
Vancomycin ≤ 1 ≤ 1 = 4 = 4 = 2 ≤ 1 = 4 = 8 
Tetracycline ≤ 2 ≤ 2 ≤ 2 ≤ 2 ˃ 16 ˃ 16 = 16 =16 
Ampicillin ≤ 0.12 ≤ 0.12 ≤ 0.12 ≤ 0.12 ˃ 16 = 4 = 4 = 2 
Gentamicin ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 ≤ 2 = 16 
Gentamicin 500 ≤ 500 ≤ 500 ≤ 500 ≥ 500 ≤ 500 ≤ 500 ≤ 500 ≥ 500 
Levofloxacin ≤ 0.25 ≤ 0.25 ≤ 0.25 ≤ 0.25 ≤ 0.25 = 0.5 = 1 = 1 
Linezolid = 2 = 2 = 2 ≤ 0.25 = 2 = 1 = 1 = 1 
Ceftriaxone ≤ 8 ≤ 8 ≤ 8 ≤ 8 ˃ 64 ˃ 64 ˃ 64 ≤ 8 
Streptomycin 1000 ≤ 1000 ≤ 1000 ≤ 1000 ≤ 1000 ≥ 1000 ≥ 1000 ≤ 1000 ≤ 1000 
Penicillin ≤ 0.06 ≤ 0.06 ≤ 0.06 = 2 ˃ 8 = 8 = 8 ˃ 8 
Rifampicin ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 = 2 = 2 
Gatifloxacin ≤ 1 ≤ 1 ≤ 1 ≤ 1 ≤ 1 ≤ 1 ˃ 8 ˃ 8 
Ciprofloxacin         
Trimethoprim/ 
sulfamethoxazole 
≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 
Oxacillin + 2% NaCl ≤ 0.25 ≤ 0.25 ≤ 0.25 ≤ 0.25 ˃ 8 ≤ 0.25 ≤ 0.25 ≤ 0.25 
GA
a
- G. africana at 3.12 mg/ml 
GA
b
- G. africana at 6.25 mg/ml 
GA
c
- G. africana at 12.5 mg/ml 
The numbers in bold represent the concentrations that exhibited a reduction in MIC compared to 
the control plates (plates that did not contain the extract). 
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Table 4.2 represents the results obtained after the treatment of MSSA (ATCC 25923) and MRSA 
(ATCC 33591) with different combinations of G. africana and antibiotics. The results showed 
that the antimicrobial agents that exhibited a decrease in their MIC, as a result of the 
combination, were clindamycin, quinupristin/dalfopristin and linezolid for MSSA (ATCC 
25923). With regard to MRSA (ATCC 33591), the antimicrobial agents that showed a decrease 
in the MIC and thus increased the susceptibility of MRSA (ATCC 33591) to these drugs, as a 
result of the combination, were clindamycin, quinupristin/dalfopristin, vancomycin, tetracycline, 
ampicillin, linezolid, ceftriaxone and oxacillin + 2% NaCl. It was easier to see the trend of a 
reduction in MIC for MRSA (ATCC 33591) as it was less susceptible to the drugs than MSSA 
(ATCC 25923) as observed by the MICs. Since MSSA (ATCC 25923) was susceptible to the 
drugs even at the lowest concentrations, a reduction in MIC could not be observed. 
4.5 Discussion 
The increase in multidrug resistant microorganisms is causing tremendous strain on the health 
care sector and is a cause of global concern (Olajuyigbe and Afolayan 2013). This multidrug 
resistance results in high death rates and causes an increase in infectious diseases that may have 
been eliminated in the past to reappear (Konate, Mavoungou et al. 2012). MRSA is resistant to a 
wide range of therapeutic agents that are commonly used in the treatment of its infections (Bachi 
and Rohrer 2002).  This increase in resistance has led to the need to explore alternative treatment 
methods to combat these drug resistant microorganisms (Barbour, Al Sharif et al. 2004). South 
African possesses a wide range of plants species that can be utilized for their health beneficial 
properties especially in the fight against drug resistant pathogens. More than 20 000 plant species 
have been identified. Medicinal plants have been used for years in the treatment of numerous 
diseases and their use as alternative therapeutic agents can be beneficial (Cherry 2005; Cha, Lee 
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et al. 2014). In this study the dried and ethanolic G. africana extracts were evaluated for their 
antibacterial activity against MSSA (ATCC 25923) and MRSA (ATCC 33591).  
The broth microdilution assay was used to determine the MIC of the two extracts against the two 
strains. The MIC of the dried extract was much higher (25 mg/ml) than that of the ethanolic 
extract (3.12 mg/ml) against both strains. This suggested that the ethanolic extract had 
significantly greater antimicrobial activity compared to the dried extract. The drying of the 
ethanolic extract could have resulted in changes in the composition of the compounds found in 
extract resulting in reduced activity. Studies evaluating the effect of aqueous and ethanolic 
extracts on bacteria such as S. aureus have also shown that the greatest inhibitory effect on 
bacteria was exhibited by ethanolic extracts. For instance, a study carried out by Mehraban et al. 
(Mehraban, Dovom et al. 2016) showed that the ethanolic extract had a greater inhibitory effect 
on the growth on the bacterial as shown by the MIC values. Another study by Behbahani  et al. 
(Behbahani, Yazdi et al. 2013) revealed that the ethanolic extract of Eucalyptus camaldulensis 
leaves were more effective against Staphylococcus aureus than the aqueous extract with MIC 
concentrations of 4 mg/ml and 8 mg/ml, respectively. Furthermore, it is suggested that plant 
extraction methods that use ethanol or Hydro alcohol extract more active compounds from plants 
compared to aqueous extraction methods. In addition, the rate at which the active compounds are 
extracted using these two solvents is higher and could contribute to the extraction of more 
compounds (Nostro, Germano et al. 2000). A study conducted by Costa and colleagues also 
showed that their ethanolic extracts were more effective than the aqueous extracts (Costa, Endo 
et al. 2015).  
For medicinal plants to be categorized as antimicrobial agents, based on susceptibility tests, they 
ought to generate an MIC in the range of 100 to 1000 mg/ml (Simoes, Bennett et al. 2009). Since 
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both the dried and ethanolic extracts produced MICs that were significantly below the stipulated 
range, they could be classified as antimicrobial agents. In order to establish whether the effect of 
treatment would be bacteriostatic or bactericidal, the MBC was determined for both extracts 
against both strains. The results revealed that the ethanolic extract was bactericidal at a 
concentration of 6.25 mg/ml for MSSA (ATCC 25923) and a concentration of 12.5 mg/ml for 
MRSA (ATCC 33951). However, the dried extract was bacteriostatic as seen by the presence of 
colonies after sub-culturing. These results were similar to those observed by Costa and 
colleagues which indicated that their extracts exhibited good bacterial activity against the S. 
aureus (ATCC 25923) strain with an MBC of 62.5 µg/ml (Costa, Endo et al. 2015). Given that 
bacteria are resistant to numerous antibiotics and the rate of resistance is also on the increase, it 
was important to assess the effect of the combination of the ethanolic extract with antimicrobial 
agents that are used in the treatment of Staphylococcal infections.  
The checkerboard assay and the Sensititre Susceptibility testing method were employed to 
evaluate the interaction between the combinations of G. africana with various antimicrobial 
agents. The FICI obtained after treating MSSA (ATCC 25923) with a combination of G. 
africana and ampicillin indicated an additive effect. This indicated that the activity of both G. 
africana and ampicillin increased as seen by the reduction in the MIC for both antimicrobial 
agents. Regarding MRSA (ATCC 33591), the FICI indicated that the result was indifference. 
This meant that the results observed were as a result of the antibacterial agent with the greatest 
effect, which was G. africana. These results are similar to those obtained by Haroun and Al-
Kayali (Haroun and Al-Kayali 2016) who demonstrated that the interactions observed between 
crude plant extracts and antibiotics were synergistic, additive and indifference against S. aureus 
with FICI ranges of 0.02 to 1.5. In addition, results of this study showed that combinations of 
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ampicillin, amikacin and cefotaxime with plant extracts had synergistic effects on the S. aureus 
strains. Another study evaluated the synergistic antimicrobial activity of Camellia sinensis and 
Juglans regia against multidrug-resistant bacteria. Results revealed that the combination of 
Juglans regia and oxacillin resulted in MRSA strains resistant to oxacillin becoming susceptible 
to oxacillin again (Farooqui, Khan et al. 2015). A study carried out by Olajuyigbe and Afolayan 
also demonstrated that there were various interactions between the plant extracts and first line 
antibiotics. These interactions included synergistic, additive/indifference and antagonistic effects 
(Olajuyigbe and Afolayan 2012).  Similar results were also seen with the Sensititre susceptibility 
testing method as observed by the reduction in the MICs of some of the antibiotics for both 
strains. Because of the advent of microorganisms that are resistant to a large numbers of 
antimicrobial agents, combination therapy has become common practice and it is advantageous 
(Rybak and McGrath 1996; Olajuyigbe and Afolayan 2012). The additive, indifference and 
synergistic interactions observed indicated that the activity of the combination of the extract and 
the antimicrobial agents were more effective than the activity of the individual antimicrobial 
agents. 
4.6 Conclusion 
The present study demonstrates the antimicrobial potential of G. africana extracts and provides 
supportive data and scientific evidence for its subsequent use for the prevention and management 
of bacterial infections. The increased activity of the various antibacterial agents combined with 
the extract demonstrate that combinations of extracts and with antibacterial drugs could be an 
effective way of treating bacterial infection including those caused by drug resistant bacteria. 
This study supplies additional information on the activity of G. africana and contributes to the 
knowledge of antimicrobial properties of plants commonly found in South Africa. However, 
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additional research such as exploring the mechanism of action and performing in vivo studies to 
corroborate the antimicrobial potential of the extract alone and in combination with antibacterial 
agents will have to be conducted. 
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5  CHAPTER 5: Antifungal activity of Galenia africana alone and 
in combination with antifungal drugs against Candida strains 
5.1 Abstract  
Background: The frequency of Candida infections have increased, in recent years, and are 
causing serious public health concern. Despite the availability of numerous antifungal drugs, 
Candida species are capable of becoming resistant to them. Hence, alternative treatment options 
are being explored, using medicinal plants, to curb this trend of drug resistance. Galenia africana 
is a South African medicinal plant that has been used in the treatment of various ailments such as 
toothaches, venereal diseases and skin infections. It has also been shown to possess antifungal 
and antimycobacterial properties. 
Objective/Purpose: The aim of this study was to evaluate the anti-Candida activity of an 
ethanolic extract of G. africana alone and combination with antifungal drugs against Candida 
albicans and Candida glabrata.   
Methods: The anti-Candida activities of the extract alone and in combination with the drugs 
were evaluated using the broth microdilution assay, checkerboard assay and the Sensititre 
YeastOne colorimetric MIC procedure. The minimum fungicidal concentration (MFC) of the 
extract was also determined. The effect of the extract on the structure of the Candida cells was 
evaluated using light and scanning electron microscopy (SEM).  
Results: The minimum inhibitory concentration (MIC) (6.25 mg/ml for both Candida strains) 
and the MFC (6.25 and 12.5 mg/ml for C. albicans and C. glabrata, respectively) indicated that 
G. africana possessed antifungal activity at relatively high concentrations. After combining with 
FLC, G. africana exerted a strong synergistic effect against C. albicans and an indifferent effect 
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against C. glabrata when interpreted by the fractional inhibitory concentration index (FICI) (0.36 
and 1.002 for C. albicans and C. glabrata, respectively). The indifferent effect with C. glabrata 
suggested that the effect depended more on the concentration and activity of G. africana. The 
MFC results confirmed the fungicidal effect of the extract and microscopic analysis revealed that 
there was cell damage including a decrease in cell size after G. africana treatment.   
Conclusion: Collectively, these results suggested that G. africana possessed antifungal activities 
against the Candida strains and a synergistic effect with FLC. Results of the Sensititre test 
showed that G. africana enhanced the activity of most of the antifungal drugs. Cell damage 
observed with SEM possibly contributed to this synergistic effect. This provides new 
information for the development of new antifungal agents using this medicinal plant. 
5.2 Introduction 
Fungal infection occurrence and frequency has been on the rise for a number of years now (Sardi, 
Scorzoni et al. 2013). In spite of the availability of treatment options, they contribute 
considerably to the high morbidity and mortality rates thus creating public health concern 
(Ibrahim, Hong et al. 2013). Candidiasis is the major cause of fungal infections especially in 
immune compromised and hospitalized individuals. It is especially common in people suffering 
from cancer, diabetes, AIDS, as well as those with severe diseases and transplant patients 
(Khatoon, Jahan et al. 2014). Candidiasis is caused by commensal fungi called Candida species 
found in the gastrointestinal tract, oral mucosal cavity, skin and vagina (Shao, Sheng et al. 2007). 
Candida species are capable of causing both superficial and systemic infections due to their 
ability to adapt to different environments. Oral candidiasis and vulvovaginal (VVC) candidiasis 
are common infections of Candida species (Yan, Hua et al. 2012; Ekanola, Ogunshe et al. 2014). 
Patients suffering from Candida infections are prone to oropharyngeal candidiasis which can 
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result in malnutrition and hinder the assimilation of therapeutic drugs (Sardi, Scorzoni et al. 
2013). This can consequently lead to treatment failure and create a global health challenge. 
Candida albicans is the leading cause of persistent and severe fungal infections (Horn, Neofytos 
et al. 2009). Even though C. albicans is the most common organism associated with severe 
Candida infections, the prevalence of infections caused by non-albicans species is on the rise 
(Sardi, Scorzoni et al. 2013). Some of the non-albicans species include Candida glabrata, 
Candida krusei, Candida tropicalis and Candida parapsilosis (Krcmery and Barnes 2002). A 
study carried out on 2019 patients in major medical centers in North America showed that a high 
proportion of infections were causes by non-albicans species. Results showed that despite C. 
albicans being the most commonly isolated species, C. glabrata was the second most isolated 
species followed by the other non-albicans species. This increase in the number of infections 
associated with non-albicans species could be attributed to severe immunosuppression, increased 
use of broad-spectrum antibiotics and an increase in the age of patients (Horn, Neofytos et al. 
2009; Panghal, Kaushal et al. 2011). These factors have also played a role in the increase and 
spread of drug resistant organisms. Antifungal drugs that are currently on the market have 
proved to be less effective in the treatment of fungal infections. This is as a result of a number of 
factors which include decreased potency, low solubility, increased toxicity leading to 
uncomfortable side effects and emergence of resistant strains (Carretto, Almeida et al. 2010). 
Over the years, it has been observed that a large number of fungal species are resistant to a 
variety of antifungal drugs. Furthermore, this trend of drug resistance has been identified 
worldwide (Ingham, Boonstra et al. 2012). Candida species have the ability to form drug-
resistant biofilms. This capability significantly contributes to their disease causing characteristic 
in humans (Rajendran, Robertson et al. 2010). Treatment of fungal infections with first-line 
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antifungal agents is proving to be futile as the organisms have become resistant to these drugs. 
This is especially seen in patients with other underlying medical conditions as well as those 
undergoing treatment with other therapeutic drugs (Ruhnke, Eigler et al. 1994; Ruhnke, 
Schmidt-Westhausen et al. 2000). The advent of fungal species resistant to frequently used 
antifungal agents and the need for treatment options with fewer side effects paves the way for the 
development of new antifungal agents (Hanif, Al-Maskari et al. 2011; Moghimipour, Sadaghi-
Nejad et al. 2014).  
Galenia africana is a medicinal plant commonly referred to as “kraalbos” (Van Wyk, De Wet et 
al. 2008). G. africana has numerous health benefits which include alleviation of toothaches, and 
treating wounds on both animals and humans (Watt and Breyer-Brandwijk 1962). It has also 
been used in the treatment of venereal disease, ringworms, relieving of eye inflammation and is 
incorporated in lotions for the treatment of skin diseases (Watt and Breyer-Brandwijk 1962). G. 
africana extracts have also demonstrated antifungal characteristics against Botrytis cinerea 
(Vries, El Bitar et al. 2005). 
In this study, the antifungal activity of G. africana was assessed using disk diffusion, broth 
microdilution, checkerboard assay and the Sensititre susceptibility testing method. The 
fungicidal and fungistatic concentrations of the ethanolic extract were also determined. 
Furthermore, the effect of the extract on the structure of the Candida cells was assessed using 
light and scanning electron microscopy. 
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5.3 Materials and Methods 
5.3.1 Preparation of the G. africana ethanolic plant extract  
The plant preparation was the same as that outlined in Chapter 2. Two types of G. africana 
extracts were used in this study. The first was a 20% (w/v) extract of air dried leaves and shoots 
of G. africana (Kraalbos) commercially prepared with 60% ethanol and then oven dried under 
negative pressure to crystals by a company called Brenn-O-Kem (Pty) Ltd (Wolseley, South 
Africa). The dried G. africana crystals were then crushed and reconstituted in RPMI 1640 
(Sigma-Aldrich, USA) media buffered with 0.165 M MOPS (Sigma-Aldrich, USA) to make a 
stock solution that was utilized in the subsequent experiments. The second was a 20% (w/v) 
extract in 60% ethanol with a pH of about 6.9. This extract was not dried and was supplied in 
liquid form. The desired concentrations of both G. africana extracts were made up in RPMI 1640 
media buffered with 0.165 M MOPS. Samples of the dried extract and neat ethanolic extract 
were sent to Cape Peninsula University of Technology (CPUT) (Bellville, South Africa) for 
analysis in order to determine their chemical composition. Once analysis was done, a certificate 
of analysis was supplied (see Appendix IV). 
5.3.2 Preparation of C. glabrata (ATCC 26512) and C. albicans (ATCC 90028)      
Suspensions and growth conditions 
Type strains of C. glabrata (ATCC 26512) and C. albicans (ATCC 90028) were a kind gift from 
Prof Charlene WJ Africa from the Microbial Endogenous Infectious Studies (MEnIS) Research 
Laboratory at the University of the Western Cape (Bellville, South Africa). Type strains were 
used in this study as they served as a good reference point for studying the effect of the extract 
on the Candia species. The Candida strains were maintained on Sabouraud Dextrose Agar (SDA) 
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(Sigma-Aldrich, USA) and checked for contamination throughout the experiments. The isolates 
were sub-cultured on to SDA and left to incubate for 24 h at 37˚C. Sterile glass test tubes, 
containing 7 ml of saline, were inoculated with colonies picked from the SDA. The inoculums 
were then adjusted to 0.5 McFarland standard with a known concentration of approximately 
3x10
8
 microorganisms per ml using a nephelometer. This is a technique used for known densities 
of microorganism suspensions for standardization (McFarland, 1907). In the broth microdilution 
assay, cell suspensions were standardized using Sabouraud Dextrose Broth (SDB) (Sigma-
Aldrich, USA) instead of sterile saline. Confirmation of the two strains was done by aseptically 
streaking the fungal strains on Oxoid chromogenic differential medium (Thermo Scientific, UK). 
On this medium, C. albicans (ATCC 90028) grew as green colonies whereas C. glabrata (ATCC 
26512) produced beige/brown or purple/mauve colonies.  
5.3.3 Disk diffusion (Kirby-Bauer) assay 
The disk diffusion assay is employed in a number of clinical microbiology laboratories for the 
susceptibility testing of antimicrobial agents. In recent times, the Clinical and Laboratory 
Standards Institute (CLSI) has published numerous standards that have been accepted and 
approved for the testing of bacteria and fungi (CLSI 2004; CLSI 2012). This method utilizes agar 
plates inoculated with an inoculum adjusted to match the turbidity of a standard (usually 0.5 
McFarland standard). This assay is more valuable compared to other methods as it is simple to 
perform, costs less than other methods, a large number of antimicrobial agents and 
microorganisms can be tested and the results are easy to interpret (Sadiki and Ibnsouda 2016). As 
a result of this, the disk diffusion assay is normally incorporated in the screening of plant extracts, 
essential oils and other drugs in order to evaluate their antimicrobial potential (Das, Tiwari et al. 
2010; Konate, Mavoungou et al. 2012). In this study, the disk diffusion assay was used to 
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evaluate the antifungal effect of G. africana extract against C. albicans (ATCC 90028) and C. 
glabrata (ATCC 26512). The extract used in this assay was prepared using crystals that were 
previously dried and then re-dissolved in 50% ethanol (Sigma-Aldrich, South Africa) to give a 
stock solution of 500 mg/ml. This solution was placed in a water bath at 37˚C to aid in dissolving 
the crystals with brief shaking in between until the crystals were completely dissolved. Sterile 
Muktell filter paper disks (9 mm) (Lasec, South Africa) were impregnated with two-fold serial 
dilution of the extract at concentrations of 3.91, 7.81, 15.63, 31.25, 62.5, 125 and 250  mg/ml. 
Control disks were also incorporated that were impregnated with 25 µg/ml fluconazole and 50% 
ethanol. The ethanol control (50%) disk was included as this was the solvent used to dissolve the 
extract. The disks were then allowed to dry at 37°C overnight before being placed on Yeast 
Nitrogen Base Glucose (YNBG) (Sigma-Aldrich, USA) agar plates. A sterile cotton swab was 
dipped into the C. albicans (ATCC 90028) and C. glabrata (ATCC 26512) inoculums (adjusted 
to 0.5 McFarland standard) and used to swab the YNBG agar plates. The disks infused with the 
extract, fluconazole and ethanol were aseptically placed on to the surface of the inoculated plates 
and left to incubate for 24 and 48 h at 37˚C. All experiments were performed in triplicate. 
Observations of antifungal sensitivity and resistance were done after 24 and 48 h of incubation 
by measuring zones of inhibition.   
5.3.4 Broth microdilution assay  
As described in Chapter 2, the broth microdilution method was used in susceptibility testing of 
antimicrobial agents as well as in the determination of the MIC. This method can be used in the 
quantitative measurement of the in vitro activity of bacteria and fungi. Cell suspensions of 
microorganisms are adjusted to 0.5 McFarland standard for use in this method. The CLSI has 
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standardized this broth microdilution method to test yeasts (CLSI 2002) and filamentous fungi 
(CLSI 2008).  
The antifungal activities of both the dried and ethanolic G. africana extracts were determined 
using the broth microdilution assay. It was performed in sterile polystyrene 96-well flat bottom 
microtitre plates according to the CLSI (CLSI 2008). Prior to conducting the assay, the cultures 
were grown on Sabouraud Glucose Agar (SGA) (Sigma-Aldrich, USA) at 37°C overnight for 18-
24 h. About 2-5 colonies were picked and homogenized in phosphate buffered saline (PBS) (Life 
Technologies, USA) and the turbidity adjusted to 0.5 McFarland standard using a nephelometer. 
A 1:100 cell suspension was prepared containing a final concentration of 1-5 x 10
3
 CFU/ml.  In 
the sterile 96-well plates, 100 µl of RPMI broth was added to columns 2-11. This was followed 
by the addition of 100 µl of the extract at a concentration of 50 mg/ml into column 2 (wells A-E) 
and serially diluted until column 11 (wells A-E). Column 1 (wells A-E) had the extract at a 
concentration of 50 mg/ml and no broth was added to the well in this column. This was done so 
as to ensure that once the cell suspensions were added, the final concentration of the extract in 
those wells would be the desired 25 mg/ml starting concentration. The concentration of the 
extract ranged from 0.024 to 25 mg/ml. Column 12 contained positive controls (100 µl cells and 
100 µl broth without extract in wells A&B), fluconazole control at a final concentration of 2 
µg/ml for C. albicans and 32 µg/ml for C. glabrata (100 µl of fluconazole and 100 µl cell 
suspension in well C), 200 µl RPMI broth control (well D) and 200 µl saline control (well E). 
The broth and saline controls were included as sterility controls. 100 µl of cell suspension was 
then added to each well except the broth and saline control wells. Each well contained a final 
volume of 200 µl and the experiments were performed in separate plates for C. glabrata (ATCC 
26512) and C. albicans (ATCC 90028). The plates were then sealed using sealing films and 
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incubated at 37°C for 24 and 48 h. After the incubation period, 40 µl of p-iodonitrotetrazolium 
chloride (INT) (a colometric agent),  at a concentration of 0.2 mg/ml, was then added to each 
well and incubated for another 30 min at 37°C. This technique relied on the ability of viable cells 
to reduce the tetrazolium salt from yellow to pink/red. The MIC was determined as the lowest 
concentration of the extract showing no color change and exhibiting complete inhibition of 
fungal growth as seen by the lack of color change from yellow to pink. 
5.3.5 MFC determination 
The MFC was determined by sub-culturing a 10 µl aliquot from each negative well (well that did 
not produce any color change) and from a positive well (cell suspension control well) onto drug-
free SGA. This was incubated for a further 18-24 h at 37ºC. The concentration that yielded no 
single bacterial colony on the solid medium was taken as the MFC (Costa, Endo et al. 2015). 
5.3.6 Checkerboard assay 
The checkerboard assay was used to assess the interaction between the ethanolic extract of G. 
africana and fluconazole as previously described (Hsieh, Yu et al. 1993; Petersen, Labthavikul et 
al. 2006), with some modifications as outlined in Chapter 2. This assay was employed to 
evaluate the effect of G. africana and fluconazole combinations against Candida cell growth. In 
this method, like in Chapter 2, the ethanolic extract of G. africana was used to assess the extract-
fluconazole combination effect. This method allowed for the evaluation of various extract-
fluconazole combinations ranging from 4 x MIC to      x MIC. This broad range enabled the 
evaluation of antagonism and synergism, as well as any other effect, to be carried out. Both G. 
africana and fluconazole were tested on their own, on the same 96-well plate, for easy 
comparison. Two-fold serial dilutions of fluconazole were made across the X-axis Row A (2-11) 
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and two-fold serial dilutions of G. africana extract were made across the Y-axis column 1 (B-H). 
Fluconazole concentrations ranged from 0.12 to 64 µg/ml and G. africana concentrations ranged 
from 0.78 to 50 mg/ml. Both the extract and fluconazole were made up at concentrations that 
were double the desired concentration to be tested. This was done in order to ensure that the 
appropriate concentrations were obtained once the cell suspensions were added to the wells. For 
example, since the starting concentration of fluconazole was 64 µg/ml and that of G. africana 
was 50 mg/ml, the necessary starting concentrations were therefore 128 µg/ml and 100 mg/ml 
for fluconazole and G. africana, respectively. In order to carry out the checkerboard assay, two 
plate panels were used for both Candida strains. Panel 1 was used for the extract-fluconazole 
combination and panel 2 was used for the preparation of the fluconazole dilutions.  In panel 1, 50 
µl of RPMI 1640 media was added to all the wells except the wells in rows A (1-A11) and B (1-
11) and column 1 (A-H). Once the broth was added, 50 µl of G. africana extract at a 
concentration of 200 mg/ml was then added to row C (2-11). Two fold serial dilutions were 
made, down the Y-axis, from each well in row C (2-11) down to row H (2-11) and 50 µl 
discarded from the last wells (to ensure that these wells only contained 50 µl of solution). Row B 
(2-11) contained 50 µl of the extract at a concentration of 200 mg/ml. This was done to ensure 
that the desired concentration was obtained once all the components were added. For panel 2, 
100 µl of RPMI 1640 media was added to wells in columns 3-11. Fluconazole at a concentration 
of 256 µg/ml was then added to column 3 and two-fold serial dilutions made until column 11. 
Care was taken to ensure that 100 µl was discarded from column 11 and not added to column 12 
as this column contained the control wells. Column 2 contained only 100 µl of fluconazole (256 
µg/ml) with no RPMI 1640 media added. This was done to make sure that the final concentration 
of fluconazole and G. africana, in the combination assay, would be the appropriate range. In 
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addition, this plate layout also ensured that the fluconazole would be added to panel 1 (plate 
containing the extract) in the same way that it appeared in panel 2 (as the wells were 
corresponding to those in panel 1). Once the concentration panels were established, 50 µl of 
fluconazole in column 2 (in panel 2) was added to column 2 (in panel 1), and the same applied to 
all the other concentrations. Once this done, panel 1 now had both fluconazole and G. africana at 
double their starting concentration (128 µg/ml and 100 mg/ml for fluconazole and G. africana, 
respectively). 100 µl of yeast cell suspension was then added to the wells (except the sterility 
control wells) and this resulted in starting concentrations of 64 µg/ml for fluconazole and 50 
mg/ml for G. africana. Control wells were also included in column 12 that contained the 
following controls: positive control (cell suspension and broth only, wells A&B); negative 
control (broth only) and de-ionized water control (water only). Well A1 was also used as a 
positive control well. All wells contained a final volume of 200 µl. The plates were then covered 
with a plastic film and incubated at 37ºC for 24 h. After the incubation period, 40 µl of 0.2 
mg/ml of p-iodonitrotetrazolium chloride (INT) was then added and the plates were then 
incubated for another 30 min at 37ºC. After the incubation period, the plates were analyzed and 
the fractional inhibitory concentration indices (FICI) were determined. 
5.3.6.1  Calculating the Fractional Inhibitory Concentration Index (FICI) 
The FICI was used to estimate the interaction between fluconazole and G. africana in the 
checkerboard assay. It was determined using the fractional inhibitory concentrations (FICs) of 
fluconazole and G. africana calculated using their MICs alone as well as in combination. The 
FICs were calculated using the negative wells (wells that exhibited no growth) in the growth-no-
growth interface. The FIC for a particular drug in a given well was established by dividing the 
concentration of that drug in that well by the control MIC of the test organism to that same drug. 
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The FIC index of a well was obtained by adding the FICs of each of the drugs present in the well. 
The FICI is calculated as follows:  
FIC index   FICx   FICy   
( )
(MICx)
  
 Y 
(MICy)
 
The (X) is the MIC of drug X in combination; (MICx) is the MIC of drug X alone; FICx is the 
fractional inhibitory concentration of drug X; and (Y), (MICy) and FICy are established in the 
same way for Y as they are for X  (Krogstad and Moellering 1986). The results were interpreted 
as follows: FICI ≤ 0.5 was defined as synergy, 0.5 ˂ FICI ˂ 1 as additive, 1 ˂ FICI ˂ 4 as 
indifference and antagonism as FICI ˃ 4 (Olajuyigbe and Afolayan 2013). 
5.3.7 Sensitire YeastOne colorimetric MIC procedure 
This testing system was conducted in order to evaluate the susceptibility of Candida species to 
various antimicrobial agents. This method relies on the same principle as the broth microdilution 
assay and offers both qualitative and quantitative analysis of the MIC. Dried plates imbedded 
with antifungal agents were used. This method is a colorimetric microdilution assay that uses a 
colorimetric indicator to indicate yeast cell growth. The plates contain antifungal agents at 
various concentrations including the colorimetric indicator. The Sensititre susceptibility test was 
performed according to the manufacturer’s instructions (TREK Diagnostics Systems, UK). 
Figure 5.1 shows the Sensititre YeastOne YO10 plate format for Candida species while Table 
5.1 shows the dilution ranges of the antifungal agents present on the Sensititre plates. The 
Sensititre YeastOne YO10 plates (for evaluating the susceptibility of yeast isolates) were 
obtained from TREK Diagnostic Systems (UK). 
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Figure 5.1: Sensititre YO10 plate format for Candida species. 
Table 5.1: Dilution ranges of antifungal agents in the Sensititre YO10 plate. 
Antifungal Agent Dilution Range µg/ml 
Amphotericin B 0.12 - 8 
5-Flucytosine 0.06 - 64 
Anidulafungin 0.015 - 8 
Caspofungin 0.008 - 8 
Micafungin 0.008 - 8  
Fluconazole 0.12 - 256 
Itraconazole 0.015 - 16 
Posaconazole 0.008 - 8  
Voriconazole 0.008 - 8  
 
Before conducting the test, the broths were allowed to come to room temperature. The 
manufacturer recommended a final organism density of approximately 1.5-8 x 10
3
 CFU/ml. 
Several well-isolated colonies were picked from a pure 24 h culture (colonies were ˃ 1 mm in 
diameter) of the yeast isolates and emulsified in sterile PBS. The suspension was then vortex to 
mix the contents for approximately 15 s to ensure that a uniform suspension was obtained. Any 
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clumps present were allowed to settle prior to adjusting the density. The density of the 
suspension was adjusted to 0.5 McFarland standard using a nephelometer. Before adding the 
adjusted cell suspension to the broth, G. africana was added. Calculations were made to ensure 
that G. africana would be at the desired final concentration but without affecting the 
recommended final organism density. The concentrations of G. africana used in this 
susceptibility test were 6.25 (the MIC) and 12.5 (2 x MIC) mg/ml. The desired concentrations 
were obtained by removing a specific amount of broth from the tube and replacing it with the 
same volume of the extract. For example, in order to have a final extract concentration of 6.25 
mg/ml, 344.4 µl of broth was removed from the tube and 344.4 µl of a G. africana ethanolic 
extract, at a concentration of 200 mg/ml, was added to that tube. This was done to make sure that 
the final volume in the tube was 11 ml and the final extract concentration was the desired one 
(either 6.25 or 12.5 mg/ml). Once this was done, 20 µl of the cell suspension was added to the 11 
ml broth-extract solution to give an inoculum concentration of 1.5-8 x 10
3
 CFU/ml. Control 
plates without the extract were also included. Care was taken to ensure that this was completed 
within 15 min. 100 µl was then transferred to the Sensititre plates (TREK Diagnostic Systems, 
UK) using a multichannel pipette. Following this step, the plates were sealed with the adhesive 
seal supplied. The plates were then incubated for 24 h at 37ºC. The plates were read manually by 
visually reading them under normal laboratory lighting. Yeast growth in the antifungal solutions 
was represented by a change in the colorimetric growth indicator from blue (negative) to red 
(positive). The manufacturer noted that some yeasts may show a purpling color as opposed to a 
completely red color. In addition, the manufacturer also explained that certain organisms may 
show purpling in wells containing posaconazole, voriconazole, fluconazole, itraconazole and 
ketoconazole. Furthermore, the manufacturer also recommended that the positive control wells 
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be examined after a 24 h incubation period especially when dealing with Candida species. They 
suggested that if the growth in the positive control wells was red, then antifungal endpoints could 
be interpreted. However, if the wells were still blue or purple, then the plates were to be re-
incubated for an extra 24 h and re-examined. The MIC was recorded as the lowest concentration 
of antifungal agent inhibiting yeast growth as evident by the lack of development of a red or 
purple color in the growth well i.e. from a blue color. The intensity of color produced was 
compared to that of the positive control wells. 
5.3.8 Microscopic analysis  
5.3.8.1 Light Microscopy 
 Light microscopy was performed in order to assess the effect of the extract on the structure of 
the Candida strains after treatment. This was done after the yeast cells were exposed to the 
extract in the disk diffusion assay. Once the plates were incubated, macro-colonies (colonies 
outside the inhibition zone area) and micro-colonies (colonies from within the inhibition zone 
area) were picked and placed on slides. This was done for both Candida strains. The slides were 
then stained with 10% Lactophenol Cotton Blue (LCB) and viewed under 1000 X magnification. 
This was done in order to observe any morphological changes that may have been caused by the 
G. africana extract.  
5.3.8.2 Scanning Electron Microscopy (SEM) 
Scanning electron microscopy (SEM) was used to evaluate the effect of the extract on the 
Candida cells. SEM was performed on yeast cells treated with the extract in the disk diffusion 
assay. Specimens were fixed onto a glass cover slip using 2.5% gluteraldehyde in phosphate 
buffer saline (PBS) for 1 h. The cover slip was then washed twice with PBS and twice with 
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sterile distilled water in 5 min cycles. Samples were then dehydrated in graded concentrations of 
ethanol (50, 70, 90 and 100%) in 10 min cycles. After the dehydration process, samples were 
then removed from the 100% ethanol and placed into the critical point dryer (CPD) or air dried 
in order to remove any remnants of ethanol. Once all samples were dried, they were then sputter-
coated with gold-palladium alloy and analyzed using the scanning electron microscope (X650 
SEM). 
5.4 RESULTS 
5.4.1 Identification of Candida species  
C. albicans (ATCC 90028) and C. glabrata (ATCC 26512) were identified using an oxoid 
chromogenic differential medium plate where C. albicans appeared as green colonies and C. 
glabrata appeared as beige/brown or purple/mauve colonies. Figure 5.2 represents the results 
obtained after the Candida species were streaked onto the oxoid chromogenic differential 
medium plate and incubated. 
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Figure 5.2: Identification of Candida species using Oxoid chromogenic differential medium 
plate. Candida albicans appear as green colonies and Candida glabrata appear as beige/brown or 
purple/mauve colonies. 
 
5.4.2 Disk diffusion assay 
The disk diffusion assay was utilized to investigate the antifungal activity of G. africana against 
C. albicans (ATCC 90028) and C. glabrata (ATCC 26512). The dried G. africana extract was 
dissolved in 50% ethanol to make up a 500 mg/ml stock solution. The results of the disk 
diffusion assay evaluating the effect of G. africana against the Candida strains are shown in 
Figures 5.3 and 5.4. 
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Figure 5.3: Inhibition zones of C. albicans treated with G. africana extract (3.91 to 250 mg/ml). 
The letters represent the following concentrations: A: 250 mg/ml; B: 125 mg/ml; C: 62.5 mg/ml; 
D: 31.25 mg/ml; E: 15.62 mg/ml; F: 7.81 mg/ml and G: 3.91 mg/ml. 
 
Figure 5.3 shows small zones of inhibition, with the presence of micro-colonies, at 
concentrations of 15.6 to 250 mg/ml against C. albicans (ATCC 90028). G. africana 
concentrations of 7.8 and 3.9 mg/ml did not produce any visible zones of inhibition. The zones 
produced after treatment of C. glabrata (ATCC 26512) with G. africana were small and 
contained micro-colonies at concentrations of 31.25 to 250 mg/ml. The zone of inhibition 
produced after treatment with 15.62 mg/ml of G. africana was not well defined but micro-
colonies were present. Concentrations of 7.8 and 3.91 mg/ml did not produce any visible 
inhibition zones (Figure 5.4). 
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Figure 5.4: Inhibition zones of C. glabrata treated with G. africana extract (3.91 to 250 mg/ml). 
The letters represent the following concentrations: A: 250 mg/ml; B: 125 mg/ml; C: 62.5 mg/ml; 
D: 31.25 mg/ml; E: 15.62 mg/ml; F: 7.81 mg/ml and G: 3.91 mg/ml. 
 
Control plates were also included that contained 50% ethanol and fluconazole (25 µg/ml). The 
control results are represented in Figures 5.5 and 5.6 for ethanol and fluconazole, respectively. 
There were no zones of inhibition present after exposure of both Candida strains to 50% ethanol. 
Treatment of the Candida species with fluconazole yielded an inhibition zone of 18 mm against 
C. albicans (ATCC 90028), with the presence of micro-colonies. However, there was only a 
small zone of inhibition produced when treated against C. glabrata (ATCC 26512). 
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Figure 5.5: Treatment of C. albicans (A) and C. glabrata (B) with 50% ethanol. No zones of 
inhibition present for both Candida species. 
 
 
 
Figure 5.6: Treatment of C. albicans (A) and C. glabrata (B) with fluconazole (25 µg/ml). 
Fluconazole produced an inhibition zone of 18 mm with the presence of micro-colonies against 
C. albicans whereas there was only a small inhibition zone present when treated against C. 
glabrata. 
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5.4.3 Broth microdilution 
The broth microdilution assay was used to evaluate the effect of both the dried and ethanolic G. 
africana extracts. The MIC of the dried G. africana extract against C. albicans (ATCC 90028) 
was 3.91 mg/ml (Figure 5.7) while the MIC of the dried extract against C. glabrata (ATCC 
26512) was 1.95 mg/ml (Figure 5.8). The ethanolic extract produced an MIC of 6.25 mg/ml 
against both C. albicans (ATCC 90028) and C. glabrata (ATCC 26512) (Figures 5.9 and 5.10, 
respectively) 
 
Figure 5.7: Broth microdilution results of C. albicans treated with the dried G. africana extract 
(0.015 to 15.63). Concentrations ranged from highest to lowest (columns 1-11, respectively). 
Column 12 contained control wells as follows: 12A&B: Positive control; 12C: Fluconazole 
control; 12D: Saline control and 12E: Broth control. 
 
 
 
 
 
 
 
  Chapter 5Antifungal studies 
226 
 
 
Figure 5.8: Broth microdilution results of C. glabrata treated with the dried G. africana extract 
(0.015 to 15.63). Concentrations ranged from highest to lowest (columns 1-11, respectively). 
Column 12 contained control wells as follows: 12A&B: Positive control; 12C: Fluconazole 
control; 12D: Saline control and 12E: Broth control. 
 
 
Figure 5.9: Broth microdilution results of C. albicans treated with G. africana ethanolic extract 
(0.024 to 25 mg/ml). Concentrations ranged from highest to lowest (columns 1-11, respectively). 
Column 12 contained the following control wells: 12A&B: Positive control; 12C: Fluconazole 
control; 12D: Broth control and 12E: Saline control. 
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Figure 5.10: Broth microdilution results of C. glabrata treated with G. africana ethanolic extract 
(0.024 to 25 mg/ml). Concentrations ranged from highest to lowest (columns 1-11, respectively). 
Column 12 contained the following control wells: 12A&B: Positive control; 12C: Fluconazole 
control; 12D: Broth control and 12E: Saline control. 
 
5.4.4 Minimum fungicidal concentration (MFC) 
The MFCs of the dried and ethanolic extracts were evaluated in order to establish whether G. 
africana was fungistatic or fungicidal. Figure 5.11 shows the results obtained after sub-culturing 
aliquots from the negative wells (wells with no growth) in the microdilution assay onto SGA. 
The results revealed that the dried G. africana extract was fungistatic at all the concentrations 
(even the highest one used) as demonstrated by the presence of growth on the SGA plates. 
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Figure 5.11: MFC results of C. albicans (A) and C. glabrata (B) treated with the dried G. 
africana extract (1.95 to 15.63 mg/ml). A1-A4 represents the different G. africana 
concentrations as follows: A1: 15.63 mg/ml; A2: 7.81 mg/ml; A3: 3.91 mg/ml and A4: 1.95 
mg/ml. 
 
The results obtained after sub-culturing the aliquot from the negative wells treated with the 
ethanolic extract are shown in Figure 5.12.  The MFC of the ethanolic extract against C. albicans 
was 6.25 mg/ml and that of ethanolic extract against C. glabrata was 12.5 mg/ml. This showed 
that the MIC=MFC=6.25 mg/ml for C. albiacans whereas the MIC=6.25 mg/ml and MFC=12.5 
mg/ml for C. glabrata.  
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Figure 5.12: MFC results of C. albicans (A) and C. glabrata (B) treated with the G. africana 
ethanolic extract (3.12 to 25 mg/ml). A1-A4 represent the different G. africana concentrations as 
follows: A1: 25 mg/ml; A2: 12.5 mg/ml; A3: 6.25 mg/ml and A4: 3.12 mg/ml. 
 
The MFC results demonstrated that the ethanolic extract exhibited greater antifungal activity 
compared to the dried extract. The ethanolic extract was fungicidal at concentrations of 6.25 and 
12.5 mg/ml for C. albicans (ATCC 90028) and C. glabrata (ATCC 26512) respectively. The 
dried extract was fungistatic and not fungicidal even at a concentration of 15.63 mg/ml (the 
highest concentration used). It is for this reason that the ethanolic extract was used in the 
checkerboard assay and Sensititre susceptibility testing method in order to assess the 
combination effects of the extract and antifungal agents. 
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5.4.5 Checkerboard assay 
The checkerboard assay was used to evaluate the effect of the extract-fluconazole combination 
on the Candida species. The effect of the combination of fluconazole and G. africana against C. 
albicans is shown in Figure 5.13. The plate layout was similar for both C. albicans (ATCC 
90028) and C. glabrata (ATCC 26512). Row A (2-11) represented concentrations of fluconazole 
ranging from 64 to 0.125 µg/ml, respectively and Column 1 (B-H) represented G. africana 
concentrations ranging from 50 to 0.78 mg/ml, respectively. In order to calculate the FICI, the 
following parameters were needed: MIC of either fluconazole or G. africana alone as well as the 
MICs of both fluconazole and G. africana in combination for both Candida species. The MIC of 
fluconazole alone was 0.5 µg/ml and the MIC in combination was 0.125 µg/ml against C. 
albicans (ATCC 90028). The MIC of G. africana alone was 6.25 mg/ml and the MIC in 
combination was 0.78 mg/ml. With these parameters, the FICI was calculated as follows: 
FICI   
0.12 µg/ml
0.5 µg/ml
   
0.78 mg/ml
6.25 mg/ml
   0.24   0.12   0.36 
The FICI value obtained was 0.36 which indicated that the interaction between fluconazole and 
G. africana against C. albicans (ATCC 90028) was synergistic since the value was < 0.5. 
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Figure 5.13: Checkerboard assay results of C. albicans treated with the G. africana ethanolic 
extract (0.78-50 mg/ml) and fluconazole (0.012-64 µg/ml). Row A (2-11) represents fluconazole 
and Column 1 (B-H) represents G. africana. The other wells represent various combinations of 
fluconazole and G. africana. 
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Figure 5.14: Checkerboard assay results of C. glabrata treated with the G. africana ethanolic 
extract (0.78-50 mg/ml) and fluconazole (0.012-64 µg/ml). Row A (2-11) represents fluconazole 
and Column 1 (B-H) represents G. africana. The other wells represent various combinations of 
fluconazole and G. africana. 
 
Figure 5.14 shows the results obtained after treating C. glabrata (ATCC 26512) with the extract-
fluconazole combinations. The results of the checkerboard assay revealed the following: the MIC 
of fluconazole alone was 64 µg/ml and the MIC in combination was 0.12 µg/ml. The MIC of G. 
africana alone and in combination was 6.25 mg/ml. Therefore, the FICI was calculated as 
follows:  
FICI   
0.12 µg/ml
64 µg/ml
   
6.25 mg/ml
6.25 mg/ml
   0.002   1   1.002 
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Since the FICI value obtained was 1.002, which was 1 ˂ FICI ˂ 4, the interaction was classified 
as being indifference. This meant that the interaction observed was as a result of the G. africana 
extract that had the greatest antifungal activity compared to fluconazole. 
5.4.6 Sensititre YeastOne colorimetric MIC procedure 
The Sensititre susceptibility test was used to evaluate the interaction between combinations of 
antifungal agents and G. africana against C. albicans (ATCC 90028) and C. glabrata (ATCC 
26512).  In this method, two G. africana concentrations (6.25 and 12.5 mg/ml) were combined 
with varying concentrations of different antifungal agents. Plates without the extract were also 
incorporated as controls in order to assess the effect of the individual drugs on the Candida 
species. Table 5.2 represents the MIC interpretive criteria as outlined by the CLSI.  
Table 5.2: MIC Interpretive Criteria (µg/ml) for Candida species. 
                                                              MIC (µg/ml) 
              C. albicans              C. glabrata References 
Antifungal 
drug 
S I R S I R  
Anidulafungin ≤0.25 0.5 ≥1 ≤0.12 0.25 ≥0.5 (Pfaller, Messer et al. 
2013b) 
Caspofungin ≤0.25 0.5 ≥1 ≤0.12 0.25 ≥0.5 (Pfaller, Messer et al. 
2013b) 
Micafungin ≤0.25 0.5 ≥1 ≤0.06 0.12 ≥0.25 (Pfaller, Messer et al. 
2013b) 
Itraconazole ≤0.12 0.25-
0.5 
≥1 ≤2  >2 (Pfaller and Diekema 
2012a) 
Fluconazole ≤2 4 ≥8  ≤32 ≥64 (Pfaller, Diekema et al. 
2013a) 
Posaconazole ≤0.06  >0.06 ≤2  >2 (Pfaller and Diekema 
2012a) 
Voriconazole ≤0.12 0.25-
0.5 
≥1 ≤0.5  >0.5 (Pfaller, Diekema et al. 
2013a) 
5-Flucytosine ≤4 8-16 ≥32 ≤4 8-16 ≥32 (Pfaller, Espinel-Ingroff 
et al. 2012b) 
Amphotericin <1  ≥1 <1  ≥1 (Pfaller, Espinel-Ingroff 
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B et al. 2012b) 
S: susceptible; I: intermediate; R: resistant 
 
The interpretation of possible test results that may be observed after the treatment of Candida 
species with various antifungal agents are summarized in Table 5.3 as outlined by the 
manufacturer. 
 
Table 5.3: Illustration and interpretation of Sensititre susceptibility test results that may occur. 
           Well Concentration (µg/ml) 
Result 1 2 4 8 16 32 R= Red: Positive growth indicator 
B= Blue: Negative growth indicator 
A R R R B B B Typical growth pattern; MIC endpoint is 8 µg/ml  
B R R R R R R Growth in all wells; MIC endpoint is ˃ 32 µg/ml 
C B B B B B B No growth in any well; MIC endpoint is ≤ 1 µg/ml 
D R R R B R R “Skipped well”. MIC endpoint is ! 32 µg/ml. Disregard “skip” when 
wells on either have growth. If more than one “skip” should occur in 
a column, the test results are invalidated 
E R R B B R R Double “skipped well”. The test should be repeated 
 
Table 5.4: Sensititre susceptibility test results of C. albicans and C. glabrata treated with G. 
africana (6.25 and 12.5 mg/ml). 
                           MIC of antifungal drug (µg/ml) 
  C. albicans    C. glabrata  
Antifungal 
agent 
No 
Extract 
Drugs + 
GA
a 
Drugs + 
GA
b
 
No Extract Drugs +  
GA
a
 
Drugs + 
GA
b
 
5-Flucytosine = 0.5 ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 ≤ 0.06 
Amphotericin B = 0.5 ≤ 0.12 ≤ 0.12 = 2 ≤ 0.12 ≤ 0.12 
Anidulafungin ≤ 0.015 ≤ 0.015 ≤ 0.015 = 0.06 ≤ 0.015 ≤ 0.015 
Caspofungin = 0.03 ≤ 0.008 ≤ 0.008 = 0.12 ≤ 0.008 ≤ 0.008 
Fluconazole = 0.25 ≤ 0.12 ≤ 0.12 = 16 ≤ 0.12 ≤ 0.12 
Itraconazole ≤ 0.015 ≤ 0.015 ≤ 0.015 = 0.5 ≤ 0.015 ≤ 0.015 
Micafungin ≤ 0.008 ≤ 0.008 ≤ 0.008 = 0.015 ≤ 0.008 ≤ 0.008 
Posaconazole ≤ 0.008 ≤ 0.008 ≤ 0.008 = 1 ≤ 0.008 ≤ 0.008 
Voriconazole ≤ 0.008 ≤ 0.008 ≤ 0.008 = 0.5 ≤ 0.008 ≤ 0.008 
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a 
GA- G. africana at 6.25 mg/ml. 
b 
GA- G. africana at 12.5 mg/ml
 
Values in bold represent changes in MIC observed after addition of the extract 
 
Table 5.4 represents the results obtained after the treatment of C. albicans (ATCC 90028) and C. 
glabrata (ATCC 26512) with antifungal agents alone as well as treatment with extract-antifungal 
agent combinations. The results revealed that G. africana enhanced the antifungal activity of 
most of the antifungal agents as seen by a decrease in the antifungal MIC against the Candida 
species. G. africana enhanced the antifungal activity of 5-flucytosine, amphotericin B, 
caspofungin and fluconazole against C. albicans (ATCC 90028). In addition, G. africana 
enhanced the antifungal activities of amphotericin B, anidulafungin, caspofungin, fluconazole, 
itraconazolem micafungin, posaconazole and voriconazole against C. glabrata. This was 
significant as the MIC of fluconazole alone against C. glabrata (ATCC 26512) in the 
microdilution assay, checkerboard assay and Sensititre susceptibility test was ≥16 µg/ml, but 
reduced significantly in the combination assays. 
5.4.7 Microscopic analysis 
5.4.7.1 Light microscopy 
Light microscopy was carried out in order to examine the effect of the extract on the structure of 
the yeast cells. Figure 5.15 shows the appearance of the untreated cells obtained from colonies 
outside the zones of inhibition (macro-colonies) and stained with 10% LCB stain. Cells appeared 
large, had an intact morphology without any disruption to the structure.  
 
 
 
 
 
  Chapter 5Antifungal studies 
236 
 
 
Figure 5.15: Light microscopic images of untreated C. albicans (A) and C. glabrata (B) cells. 
Cells were obtained from macro-colonies stained 10% LCB stain. Magnification was 1000 X and 
slides were viewed under oil immersion. 
 
Figure 5.16 shows the result obtained after the cells were treated with G. africana at a 
concentration of 250 mg/ml. The cells were collected from micro-colonies and stained with 10% 
LCB. The cells appeared smaller and fewer in number compared to the untreated cells.  
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Figure 5.16: Light microscopic image of Candida cells. Cells were obtained from micro-
colonies after treatment with G. africana concentration (250 mg/ml) and stained with 10% LCB 
and viewed at 1000 X magnification. Cells appear smaller and less in number compared to the 
untreated cells. 
 
5.4.7.2 Scanning Electron Microscopy (SEM) 
Scanning electron microscopy was also employed to examine the structural changes of Candida 
cells after treatment with the extract. Figure 5.17 shows the appearance of the Candida cells 
prior to treatment. The cells appeared rounded with smooth surfaces. Figures 5.18 and 5.19 
represent scanning electron micrographs of C. albicans (ATCC 90028) and C. glabrata (ATCC 
26512) cells after treatment with G. africana at a concentration of 250 mg/ml, respectively. The 
structure of both Candida cells appeared distorted and only remnants of other cells could be seen. 
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Figure 5.17: Scanning electron micrograph of untreated C. albicans (A) and C. glabrata (B) at a 
magnification of 10 000 X. Cells are rounded and smooth with signs of budding.  
 
 
Figure 5.18: Scanning electron micrograph of C. albicans treated with G. africana extract (250 
mg/ml). Cells were viewed at a magnification of 5 000 X (A) and 10 000 X (B). Cells appeared 
desiccated and craggy after treatment. The structural appearance was rough compared to the 
untreated cells. 
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Figure 5.19: Scanning electron micrograph of C. glabrata treated with G. africana extract (250 
mg/ml). Cells were viewed at a magnification of 5 000 X (A) and 10 000 X (B). Some cells 
appeared distorted while only remnants of other cells could be seen. The structural appearance of 
the cells was rough compared to the untreated cells. 
 
5.5 Discussion 
The appearance of Candida species that are resistant to a number of antifungal agents is as a 
result of the rise in the use these antifungal agents (Pemmaraju, Pruthi et al. 2013). An example 
of an infection caused by Candida species, particularly C. albicans, is oral candidiasis. This 
infection is normally associated with HIV-positive patients as a result of their weakened immune 
system. In addition, oral candidiasis can result in high mortality rates (Pomarico, de Souza et al. 
2010; Abrantes, McArthur et al. 2014). Treatment of candidiasis is usually achieved by the 
administration of amphotericin B and fluconazole with fluconazole frequently being given as the 
first line of treatment when dealing with systemic infections. Unfortunately, Candida strains are 
developing resistance to fluconazole (Abrantes, McArthur et al. 2014). The rise in multi-drug 
resistant organisms prompted health institutions to propose the use of combination therapy in an 
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effort to avoid these organisms from developing resistance and increase the effectiveness of the 
drugs against infectious agents (Sukandar, Kurniati et al. 2016). Medicinal plants possess 
numerous health beneficial compounds that can be used in the development of new antimicrobial 
agents (Sukandar, Kurniati et al. 2016). In this, study, the antifungal activities and synergistic 
effects of G. africana and fluconazole were evaluated using the disk diffusion, broth 
microdilution and checkerboard assay. Fluconazole was selected because it is extensively used in 
the treatment of fungal infections as a result of its high bioavailability and low toxicity (Kohli, 
Smriti Mukhopadhyay et al. 2002). The Sensititre susceptibility testing method was used to 
evaluate the effect of combinations of the ethanolic extract with a selection of antifungal drugs. 
The effect of the G. africana extract on the structure of the Candida cells was assessed using 
light microscopy and scanning electron microscopy.  
The results of the disk diffusion assay showed that the G. africana extract was not as effective in 
inhibiting the growth of the Candida strains, even at a concentration of 250 mg/ml, as seen by 
the lack of large inhibition zones. This lack of inhibitory activity could be attributed to the fact 
that natural plant products tend to diffuse out the disks much slower than conventional 
antimicrobial agents (Klancnik, Piskernik et al. 2010). In addition, polarity also influences the 
rate of diffusion of a compound with more polar compounds diffusing out of the disk faster than 
less polar compounds (Moreno, Scheyer et al. 2006). The results of the broth dilution assay 
revealed that the dried G. africana was more effective than the ethanolic as seen by the lower 
MIC against the Candida strains. The MIC of the dried extract against C. albicans (ATCC 90028) 
was 3.91 mg/ml while that of the ethanolic extract was 6.25 mg/ml. The MIC of the dried extract 
against C. glabrata (ATCC 26512) was 1.95 mg/ml while that of the ethanolic extract was 6.25 
mg/ml. A number of studies have been carried to evaluate the antifungal potential of medicinal 
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plants (Isa, Awouafack et al. 2014; Goncalves, Piras et al. 2015; Sharifzadeh, Khosravi et al. 
2015). For instance, a study conducted to assess the anticandidal activity of Ecballium elaterium 
fruit extracts and bifonazole against C. albicans isolates revealed that the fruit extracts exhibited 
good anticandidal activity with MIC values that ranged from 0.048 to 6.25 mg/ml (Adwan, 
Salameh et al. 2011). Another study carried out by Martins et al. (Martins, Barros et al. 2015) 
evaluated the antifungal activity of ten plant extracts, frequently used in traditional medicine, 
against nineteen Candida strains. Results showed that two hydro methanolic extracts of Juglans 
regia and Eucalyptus globulus leaves demonstrated good antifungal activity against all the 
Candida strains tested.  
The MFCs were determined for both the dried and ethanolic extracts. The dried extract was 
fungistatic, and this was shown by the presence of colonies when sub-cultured on SGA at even 
the highest concentration (15.63 mg/ml). On the other hand, the ethanolic extract was fungicidal 
at concentrations of 6.25 and 12.5 mg/ml for C. albicans (ATCC 90028) and C. glabrata (ATCC 
26512), respectively. This result showed that the ethanolic extract had a greater ability to kill the 
yeast cells compared to the dried extract. The drying process of the extract could have had an 
effect on the activity of some of the compounds found in the extract resulting in reduced activity. 
It was for this reason that the ethanolic extract was used in the checkerboard assay and Sensititre 
susceptibility test. A study carried out by Avijgan et al. (Avijgan, Mahboubi et al. 2014) 
evaluated the synergistic anticandidal activity of Echinophora platyloba DC ethanolic extract 
against 27 C. albicans clinical isolated. The results indicated MIC values of 3.1 to 6.25 mg/ml 
and MFC values of 6.2 to 12.5 mg/ml. The significant antifungal effect of the ethanolic extract 
compared to extracts prepared from other solvents can also be seen with other medicinal plants. 
A study carried out on ethanolic and methanolic leaf extracts of Pogostemon parviflorus Benth. 
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revealed that the ethanolic extract had greater antifungal activity compared to the methanolic 
extract. This could be seen from the mean MICs of the ethanolic extract against Candida species, 
such as C. albicans and C. glabrata, of 5.7 mg/ml compared to that of 6.6 mg/ml of the 
methanolic extract (Najafi and Sadeghi-Nejad 2011).  
The checkerboard assay results showed that the interaction between G. africana and fluconazole 
against C. albicans (ATCC 90028) was synergistic as evident by the FICI of 0.36 which was < 
0.5. A number of studies evaluating the synergistic effects of medicinal plants and antifungal 
drugs, such a fluconazole, have been conducted. For example, a study carried out on glabridin (a 
compound found in Glycyrrhiza glabra) against Canadida species, such as drug-resistant C. 
albicans, revealed that the combination of fluconazole and glabridin demonstrated synergistic 
effects (Liu, Li et al. 2014). Another study evaluating the antimicrobial interaction of ethanolic 
extracts of Zingiber officinale var rubrum rhizome, Boesenbergia pandurata rhizome and Stevia 
rebaudiana leaves with certain antibiotics against infectious mouth microbes revealed that the 
combination of all the plant extracts with ketoconazole showed a synergistic effect against C. 
albicans (Sukandar, Kurniati et al. 2016). A study conducted by Costa and colleagues also 
demonstrated that the combination of plant extracts with antifungal agents such as fluconazole 
and nystatin exhibited synergistic effects against C. albicans with FICI of less than 0.5 (Costa, 
Endo et al. 2015). A study focusing on the evaluation of the combination of berberine (an 
alkaloid used in traditional Chinese medicine) and fluconazole against fluconazole-resistant C. 
albicans also showed a synergistic effect (Li, Xu et al. 2013). In the present study, the interaction 
of G. africana and fluconazole against C. glabrata (ATCC 26512) was indifference as seen by 
the FICI value of 1.002. This result was similar to a study conducted to investigate the 
interaction between ferulic acid and caspofungin against Candida albicans and Candida glabrata 
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that showed that there was a synergistic effect against C. albicans (FICI of < 0.5). However, the 
interaction was not synergistic against C. glabrata (FICI of > 0.5) (Canturk 2017). The Sensititre 
susceptibility test showed that the combination of G. africana and the antifungal agents was 
more effective against the Candida strains than the antifungal agents on their own. This could be 
seen in the reduction of the MIC of most of the antifungal agents for both C. albicans (ATCC 
90028) and C. glabrata (ATCC 26512). This was an important result because C. glabrata 
(ATCC 26512) was showing less susceptibility to the antifungal agents compared to C. albicans 
(ATCC 90028).  
The microscopic analysis revealed that G. africana had an effect on the yeast cells. This could be 
seen by the distorted structure of the cells and the cell remnants that were present after treatment. 
These results were seen despite G. africana not showing much antifungal activity against the 
Candida strains in the disk diffusion assay. The results observed after microscopic analysis of 
yeast cells following treatment with G. africana are similar to those obtained after treatment of C. 
albicans with Euphorbia hirta L. leaf extract. Transmission electron micrographs taken after 
treatment of C. albicans with the E. hirta leaf extract revealed significant alterations to the 
microstructure of the C. albicans cells. These alterations included changes in the morphology of 
the cells, lysis and total disintegration of the cells after 36 h of exposure to the extract. The 
control cells, on the other hand, demonstrated the usual Candida morphology with a regular 
undamaged cell wall (Basma, Zuraini et al. 2011). 
5.6 Conclusion 
The results obtained in this study indicate that G. africana is a potential source of new antifungal 
agents. The results revealed that G. africana enhanced the antifungal activities of fluconazole 
 
 
 
 
  Chapter 5Antifungal studies 
244 
 
and other antifungal agents in both the checkerboard assay and the Sensitire susceptibility test as 
seen by the reduction of the MICs. The ethanolic G. africana extract also demonstrated 
fungicidal effects against the Candida strains. The fungicidal effects as well as the synergistic 
effects exhibited by the G. africana extract support the growing need for the use of medicinal 
plant extracts as therapeutic agents in the fight against multi-drug resistant pathogens. However, 
additional research such as exploring the effect of G. africana on clinical Candida isolates as 
well other fungal species of medical importance would be essential in future studies.  
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6 CHAPTER 6: Effect of Galenia africana alone and in 
combination with doxorubicin on human breast cancer (MCF-7) 
and normal human fibroblast (KMST-6) cells lines 
6.1 Abstract 
Background: Breast cancer is considered to be the second leading cause of cancer-related deaths 
among women worldwide. Despite the availability of several chemotherapeutic drugs, they are 
normally associated with severe adverse effects and toxicity due to them not being able to 
differentiate cancer cells from normal cells. In addition, the increased resistance to anticancer 
drugs is a growing challenge. Medicinal plant extracts have shown potential as alternative 
sources for the treatment of breast cancer. Galenia africana is a woody shrub reported to have 
various therapeutic effects including antibacterial and antifungal properties. However, current 
research about the mechanisms of its anticancer potential is limited.  
Objective/Purpose: This study was aimed at investigating the cytotoxicity of G. africana alone 
and in combination with doxorubicin in human breast cancer cell lines (MCF-7) and normal 
fibroblast (KMST-6) cells. This study also investigated the ability of G. afrciana to alter gene 
expression, induce apoptosis and impact the cell cycle process of MCF-7 cells.  
Methods: The cytotoxic effects of the G. africana extract alone and in combination with 
doxorubicin were evaluated using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. The ability of G. africana to have an effect on gene 
expression, induce apoptosis and affect the cell cycle was assessed using the RT
2
 Profiler PCR 
Array. 
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Results: Results from the MTT assay revealed that G. africana extract inhibited the proliferation 
of MCF-7 and KMST-6 in a dose-dependent manner. The extract demonstrated a greater 
anticancer effect against the MCF-7 than the KMST-6 cells as determined by the IC50 values. 
The underlying mechanism of growth inhibition in MCF-7 cells involved the up-regulation of 
genes involved in apoptosis such as BCL2L11, CASP2, CASP7/9 and cellular senescence such as 
IGFBP 3, 5 and 7.  Furthermore, G. africana caused the inhibition of angiogenesis as indicated 
by a down-regulation of ANGPT1 and ANGPT2. In addition, G. africana affected the cell cycle 
as indicated by the down-regulation of STMN1 and WEE1 genes as well as metabolism as 
indicated by the down-regulation of ACLY, ACSL4 and PFKL genes.  
Conclusion: Overall, this study demonstrates the potential applications of G. africana as an 
anticancer drug for breast cancer treatment. In addition, the synergistic effect exhibited when 
combined with doxorubicin suggests that it can complement current chemotherapy. 
6.2 Introduction 
Cancer has been a global healthcare problem for years and a large amount of money has been 
invested in investigating it (Prakash, Kumar et al. 2013). Breast cancer is the major type of 
cancer diagnosed in women and accounts for the highest number of deaths in women worldwide 
(Abdulrahman and Rahman 2012; Seymour, Wainstein et al. 2016). Statistical data obtained 
from the South African National Cancer Registry 2010 indicates that 1 in 35 women is at risk of 
having breast cancer at some point in their lives (Parag and Buccimazza 2016). Reports have 
shown that as much as 10% of breast cancer cases are due to germline mutations in genes that are 
prone to cancer such as BRCA1 and BRCA2 (Diamond, Sutphen et al. 1998; Seymour, Wainstein 
et al. 2016). In addition, older women are at a higher risk of developing breast cancer as the risk 
increases with age (Bernardi, Errante et al. 2008). Despite the availability of screening plans and 
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the introduction of more chemotherapeutic agents, particularly in developed countries, cancer 
resistance has still been an important healthcare crisis (Ahmad 2013). It has been observed that 
in 30% of women presenting with early-stage breast cancer, the disease is persistent. 
Furthermore, drug resistance develops in no less than one quarter of all cases (Gonzalez-Angulo, 
Morales-Vasquez et al. 2007; Musgrove and Sutherland 2009).   
Plants and plant derived compounds have been used, for centuries, for their healing properties 
and incorporated as therapeutic agents. Approximately 80-85% of the population worldwide 
depends on herbal medicines, in the form of plant extracts or their active compounds, to treat 
numerous ailments (Tomlinson and Akerele 1998; Elujoba, Odeleye et al. 2005; Ignacimuthu, 
Ayyanar et al. 2006). Medicinal plants have been used in the treatment of various infections 
including cancers (Kuete, Wabo et al. 2011). Some of the chemotherapeutic drugs that are 
derived from medicinal plants include vincristine, irinotecan, etoposide and paclitaxel (Da Rocha, 
Lopes et al. 2001). The majority of chemotherapeutic agents are associated with numerous 
extremely uncomfortable side effects. This is the reason why medicinal plants and plant derived 
products are being used in an effort to fight cancer (Prakash, Kumar et al. 2013).  
In this study, the anticancer activity of G. africana was assessed using the MTT assay. The gene 
expression was assessed in MCF cells after treatment using the RT PCR Array profiler.  
6.3 Materials and Methods 
6.3.1 Plant material extraction and preparation 
A 20% (w/v) G. africana extract was commercially prepared with 60% ethanol using the dried 
leaves and shoots. The drying process was conducted by Brenn-O-Kem (Pty) Ltd (Wolseley, 
South Africa) and involved the use of a commercial vacuum drying chamber to dry the ethanolic 
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extract under reduced pressure at a temperature of 50 ºC. This was done in order to dehydrate the 
extract and get rid of any excess absorbed solvent and water and to attain a crystal-form of the 
extract that would be used in subsequent experiments. In order to be used in the MTT assay, the 
crystals were reconstituted in Dulbecco's Modified Eagle Medium (DMEM) (Life technologies, 
UK) to make a stock solution of 60 mg/ml. This was done by weighing out 800 mg of the G. 
africana crystals and reconstituting them in 13.3 ml of DMEM to have a concentration of 
60mg/ml. Once the crystals were weighed out, they were placed in a 15 ml greiner tube 
containing the media (13.3 ml) and sterile forceps were used to crush them. This process was 
performed in a laminar flow. The tube with the reconstituted extract was then centrifuged at 
maximum speed for 7 min so as to obtain a clear liquid. This clear extract liquid was then sterile 
filtered using 0.45 µm sterile filters. This liquid extract was used as a stock solution and was 
stored at 4ºC. A sample of the reconstituted dried extract was sent to Cape Peninsula University 
of Technology (CPUT) (Bellville, South Africa) for analysis in order to determine the chemical 
composition. Once analysis was done, a certificate of analysis was supplied (see Appendix V). 
6.3.2 Cell culture conditions 
The human breast cancer cell line (MCF-7) (ATCC HTB-22) and the immortalized human 
normal fibroblast cells (KMST-6) were obtained from Prof Meyer (Biotechnology Department, 
University of the Western Cape, Bellville, South Africa). The MCF-7 and KMST-6 cells were 
grown in DMEM (Life technologies, UK) supplemented with 10% v/v fetal bovine serum (FBS) 
(Gibco, UK), 100 U/ml of penicillin (Gibco, Life Technologies), and 100  g/ml of streptomycin 
(penstrep) (Gibco, UK) as a complete growth medium. Cells were maintained in complete 
growth media in 75 cm
2
 flasks and incubated in a humidified incubator at 37°C with 5% CO2. 
Doxorubicin was supplied by Sigma-Aldrich, USA. 
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6.3.3 Cytotoxic assay (MTT assay)  
In vitro cytotoxicity of G. africana alone, doxorubicin alone as well as a combination of the two 
was carried out using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay) 
(Sigma-Aldrich) based on methods described in previous studies (Ayob, Mohd Bohari et al. 
2014). This assay was performed after 12, 24, 36 and 48 h time periods. Prior to conducting the 
MTT assay, the laminar flow was cleaned with 70% ethanol and all materials to be used in this 
assay were sterilized, by using UV lighting, within the laminar flow. In addition, the microscope 
and all other working surfaces were sterilized prior to conducting the assay. In this assay, cells 
were harvested once they reached a confluency of 70-80% and this was confirmed by observing 
them under the microscope. Upon being confluent, excess media was removed from the flask and 
the cells were washed 3 times with 5 ml of phosphate buffered saline (PBS) (Life Technologies, 
USA). After washing the cells, any excess PBS was removed and 1-3 ml of trypsin (Lonza, 
Belgium) was added to the flask. Care was taken to ensure that the trypsin covered the entire 
surface of the flask. The flask was then incubated for 2-3 min at 37ºC in a humidified incubator 
with 5% CO2. The flask was removed from the incubator and viewed under the microscope to 
check if the cells had detached from the surface of the flask. Once cells were detached, 5 ml of 
complete media was added in order to neutralize the trypsin. The cell suspension was transferred 
to a 15 ml greiner tube and centrifuged at 500 rpm for 5 min. The media was removed and the 
cells were re-suspended in 1 ml of complete media. Cells were then counted by removing 20 µl 
of cells and adding this to 20 µl of trypan blue in a 1.5 ml micro centrifuge tube and gently 
pipetted to mix. Cells were aseptically counted using a counting chamber, referred to as a 
hemocytometer, and the number of cells per ml was recorded. The cells were diluted using 
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complete media. 100 µl of cells, at a density of 2.5 x 10
3
 cells, were added into each well of the 
96-well flat bottom plate and incubated for 24 h at 37ºC in a humidified incubator with 5% CO2.  
The following day, the cells were treated with the G. africana extract at concentrations ranging 
from 1.25 to 20 mg/ml (made up in DMEN) and doxorubicin at concentrations of 0.1, 0.5, 2.5 
and 5 µM (reconstituted in DMSO (Sigma-Aldrich, USA) but working solutions made up in 
DMEM). This was done by adding 100 µl of either the extract or doxorubicin to the cells and 
incubating for 12, 24, 36 and 48 h (for treatment with the extract) and 12 and 24 h (for treatment 
with doxorubicin). On the third day, a stock solution of 5 mg/ml MTT was prepared in PBS and 
filter sterilized using 0.22 µm sterile filters. The tube containing the MTT was covered in foil as 
it is light sensitive. 20 µl of 5 mg/ml MTT (final concentration of 0.5 mg/ml in incubation media) 
was then added to each well and the plates were incubated, covered in foil, for 4 h at 37ºC in a 
humidified incubator with 5% CO2. The above mentioned processes were performed aseptically 
in the laminar flow. Control wells were also included that contained staurosporine (Sigama-
Aldrich, USA) (positive apoptosis control), cells only (negative control), as well as pinocembrin 
(Sigma-Aldrich, USA) and naringenin (Sigma-Aldrich, USA) (components found in the extract). 
After the incubation period, the media was carefully removed without disturbing the cells and the 
MTT crystals in the wells. 100 µl of isopropanol was added to each well to dissolve the MTT 
formazan crystals and incubated for 20-30 min in a shaking incubator. The plates were read at 
570 nm using a microplate reader (Glomax Multi Detection System, Promega, Madison, USA) 
and the absorbance readings recorded.  
6.3.3.1  Statistical analysis 
The cell viabilities of the treated MCF-7 and KMST-6 cell lines were calculated as follows:   
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Cell viability  %    
Mean OD
Control OD
 x 100% 
The cell viability results were then used to determine the IC50 values of the extract and 
doxorubicin as well as their combination against MCF-7 and the KMST-6 cells. The IC50 values 
were determined using nonlinear regression (log (inhibitor) vs. response-variance slope) in 
GraphPad Prism 5. The IC50 values represented the concentrations of the extract required to 
decrease the absorbance readings of treated cells by 50% compared to the untreated cells (cells 
only control) (Ahmad, Ali et al. 2005).  Grouped data was analyzed using two-way analysis of 
variance (ANOVA). The analysis included row means with SD, multiple t-tests (one-per row) 
and multiple comparisons. A p value ≤ 0.05 was considered to be statistically significant. The 
IC50 values obtained after the treatment of cells with G. africana alone, doxorubicin alone as 
well as the combination of the two were used for subsequent experiments.  
6.3.4 Purification of Total RNA from animal cells using the Spin Technology 
Purification of total RNA was done using the RNeasy Mini kit (Qiagen, Germany). Use of the 
correct quantity of starting material was essential in obtaining the optimal yield and purity of 
RNA. According to the protocol, the minimum amount of starting material is usually 100 cells 
while the maximum starting material will depend on a number of factors. These factors include 
RNA content of the cell type, the RNA binding capacity of the RNeasy spin column (100 µg 
RNA) and the volume of Buffer RLT required for efficient lysis (the maximum volume of Buffer 
RLT that can be used limits the maximum amount of starting material to 1 x 10
7
 cells). In 
addition, RNA content can vary significantly between cell types. Table 2 (page 17 of the RNeasy 
Mini Handbook) outlined the typical yields of total RNA that would be obtained with the 
RNeasy Mini spin column kit. Since this study focused on MCF-7 cell lines, which were not 
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included in Table 2, the protocol recommended starting with no more than 3-4 x 10
6
 cells. Prior 
to extraction and purification of RNA, cells were grown in 6 well plates, with a diameter of 9-9.5 
cm
2
, at a density of 0.3 x 10
6
 per well for the four groups. The number of cells at confluency was 
expected to be 1-1.2 x 10
6
 cells per well.  
The cells were harvested and the required number of cells determined. The medium was 
aspirated and the cells were washed with PBS. The PBS was then aspirated and 2 ml of 0.25% 
trypsin was added. Once the cells detached from the wells, medium containing serum was added 
to inactivate the trypsin. This was then transferred to a polypropylene centrifuge tube and 
centrifuged at 300 x g for 5 min. After centrifuging, the supernatant was completely aspirated. 
The appropriate volume of Buffer RLT to be added to the pelleted cells was outlined in Table 5 
of the RNeasy Mini Handbook. The pellet was loosened thoroughly by flicking the tube. Since 
the staring cell density was < 5 x 10
6
, 350 µl of Buffer RLT was added. This was vortexed in 
order to facilitate efficient lysis and increase RNA yields. The lysate was homogenized by 
passing it at least 5 times through a blunt 20-gauge needle (0.9 mm diameter) fitted to an RNase-
free syringe. 350 µl of 70% ethanol (Merck, Germany) was added to the homogenized lysate and 
mixed well by pipetting (some precipitation was visible after addition of ethanol but this did not 
affect the procedure). 700 µl of the sample, including the precipitate was transferred to an 
RNeasy spin column placed in a 2 ml collection tube. The lid was closed gently and this was 
then centrifuged for 15 s at ≥ 8000 x g (≥ 10 000 rpm). The flow-through was discarded. Since 
the volume exceeded 700 µl, successive aliquots were centrifuged in the same RNeasy spin 
column and the flow-through discarded after each centrifugation step.  
An optional on-column DNase digestion genomic DNA elimination step was performed using 
the High Pure RNA isolation kit (Roche, USA). 90 µl of DNase Incubation Buffer was pipetted 
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into a sterile reaction tube and 10 µl of DNase I added. This was mixed thoroughly and the 
solution (entire volume) pipetted in the upper reservoir of the RNeasy spin column and incubated 
for 60 min at 15-25°C. 500 µl Buffer RPE was then added to the RNeasy spin column. The lid 
was closed gently and the spin column centrifuged for 15 s at ≥ 8000 x g (≥ 10 000 rpm) to wash 
the spin column membrane. The flow-through was discarded and the collection tube reused. 
Another 500 µl of Buffer RPE was added to the spin column. The lid was closed gently and 
centrifuged for 2 min at ≥ 8000 x g (≥ 10 000 rpm) to wash the membrane. This longer 
centrifugation step dried the spin column membrane ensuring that no ethanol was carried over 
during RNA elution which would interfere with downstream reactions. After centrifugation, the 
spin column was carefully removed from the collection tube to avoid contact with the flow-
through otherwise carryover of ethanol would occur. The spin column was then placed in a new 
collection tube, the lid closed gently and centrifuged at full speed for 1 min. This step eliminated 
any possible carryover of Buffer RPE or residual flow-through remaining on the outside of the 
spin column. The spin column was then placed in a new 1.5 ml collection tube. 30 µl of RNase-
free water was added directly to the spin column membrane. The lid was carefully closed and 
centrifuged for 1 min at ≥ 8000 x g (≥ 10 000 rpm) to elute the RNA. This was then used to 
synthesize cDNA. 
6.3.5 Determination of RNA quantity and quality 
RNA samples were sent to Stellenbosch University (Stellenbosch, South Africa) to be analyzed 
using the Aligent 2100 Bioanalyzer system per the manufacturer’s instructions (Aligent 
Technologies, USA). This instrument utilized the RNA integrity number (RIN) to measure the 
integrity of the RNA while also giving the RNA concentration. The RIN value was calculated 
based on the association between the areas of 18S rRNA and 28S rRNA (Schroeder, Mueller et 
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al. 2006). Furthermore, if a ratio of 28S:18S bands is 2 or higher, then the RNA is considered to 
be of high quality (Schroeder, Mueller et al. 2006). RIN values are classified using a numbering 
system from 1 to 10. 1 denotes the most degraded RNA while 10 denotes the most intact RNA 
(Ondracek, Cheng et al. 2015). In addition, RIN values above 8 demonstrate that the RNA 
obtained after the extraction method employed was not degraded  (Ruocco, Costantini et al. 
2017). 
6.3.6 cDNA synthesis using the RT2 First Strand Kit and quantification 
The RT
2
 First Strand kit (Qiagen, USA) was essential for acquiring optimal results and for 
detecting the reverse transcription controls contained in the RT
2
 Profiler PCR Array. The 
protocol recommended using a starting total RNA concentration of 0.5 µg for the 96-well plate 
formats for first-time users. Since this was the first time this kit was used, 0.5 µg total RNA was 
the starting concentration for cDNA synthesis. 
The reagents of the RT
2
 First Strand kit were thawed and briefly centrifuged to bring the contents 
to the bottom of the tubes. The genomic DNA elimination mix was prepared (Table 6.1) as 
outlined in the RT
2
 Profiler PCR Array Handbook. The elimination mix was mixed gently by 
pipetting up and down and subsequently centrifuged briefly. 
Table 6.1: Genomic DNA elimination mix. 
Component Amount 
RNA 0.5 µg 
Buffer GE 2 µl 
RNase-free water variable 
Total volume 10 µl 
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The genomic DNA elimination mix was incubated at 42°C for 5 min and then immediately 
placed on ice for at least 1 min. This was followed by the preparation of the reverse-transcription 
mix (Table 6.2).   
Table 6.2: Reverse-transcription mix. 
Component Volume for 1 reaction 
(µl) 
Volume for 2 reactions 
(µl) 
Volume for 4 reactions 
(µl) 
5x Buffer BC3 4 8 16 
Control P2 1 2 4 
RE3 Reverse 
Transcriptase Mix 
2 4 8 
RNase-free water 3 6 12 
Total volume 10 20 40 
 
Since cDNA from the four groups was required, the volume for 4 reactions was used (total 
volume of 40 µl). 10 µl of reverse-transcription mix was added to each tube containing 10 µl 
genomic DNA elimination mix and mixed gently by pipetting up and down several times. This 
was incubated for exactly 15 min at 42°C. After incubation, the reaction was immediately 
stopped by incubating it at 95°C for 5 min. 91 µl of RNase-free water was then added to each 
reaction and mixed by pipetting up and down several times. The reactions were placed on ice for 
use in the real-time PCR step. cDNA was quantified using the NanoDrop 2000 
spectrophotometer. 
6.3.7 Real-Time PCR for RT2 Profiler PCR Array Formats A, C, D, E, F, G 
This array relied on the use of RT
2
 SYBR Green Mastermixes (Qiagen, Germany) to obtain 
accurate results from the RT
2
 Profiler PCR Array (Qiagen, Germany). It was crucial to ensure 
that the RT
2
 SYBR Green Mastermix and the RT
2
 Profiler PCR Array were suitable for the real-
time cycler being used. The format of the RT
2
 Profiler PCR Array was indicated by the last letter 
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of the catalog number. A summary of genes present in the RT² Profiler PCR Array are 
summarized in Appendix VI. To prepare the PCR components mix, the RT
2
 SYBR Green 
Mastermix was briefly centrifuged for 10-15 s to bring the contents to the bottom of the tube. A 
total volume of 2700 µl of the PCR components mix was prepared (Table 6.3) for each 
experimental group in a 5 ml tube as described in the RT
2
 Profiler PCR Array Handbook. 
Table 6.3: PCR components mix. 
Component Array format : 96-well A, C, D, F 
2x RT
2
 SYBR Green Mastermix 1350 µl 
cDNA synthesis reaction 102 µl 
RNase-free water 1248 µl 
Total volume 2700 µl 
 
The RT
2
 Profiler PCR Array was carefully removed from the sealed bag. This was followed by 
the addition of 25 µl of PCR components mix to each well of the PCR Array plate. Tips were 
changed following each pipetting step to avoid cross-contamination between wells. PCR Array 
plates were then carefully and tightly sealed with the optical adhesive film supplied. The PCR 
Array plates were centrifuged for 1 min at 1000 x g at room temperature (15-25°C) to remove 
bubbles as they would interfere with results. The PCR Array plates were then placed on ice while 
the PCR cycling program was being set up. Figure 6.1 shows the PCR Array plate layout. The 
real-time cycler was programmed according to the conditions outlined in the RT
2
 Profiler PCR 
Array Handbook. The recommended cycling conditions for the Roche LightCycler 480 are 
outlined in Table 6.4. The ramp rate was adjusted to 1.5°C/s. A dissociation (melting) curve 
analysis was performed to verify the PCR specificity using the real-time cycler software.   
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Figure 6.1: RT
2
 Profiler PCR Array layout. Wells A1 to G12 each contain a real-time PCR assay 
for a pathway/disease/functionally related gene. Wells H1 to H5 contain a housekeeping gene 
panel to normalize array data (HK1–5). Well H6 contains a genomic DNA control (GDC). Wells 
H7 to H9 contain replicate reverse-transcription controls (RTC). Wells H10 to H12 contain 
replicate positive PCR controls (PPC). 
Table 6.4: Cycling conditions for Roche LightCycler 480. 
Cycles Duration Temperature Comments 
1 10 min 95°C HotStart DNA Taq 
Polymerase is activated 
by this heating step. 
45 15s 95°C  
 1 min 60°C Perform fluorescence 
data collection. 
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After programming the cycling conditions, the PCR Array plate was placed into the real-time 
cycler. The threshold cycle (CT) for each well was calculated using the real-time cycler software.  
The second derivate max setting was used to calculate the CT. Once the CT values for all wells 
were obtained, they were exported to a blank Excel spreadsheet for use in the SABiosciences 
PCR Array Data Analysis Web-based software. 
6.3.7.1  RT2 Profiler PCR Array Data Analysis 
Data analysis was performed according to the RT
2
 Profiler PCR Array Data Analysis v3.5 
Handbook. The CT values were calculated for each well using the second derivate maximum 
setting (recommended analysis method for the LightCycler 480 software). The second derivate 
maximum setting is recommended because the algorithm is based on the kinetics of the PCR. 
The CT value in this method is identified as the point where the reaction’s fluorescence reaches 
the maximum of the second derivative of the amplification curve, which corresponds to the point 
where the acceleration of the fluorescence signal is at its maximum. As a result, this crossing 
point should always be located in the middle of the log-linear portion of the PCR amplification 
plot. The advantage of this analysis method is that it requires little user input. The CT values 
were then exported from the experimental run into an excel spreadsheet. These CT values were 
analyzed to calculate changes in gene expression. After being exported from the qPCR 
instrument, the CT values were formatted into a new Excel spreadsheet. This was done to enable 
the PCR Array Data Analysis Webportal to correctly read and import data as the Webportal only 
accepts Excel spreadsheets. All plates and wells were copied into a single worksheet. The raw CT 
values for each sample were in a single column that lined up correctly with the correct well 
location on the PCR Array. Once the spreadsheet was correctly filled with the required 
information, the data was uploaded onto the Data analysis Webportal. An automated data 
 
 
 
 
  Chapter 6Anticancer studies 
268 
 
analysis system was employed using the Qiagen online software. A data QC step was performed 
to ensure that each sample passed the PCR Array reproducibility, RT (reverse transcription) 
efficiency, and Genomic DNA contamination quality controls. Data normalization was 
performed using the housekeeping genes before analysis was carried out. The data was reviewed 
to see each group’s distribution of threshold cycle values and the average raw data in each group. 
Analysis was performed and the fold regulation, fold change, average ∆CT and the 2
^
- ∆CT 
reviewed from the calculations processed by the software from the imputed data. Plots and charts 
were formulated using the defined groups and the specified fold-change boundary (threshold) for 
the genes of interest. The figures/images were then saved and gene expression was analyzed by 
screening genes to verify the target differentially expressed genes compared to the control.   
6.4 Results  
6.4.1 Cytotoxic assay (MTT assay) 
The results of the MTT assay revealed that G. africana had a more cytotoxic effect on the MCF-
7 cells compared to the KMST-6 cells. This was evident from the high IC50 values obtained after 
treatment of the KMST-6 cells with the extract at the four different time lines. The IC50 values 
obtained after a 12 h treatment of KMST-6 and MCF-7 cells with different G. africana 
concentrations were 4.161 and 1.635 mg/ml, respectively whereas those obtained after a 24 h 
treatment period were 3.625 and 1.692 for KMST-6 and MCF-7 cells, respectively. Treatment of 
both KMST-6 and MCF-cells with the extract for 36 h produced IC50 values of 2.367 and 1.484 
mg/ml, respectively. The IC50 values obtained after treating the KMST-6 and MCF-7 cells for 48 
h with the extract were 1.983 and 1.25 mg/ml, respectively (Figure 6.2).  
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Figure 6.3 represents the results obtained after the treatment of the two cell lines with four 
doxorubicin concentrations for 12 and 24 h. The IC50 values could not be determined after 12 h 
of treatment with doxorubicin as the cell viabilities were above 50% at all the concentrations for 
both cell lines. However, the IC50 value obtained after 24 h of treatment of MCF-7cells was 0.3 
µM whereas that obtained after treating the KMST-6 cells was 18.93 µM.  
Figure 6.4 represents the effect of the combination of G. africana with doxorubicin after a 12 h 
treatment period. Treatment of KMST- 6 and MCF-7 cells with a combination of G. africana and 
0.1 µM doxorubicin produced IC50 values of 6.989 and 1.842 mg/ml, respectively. Treatment 
with G. africana and 0.5 µM doxorubicin produced IC50 values of 6.257 and 2.311 mg/ml for 
KMST-6 and MCF-7 cells, respectively. Treatment with G. africana and 2.5 µM doxorubicin 
produced IC50 values of 5.025 and 1.969 mg/ml for KMST-6 and MCF-7 cells, respectively.  
Figure 6.5 represents the effect of the combination of G. africana with doxorubicin after a 24 h 
treatment period. Results obtained after a combination of G. africana and 0.1 µM doxorubicin 
produced IC50 values of 8.814 and 1.144 mg/ml for KMST-6 and MCF-7 cells, respectively. 
Treatment with G. africana and 0.5 µM doxorubicin produced values of 4.134 and 1.228 mg/ml 
for KMST-6 and MCF-7 cells, respectively. Treatment with G. africana and 2.5 µM doxorubicin 
produced IC50 values of 3.885 mg/ml and 0.116 mg/ml for KMST-6 and MCF-7 cells, 
respectively. 
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Figure 6.2: Cell viabilities of KMST-6 and MCF-7 cells treated with G. africana (1.25 to 20 mg/ml). (A) 12 h of treatment; (B) 24 h 
of treatment; (C) 36 h of treatment and (D) 48 h of treatment. Values are expressed as mean ± SD (n=5). p < 0.001 (p < 0.05). 
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Figure 6.3: Cell viabilities of KMST-6 and MCF-7 cells treated with doxorubicin (0.1 to 5 µM). (A) 12 h of treatment and (B) 24 h of 
treatment. Values are expressed as mean ± SD (n=5). p < 0.001 (p < 0.05). 
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Figure 6.4: 12 h treatment of KMST- and MCF-7 cells with combinations of G. africana (1.25 to 20 mg/ml) and doxorubicin (0.1, 0.5 
and 2.5 µM). (A) G. africana alone, (B) doxorubicin alone, (C) G. africana and doxorubicin (0.1 µM), (D) G. africana and 
doxorubicin (0.5 µM) and (E) G. africana and doxorubicin (2.5 µM). Values are expressed as mean ± SD (n=5). p < 0.001 (p < 0.05). 
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Figure 6.5: 24 h treatment of KMST- and MCF-7 cells with combinations of G. africana (1.25 to 20 mg/ml) and doxorubicin (0.1, 0.5 
and 2.5 µM). (A) G. africana alone, (B) doxorubicin alone, (C) G. africana and doxorubicin (0.1 µM), (D) G. africana and 
doxorubicin (0.5 µM) and (E) G. africana and doxorubicin (2.5 µM). Values are expressed as mean ± SD (n=5). p < 0.001 (p < 0.05). 
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Table 6.5: Comparison of IC50 values of MCF-7 and KMST-6 cells lines treated with G. 
africana, doxorubicin and a combination of the two after 12, 24, 36 and 48 h. 
                          IC50 values                        
 KMST-6                         MCF-7  
Treatment 12 h 24 h 36 h 48 h 12 h 24 h 36 h 48 h 
G. africana 
alone 
4.161 3.625 2.367 1.983 1.635 1.692 1.484 1.25 
Doxorubicin 
alone 
─ 18.93 ND ND ─ 0.30 ND ND 
0.1 µM Dox 
+ G. 
africana 
6.989 8.814 ND ND 1.842 1.144 ND ND 
0.5 µM Dox 
+ G. 
africana 
6.257 4.134 ND ND 2.311 1.228 ND ND 
2.5 µM Dox 
+ G. 
africana 
5.025 3.885 ND ND 1.969 0.116 ND ND 
ND- Not determined, as the effect of doxorubicin alone, as well as the combination of G. 
africana and doxorubicin against the cells was only evaluated after 12 and 24 h. The effect 
observed was significant enough for experiments not to go beyond these two time lines. 
 
Table 6.5 shows the IC50 values obtained after treating the KMST-6 and MCF-7 cells with G. 
africana alone (12, 24, 36 and 48 h), doxorubicin alone (12 and 24 h) as well as a 
combination of the two (12 and 24 h). The IC50 values obtained in the combination 
experiments demonstrated the changes in the concentration of G. africana required to have an 
effect on cell viability. The IC50 values of G. africana alone and doxorubicin alone after a 24 
h treatment period were 1.692 mg/ml and 0.3 µM, respectively. For the combination study, it 
was observed that the IC50 value of the extract reduced from 1.692 (when used alone) to 
1.144 mg/ml when combined with 0.1 µM doxorubicin after 24 h of treatment. This result 
also revealed that there was an increase in the activity of both the extract and doxorubicin as 
the IC50 value of the extract reduced with a doxorubicin concentration of 0.1 µM, which was 
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lower than its IC50 of 0.3 µM. These IC50 concentrations were used for the RNA extraction 
process. 
6.4.2 Determination of RNA quantity and quality  
The RNA quality and concentration was determined using the Aligent 2100 Bioanalyzer. 
Results revealed that the RNA obtained from the untreated cells had two distinct bands 
whereas the RNA obtained from the three treatment groups showed smearing (Figure 6.6). 
Figure 6.7 shows results of the RNA obtained from MCF-7 cells treated with a combination 
of G. africana and doxorubicin (MCF CB) and G. africana alone (MCF GA) that had RIN 
values of 2.6 and 2.4, respectively. This showed that the RNA was degraded as a result of the 
treatment. Figure 6.8 shows results of the RNA obtained from MCF-7 cells treated with 
doxorubicin (MCF_Dox) and the untreated cells (MCF_UT) that produced RIN vales of 2.7 
and 8.9, respectively. These results showed that the untreated cells had RNA that was not 
degraded as demonstrated by the RIN values. The RNA concentrations were 255 ng/µl for 
doxorubicin, 237 ng/µl for G. africana, 259 ng/µl for the combination of the two and 1110 
ng/µl for the untreated cells.   
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Figure 6.6: Agilent Bioanalyzer electropherograms and electrophoresis file run summaries of 
MCF-7 cells. (A) treatment with a combination of G. africana (1.144 mg/ml) and 
doxorubicin (0.1 µM) (MCF_CB), (B) treatment with G. africana only (1.692 mg/ml) 
(MCF_GA), (C) treatment with doxorubicin only (0.3 µM) (MCF Dox) and (D) untreated  
cells (MCF_UT). RIN values are also reported. 
 
 
Figure 6.7: Agilent Bioanlyzer electropherograms of MCF-7 cells. (A) treatment with a 
combination of G. africana (1.144 mg/ml) and doxorubicin (0.1 µM) (MCF_CB) and (B) 
treatment with G. africana only (1.692 mg/ml). RIN values, RNA concentrations and rRNA 
(28s/18s) ratios are also reported. 
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Figure 6.8: Agilent Bioanlyzer electropherograms of MCF-7 cells. (A) treatment with 
doxorubicin only (0.3 µM) (MCF Dox) and (B) untreated cells (MCF_UT). RIN values, RNA 
concentrations, 28s:18s ratios are also reported. 
 
6.4.3 cDNA quatification (NanoDrop) 
After obtaining the RNA, it was then used to synthesize cDNA. The concentrations of the 
cDNA are outlined in Table 6.6. Despite the RNA concentration for the untreated cells being 
higher than the treatment groups, the cDNA concentration was within the same range of 200 
to 225 ng/µl. This was important so as to ensure that the same amount of cDNA was used for 
subsequent experiments. 
Table 6.6: cDNA results obtained after quantification using the NanoDrop 2000 
Spectrophotometer. 
a 
MCF-7 cells treated with a combination of G. africana and doxorubicin 
b 
MCF-7 cell treated with G. africana only 
Sample Concentration (ng/µl) 
MCF CB
a 
212 
MCF GA
b 
224.5 
MCF Dox
c 
213.7 
MCF UT
d 
212.8 
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c 
MCF-7 cell treated with doxorubicin only 
d 
Untreated MCF-7 cells 
 
6.4.4 RT PCR Array 
Figure 6.9 and Table 6.7 outline the distribution of genes after treating the MCF-7 cells with 
G. africana alone (Group 1), doxorubicin alone (Group 2) and a combination of the two 
(Group 3) for 24 h. The Control Group included untreated MCF-7 cells. 
 
 
Figure 6.9: Percent distribution of genes based on threshold cycle value ranges in MCF-7 
cells. Cells were treated with the IC50 values of G. africana, doxorubicin and a combination 
of the two after 24 h. (A) Control Group (untreated), (B) Group 1 (cells treated with G. 
africana only); (C) Group 2 (cells treated with doxorubicin only) and (D) Group 3 (cells 
treated with a combination of the two). 
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Table 6.7: Distribution of threshold cycle (Ct) value ranges in treatment Groups 1, 2 and 3 
and the Control Group. 
Distribution of Ct Values 
Ct Range Control Group Group 1 Group 2 Group 3 
<25 13 7 10 8 
25-30 12 8 10 9 
30-35 11 15 13 11 
Absent Calls 32 44 42 50 
Percent Distribution of Ct Values 
<25 13.54% 7.29% 10.42% 8.33% 
25-30 12.50% 8.33% 10.42% 9.38% 
30-35 11.46% 15.62% 13.54% 11.46% 
Absent Calls 33.33% 45.83% 43.75% 52.08% 
 
Tables 6.8 and 6.9 represent genes that were down- and up-regulated as result of the different 
treatments, respectively. Classification of genes as being down- or up-regulated was achieved 
by comparing their expression levels to the control group. There were a total of 19 genes that 
were down-regulated and these genes were similar across the treatment groups. There were a 
total of 15 genes that were up-regulated as a result of treatment. It was also observed that 
these genes were similar across the treatment groups. These results demonstrated that G. 
africana may have a similar mode of action as doxorubicin.  
Table 6.8: Comparison of down-regulated genes in Groups 1 (G. africana only), Group 2 
(doxorubicin only) and Group 3 (combination of the two). 
Gene Group 1 Group 2 Group 3 
ACLY + + + 
ACSL4 + + + 
ANGPT1 + + + 
ANGPT2 + + + 
BIRC3 + + + 
BMI1 + + + 
CCND3 + + + 
CDH2 + ─ + 
FGF2 + + + 
FLT1 + + + 
G6PD + + + 
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LDHA + + + 
MAPK14 + + + 
PFKL + + + 
SNAI1 + + + 
SOD1 + + + 
STMN1 ─ ─ + 
UQCRFS1 + + + 
WEE1 + + + 
+ gene present;  gene absent 
Table 6.9: Comparison of up-regulated genes in Groups 1 (G. africana only), Group 2 
(doxorubicin only) and Group 3 (combination of the two). 
Gene symbol Group 1 Group 2 Group 3 
BCL2L11 + + + 
CASP2 + + + 
CASP7 + + + 
CASP9 + + + 
DDB2 + + + 
DDIT3 ─ + + 
DSP + + + 
FASLG + + + 
GADD45G + + + 
IGFBP3 ─ ─ + 
IGFBP5 + + + 
IGFBP7 + + + 
OCLN + + + 
PINX1 + + + 
PPP1R15A + + + 
+ gene present;  gene absent 
6.5 Discussion 
In this study, the cytotoxic effects of G. africana, doxorubicin and a combination of the two 
were evaluated. G. africana was chosen for this study due to its antimycobacterial activities 
(Mativandlela, Meyer et al. 2008), cytotoxicity capabilities (Mativandlela, Muthivhi et al. 
2009), antifungal properties (Fielding, Knowles et al. 2015) and wound healing properties 
(Watt and Breyer-Brandwijk 1962). The stock solutions of the extract and doxorubicin were 
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prepared in DMEM. Despite doxorubicin initially being reconstituted in DMSO at 
concentrations as high as 100 mg/ml, the final concentration of DMSO was not more than 
0.2% and not toxic to the cells as described in previous studies (Graidist, Martla et al. 2015). 
Therefore, it was concluded that the cytotoxic effects observed were due to doxorubicin and 
not the solvent. This study utilized the MTT cell viability assay to assess the cytotoxicity of 
G. africana alone, doxorubicin alone and a combination of the two against MCF-7 (human 
breast cancer) and KMST-6 (normal fibroblast) cells. This was done in order to establish the 
individual cytotoxic effects of G. africana and doxorubicin as well as the effect of their 
combination. MCF-7 cells were used in this study because they are the most frequently used 
in vitro models for breast cancer studies (Lacroix and Leclercq 2004). The non-cancerous 
normal fibroblasts KMST-6 cells were used as controls. The survival of the MCF-7 and 
KMST-6 cells after treatment with the G. africana extract (after 12, 24, 36 and 48 h) and 
doxorubicin (after 12 and 24 h) was determined. In addition, the survival of the two cell lines 
after treatment with a combination of the G. africana and doxorubicin after 12 and 24 h was 
also determined. The responses of MCF-7 and KMST-6 cells to increasing concentrations of 
the extract and doxorubicin are shown in Figures 6.1 and 6.2, respectively. The results 
showed that the extract had a biphasic effect on both cell lines at all time points (with the 
greatest effect seen on MCF-7 cells), whereas the growth of both cell lines decreased 
considerable in a dose-dependent manner (with the greatest effect seen on MCF-7) after 
treatment with doxorubicin. The IC50 values obtained after treatment of MCF-7 and KMST-6 
cells with various concentrations of the G. africana extract, doxorubicin and a combination of 
the two are shown in Table 6.5. The results showed that the IC50 values obtained after 
treatment of the MCF-7 cells with the extract were much lower than those of the KMST-6 
cells. This indicated that the extract had a greater cytotoxic effect on the MCF-7cells than the 
KMST-6 cells. These results were similar to those obtained by Abdullah and colleagues, who 
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demonstrated that the Mangifera indica extract was significantly cytotoxic to MDA-MB-231 
and MCF-7 breast cancer cells, while being less toxic to normal breast cells (Abdullah, 
Mohammed et al. 2014). IC50 values of doxorubicin could not be obtained after 12 h of 
treatment because none of the concentrations reduced the growth of the cells by 50%. 
However, after 24 h of treatment, the IC50 value obtained for the MCF-7 cells was also lower 
than that of the KMST-6 cells. The combination interaction that produced the greatest activity 
at the lowest doxorubicin dose (0.1 µM) was seen after 24 h of treatment. The IC50 value of G. 
africana reduced from 1.692 to 1.144 mg/ml when used alone and in combination with 
doxorubicin (0.1 µM), respectively. The IC50 value of the extract increased from 3.625 to 
8.814 mg/ml, for KMST-6 cells, when used alone and in combination with doxorubicin (0.1 
µM) respectively, after 24 h of treatment. This synergistic effect could be attributed to the 
interaction between the extract and doxorubicin which contributed to the increased cytotoxic 
effect seen in the combination studies. Despite the extract having an IC50 value of 0.116 
mg/ml, after 24 h of treatment, when combined with 2.5 µM of doxorubicin, the doxorubicin 
concentration was too high and this study aimed at using the lowest concentration of 
doxorubicin. Even though doxorubicin is widely used to treat numerous types of cancer, it is 
associated with adverse effects such as cardiotoxicity (Antonowa, Asbahr et al. 2017).   
Plant extracts are considered to be effective anticancer agents only if they destroy cancer cells 
without causing too much damage to normal cells (Lacroix, Toillon et al. 2006). 
Phytochemical analysis of G. africana showed that it was mainly composed of flavonoids 
(Ticha, Klaasen et al. 2015). Flavonoids have been shown to possess numerous biologically 
active compounds. These compounds contribute to flavonoids having the ability to promote 
health and prevent diseases (Mikell and Khana 2012). Some of the flavonoids found in G. 
africana were similar in structure to chrysin, sakuranetin and pinocembrin (Ticha, Klaasen et 
al. 2015). Results from a study conducted to assess whether chrysin increased TRAIL-
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induced cell death revealed that it enhanced TRAIL-induced apoptosis in human cancer cell 
lines such as Hela (cervical cancer) cells. Furthermore, it was shown that the apoptosis was 
caspase-dependent. Chrysin has also been shown to stimulate cell cycle arrest (Xin Li, Wang 
et al. 2011). It has also been shown that chrysin is more toxic to cancer cells than to normal 
cells. Studies have demonstrated that normal cells, such as epithelial and fibroblasts, 
exhibited increased resistance to the cytotoxic effect of chrysin compared to cancer cells 
(Kasala, Bodduluru et al. 2015). Pinocembrin has been shown to be cytotoxic to cancer cells, 
such as HCT-116 and SW480 (colorectal adenocarcinoma), MCF-7 (human breast cancer) 
and Hela (cervical cancer), but less toxic to normal cells, such as human umbilical cord 
endothelial cells (Kumar, Biswas et al. 2017). The results obtained from these studies explain 
why the G. africana extract exhibited strong anticancer properties as chrysin and 
pinocembrin constitute part of the chemical compounds found in G. africana.      
The IC50 values obtained after 24 h of treatment were selected for the RT PCR profiler array 
to analyze gene expression. This array allowed for the determination of genes that would be 
up or down regulated in comparison to the untreated group (control group). The results of the 
RT PCR array showed that there was no significant difference in the number of genes that 
were up and down regulated between the G. africana extract and doxorubicin treated groups. 
The genes that were down- and up-regulated after exposure of the MCF-7 cells to the 
different treatment groups are shown in Tables 6.8 and 6.9, respectively. Tables 6.10 and 6.11 
show the fold changes and functions of the genes that were down- and up-regulated, 
respectively, after 24 h of treatment. The results revealed that the genes that were down 
regulated (Table 6.10) included those that played a role in angiogenesis (ANGPT1, ANGPT2 
and FLT1), apoptosis (BIRC3), cell cycle (CCND3, STMN1 and WEE1), cellular senescence 
(MAPK14 and SOD1), epithelial-to-mesenchymal transition (EMT) (CDH2 and SNAI1), 
hypoxia signaling (LDHA) and metabolism (ACLY, ACSL4, G6PD, PFKL and UQCRFS1). 
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The results further revealed that the genes that were up-regulated (Table 6.11) included those 
that played a role in apoptosis (BCL2L11, CASP2, CASP7, CASP9 and FASLG), cellular 
senescence (IGFBP3, IGFBP5 and IGFBP7), DNA damage and repair (DDB2, DDIT3, 
GADD45G and PPP1R15A) and epithelial-to-mesenchymal transition (OCLN).   
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Table 6.10: Comparison of fold regulation changes of down-regulated genes in Groups 1, 2 and 3 (fold change < 1 or 
negative fold change).  
 Fold change  
Gene 
symbol 
Group 
1
a 
Group 
2
b 
Group 
3
c 
Function 
ACLY -4.01 -1.06 -1.88 ATP-citrate lyase (ACLY) is a cytosolic enzyme responsible for the production of acetyl 
CoA (essential for the generation of fatty acids and cholesterol) from citrate.  ACLY is 
over-expressed in numerous types of cancers. When it is under-expressed or inhibited, it 
causes proliferation in cancer cells to cease both in vitro and in vivo (Zaidi, Swinnen et al. 
2012). 
ACSL4 4.04 -1.50 -2.64 Acyl-CoA synthetase long-chain family member 4 Catalyzes the biosynthesis of lipids by 
generating fatty acyl-CoA esters from fatty acids. They also function in the breakdown of 
fatty acids. This enzyme is up-regulated in breast, colon and liver cancers (Wu, Li et al. 
2013; Wu, Deng et al. 2015) 
ANGPT1 -1.99 -6.04 -1.92 Angiopoietin 1 stimulates the assembly and maturation of blood vessels by enabling 
endothelial cells to survive stressful conditions (Davis, Aldrich et al. 1996). 
ANGPT2 -2.56 -1.17 -1.77 Angiopoietin 2 stimulates endothelial cells to respond to angiogenic factors like VEGF 
(vascular endothelial growth factor). It also enables the vascular system to form branches 
and grow  (Kim, Kim et al. 2000; Daly, Pasnikowski et al. 2006) 
BIRC3 -3.59 -3.62 -4.82 BIRC3 is a member of a group of proteins referred to as inhibitors of apoptosis proteins 
(IAP) (Smolewski and Robak 2011; Saleem, Qadir et al. 2013). These proteins inhibit 
apoptosis and exert their functions by preventing the activity of caspase 3/7. BIRC3 has 
been shown to be highly expressed in numerous types of cancers (Gan, Liu et al. 2016) 
such as breast (Lu, Ning et al. 2016; Wang, Xu et al. 2016), pancreatic (Gan, Liu et al. 
2016) and bladder (Kim, Ho et al. 2016). 
BMI1 -4.15 -1.71 -1.69 BMI1 is a member of a group of proteins known as the Polycomb Group (PcG) gene family 
that act by altering the structure of chromatin thus regulating the transcription process of 
several genes (Cao, Bombard et al. 2011). This gene also functions in maintaining the 
integrity of stem cells in addition to cancer progression (Valk-Lingbeek, Bruggeman et al. 
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2004). Studies have shown that BMI1 is up-regulated in cancers such as breast cancer (Cao, 
Bombard et al. 2011). In addition to the above mentioned functions, studies have indicated 
that BMI1 enhances angiogenesis, enables tumors to become more aggressive, and causes 
glioma cells to become resistant to apoptosis through the activation of resistance pathways 
(Paranjape, Balaji et al. 2014). 
CCND3 -2.49 -1.21 -2.73 Cyclin D3 plays a role in the cell cycle and controls/regulates the action of Cyclin-
dependent kinases 4 and 6 (Cdk4 and Cdk6). This gene is Up-regulated cancers such as 
bladder carcinoma in situ, a number of human B-lymphoid malignancies and breast cancer 
(Chi, Huang et al. 2015). 
CDH2 -2.84 ─ -2.46 CDH2 is a transmembrane protein responsible for cell-cell adhesion. It is up-regulated in 
cancers such as gastric, pancreatic and  hepatocellular cancer (Yan, Yan et al. 2015). 
FGF2 -9.60 -2.35 -1.27 FGF2 plays a role in angiogenesis, stimulates blood vessel development, endothelial cell 
growth and wound healing. It is also an effective angiogenic factor (Massabeau, Rouquette 
et al. 2009) 
FLT1 -9.88 -2.90 -9.38 This gene plays a role in regulating angiogenesis, cell survival, and cell migration. It 
facilitates the ability of cancers to invade different tissue. FLT1 also functions in enhancing 
the growth of endothelial cells (Hoffmann, Goekkurt et al. 2013). 
G6PD -1.92 -1.23 -1.11 This gene codes for the glucose-6-phosphate dehydrogenase (G6PD) enzyme that plays a 
role in catalyzing the initial step of the pentose phosphate pathway. This pathway is 
essential for the production of nicotinamide adenine dinucleotide phosphate (NADPH), a 
coenzyme involved in the synthesis of lipids and nucleic acids, as well as ribose which is 
also required for the synthesis of DNA. It has been reported that there is a link between 
G6PD deficiency and reduced susceptibility to developing colorectal cancer (Luzzatto 
2001; Dore, Davoli et al. 2016). Furthermore, results from a study conducted on breast 
cancer patients showed that increased expression of G6PD was linked to an increased risk 
of recurrent metastasis and poor progression-free survival in primary breast carcinoma (Pu, 
Zhang et al. 2015). 
LDHA -3.72 -1.36 -2.13 LDHA codes for an enzyme that plays a role in aerobic glycolysis as well as tumor 
development. It is responsible for catalyzing the final step in the aerobic glycolytic pathway 
(Xian, Liu et al. 2015). LDHA is highly expressed in pancreatic cancer (Shi, Cui et al. 
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2014) and breast cancer (Zhao, Zhou et al. 2009). Studies indicated that down-regulation of 
LDHA caused a reduction in the ability of cancer cells to become malignant and 
significantly slowed down the tumor development process (Fantin, St-Pierre et al. 2006).   
MAPK14 -12.41 1.52 -3.34 Studies carried out on various cancer cell lines have demonstrated  that MAPK14 functions 
in enhancing cancer cell migration, enabling the spread of tumors and metastasis (Emerling, 
Platanias et al. 2005; Junttila, Ala-Aho et al. 2007). 
PFKL -4.10 -3.64 -5.03 PFKL is involved in catalyzing the phosphorylation 
of fructose-6-phosphate to fructose-1,6-bisphosphate, which is essential for glycolysis to 
occur (Wegener and Krause 2002). It has been shown that inhibiting the expression of 
PFKL prevented cell growth as well as their ability to become tumorgenic (Yi, Clark et al. 
2012). 
SNAI1 -1.47 -2.21 -2.53 SNAI1 belongs to a family of transcription factors. It acts by repressing the function of E-
cadherin and is believed to play a role in enabling tumor cells become metastatic (Schwock 
and Geddie 2011). SNAI1 has been implicated in a number of conditions which include 
tissue fibrosis and cancers such as breast and ovarian cancer (Schwock and Geddie 2011). 
It also regulates and stimulates epithelial-mesenchymal transition (EMT) and facilitates the 
spread of cancer cells such as head and neck squamous cell carcinoma (HNSCC) (Ota, 
Masui et al. 2016). 
SOD1 -7.75 -1.87 -3.71 SOD1 is essential for converting superoxide to hydrogen peroxide. It is predominantly 
found in the cytoplasm though it is also present in the inter-membrane space (IMS) (Papa, 
Manfredi et al. 2014). A study conducted on lung cancer cells revealed that up-regulation 
of SOD1 enhanced proliferation of the cancer cells and caused decreased apoptosis 
(Somwar, Erdjument-Bromage et al. 2011). 
STMN1 ─ ─ -2.91 This gene codes for a protein that functions in regulating the assembly and disassembly of 
the mitotic spindles. It also enables the process of mitosis to take place and stimulates the 
proliferation of malignant tumor cells. This proliferation of tumor cells is uncontrolled and l 
leads to an increase in the number of tumor cells (Karst, Levanon et al. 2011). STMN1 is 
also regarded as an oncoprotein (Steinmetz 2007). A study conducted by Kang and 
colleagues revealed that there was an increase in the expression of STMN1 in 80% of 
primary gastric adenocarcinomas at protein level and in 56% at mRNA level (Kang, Tong 
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et al. 2012). Furthermore, it has been shown that silencing STMN1 or reducing its 
expression increased the susceptibility of gastric cancer cells to docetaxel treatment (Meng 
and Tao 2015). Studies have shown that the expression of STMN1 increased in cancers 
such as breast and lucng cancer. Studies have also shown that this gene ehnaced the abiliy 
of the the cancer cells to grow and spread causing advanced disease and increased chances 
of death  (Guo, Luo et al. 2016). 
UQCRFS1 -1.86 -2.09 -1.77 UQCRFS1 is the major subunit of the the cytochrome bc1 complex (complex III) of the mi-
tochondrial respiratory chain responsible for generating electrochemical potential linked to 
adenosine triphosphate (ATP) production (Jun, Kim et al. 2012). Experiments conducted on 
breast cancer cell lines that involved knocking out the UQCRFS1 gene showed that there 
was reduction in the mitochondrial membrane potential and reduced ability of cancer cells 
to invade tissues (Owens, Kulawiec et al. 2011). This demonstrated that up-regulation  of 
UQCRFS1 can enhance production of oxygen radicals, speed up cancer cell growth and 
increase the spread of cancer cells through the rapid production of ATP (Jun, Kim et al. 
2012). 
WEE1 -1.08 -1.37 -2.89 Regulation of the cell cycle is necessary to prevent cells from becoming genomically 
unstable. In cancer cells, this regulatory mechanism is lost and hence, leads to genomic 
instability (Williams and Stoeber 2012). DNA damage is assessed and verified in the G1 
and G2 phases of the cell cycle. However, the G1 phase is absent in cancer cells and thus 
depend on G2 arrest for growth (Vriend, De Witt Hamer et al. 2013). WEE1 functions in 
maintaining the integrity of the genetic material and regulates the G2 phase. This gene is up-
regulated in numerous cancer including osteosarcoma (PosthumaDeBoer, Wurdinger et al. 
2011) and breast cancer (Wang, Huang et al. 2011). 
a
 Cells treated with G. africana only 
b 
Cells treated with doxorubicin only 
c
 Cells treated with a combination of G. africana and doxorubicin 
─ gene absent 
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Table 6.11: Comparison of fold regulation changes of up-regulated genes in Groups 1, 2 and 3 (fold change ˃1 or positive 
fold change).  
    Fold change  
Gene 
symbol 
Group 
1
a 
Group 
2
b 
Group 
3
c 
Function 
BCL2L11 8.03 2.65 8.46 BCL2L11 belongs to the pro-apoptotic family and is responsible for initiating the 
mitochondrial apoptotic pathway (Bouillet, Metcalf et al. 1999). It also plays a role in 
tumor suppression and acts as a tumor suppressor (Tagawa, Karnan et al. 2005). 
Inhibition or deletion of the BCL2L11 gene results in resistance mechanisms in cells 
thus enabling them not to respond to various pro-apoptotic agents such as calcium 
ionophores (Bouillet, Metcalf et al. 1999; Herold, Stuchbery et al. 2014). 
CASP2 8.03 2.65 8.46  CASP2 is involved in apoptosis resulting from various intrinsic and extrinsic factors 
such as DNA damage, reactive oxygen species (ROS) and cytoskeletal disturbances 
(Kumar 2009). It also functions as a tumor suppressor  (Puccini, Dorstyn et al. 2013). 
Resistance to chemotherapeutic agents in conditions such as childhood acute 
lymphoblastic leukemia (ALL) had been linked to the down-regulation or under-
expression of CASP2 (Holleman, den Boer et al. 2005).  CASP2 has also been shown 
to play a role in cell growth and transformation regulation (Gitenay, Lallet-Daher et al. 
2014). 
CASP7 8.03 2.65 8.46 CASP7 belongs to a family of genes needed for the maintenance of homeostasis by 
means of cell death regulation and inflammation. Caspases act on peptide bonds, via 
hydrolysis, which results in the activation of chemicals that play a role in apoptosis 
and inflammation (McIlwain, Berger et al. 2013; Chaudhary, Madhukrishna et al. 
2016). Caspases that play a role in apoptosis can either be classified as being initiator 
caspases or executioner caspases. Executioner caspases are activated by initiator 
caspases (McIlwain, Berger et al. 2013). CASP7 codes for a protease enzyme that is 
an example of an executioner caspase. Activation of executioner caspases, like 
caspase-7, leads to the activation of additional executioner caspases that also play a 
role in apoptosis (McIlwain, Berger et al. 2013). 
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CASP9 8.03 2.65 8.46 Apoptosis is a process that involves both the intrinsic and the extrinsic pathways and is 
necessary for controlling the amount and quality of cells (Druškovič, Šuput et al. 
2006). CASP9 encodes caspase-9, which is the main enzyme involved in the intrinsic 
apoptotic pathway. Activation of caspase-9 leads to the activation of caspase-3 
resulting in apoptosis (Kim, Srivastava et al. 2015). Caspase-9 inhibition causes 
testicular tumors to become resistant to apoptosis (Mueller, Voigt et al. 2003). It has 
been shown that the mode of action of several cytotoxic agents is the initiation of cell 
death through the activation of the cytochrome c/Apaf-1/Caspase- 9-dependent 
intrinsic pathway (Debatin 2004). Studies have shown that natural compounds are 
beneficial in the fight against cancer as they have the potential to prevent cancer 
growth, cancer spread as well as drug resistance. They inhibit cancer development in 
many types of cancers by triggering apoptosis through the activation of caspase-9 
(Kim, Srivastava et al. 2015). 
DDB2 8.03 2.65 8.46 The prevalence and death rates of metastatic breast cancer are on the rise and knowing 
the exact mechanism by which metastasis takes place is very important. The ability of 
breast cancer to become metastatic and invade neighboring and distant tissues is 
coupled with changes in cellular structure and cellular communication. Data has 
shown that DDB2 is able to decrease the invasive capabilities of mammary tumors 
(Ennen, Klotz et al. 2013; Zhao, Han et al. 2014).  A study conducted to evaluate the 
tumor suppressive role of the DDB2 gene revealed that mice that lacked the gene were 
prone to UV-induced carcinogenesis and they easily had malignant tumors (Yoon, 
Chakrabortty et al. 2005; Itoh, Iwashita et al. 2007).  
DDIT3 ─ 1.37 1.35 DDIT3 codes for a protein that is involved in stress related responses. The expression 
of DDIT3 is stimulated by DNA damage, hypoxia, ER stress as well as starvation 
(Jauhiainen, Thomsen et al. 2012). Stimulated expression of DDIT3 results in the 
inhibition of the cell cycle process in some cells with apoptosis occurring in other 
types of cells. It is for this reason that DDIT3 is regarded as an apoptotic transcription 
factor (Zinszner, Kuroda et al. 1998; Wu, Sun et al. 2014). 
DSP 8.03 2.65 8.46 Cancers become metastatic when  the cell-cell adhesion properties at the original 
tumor location are lost (Behrens 1999). Desmosomes are specific cellular components 
 
 
 
 
                             
                                                                                                                                                      Chapter 6Anticancer studies 
291 
 
that are responsible for cell-cell adhesion and studies have indicated that they play a 
role in regulating cell motility, growth, apoptosis and differentiation (Yang, Chen et al. 
2012). DSP belongs to the plankin family and the proteins are extensively expressed in 
several tissues. Reports from numerous studies have shown that a decrease in the 
number of desmosomes resulted in tumor cells being invasive (Yang, Chen et al. 
2012). Down-regulation of desmosomal proteins was also observed in breast cancer 
(Oshiro, Kim et al. 2005), cervical carcinoma (Alazawi, Morris et al. 2003) and 
pancreatic cancer (Hamidov, Altendorf-Hofmann et al. 2011). 
FASLG 8.03 2.65 8.46 The FASLG gene codes for a protein that is a member of the tumor necrosis factor 
(TNF) family. The primary function of the encoded transmembrane protein is the 
initiation of apoptosis triggered by binding to FAS (Xu, Zhou et al. 2013). 
GADD45G 14.68 1.13 ─ GADD45G gene plays a role in a number of processes such as cellular stress responses 
and tumor suppression  (Liebermann and Hoffman 2007; Tamura, de Vasconcellos et 
al. 2012). It has been shown that there is an interaction between the GADD45G gene 
and  numerous other proteins that are responsible for DNA repair, apoptosis, cell cycle 
control and senescence (Johnen, González-Silva et al. 2013). A reduction in the 
expression levels of GADD45G has been linked to several types of cancers (Zhang, 
Yang et al. 2014) 
IGFBP3 ─ ─ 1.83 IGFBP3 codes for the Insulin-like growth factor binding protein 3 (IGFBP3) which 
belongs to the IGF family. IGFBP3 is involved in cellular proliferation, differentiation, 
apoptosis, and mammary carcinogenesis (Schedlich and Graham 2003). Studies have 
indicated that IGFBP3 helps the transforming growth factor-1 to function in inhibiting 
cell growth and it also stimulates apoptosis by means of the tumor suppressor gene 
(p53) in breast cancer patients (Marshman and Streuli 2002). Reduced IGFBP3 levels 
have been linked to an increase in the risk of cancer development. This has been seen 
in cases where genetic polymorphisms in IGFBP3 have resulted in changes in the 
circulating levels of IGFBP3 thus increases the chances of developing different types 
of carcinomas (Yang, Liu et al. 2014) including breast cancer (Safarinejad, Shafiei et 
al. 2011; Ma, Kang et al. 2015) 
IGFBP5 8.03 2.65 8.46 IGFBP5 codes for a protein that belongs to the Insulin-like growth factor binding 
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protein (IGFBP) family. Studies have shown that the up-regulation of IGFBP5 in 
breast cancer cell models induced apoptosis and inhibited cell proliferation. 
Furthermore, it inhibited tumor cell growth in in vivo studies (Butt, Dickson et al. 
2003). 
IGFBP7 8.03 2.65 8.46 IGFBP7 also encodes a protein that is a member of the IGFBP family.  IGFBP7 is 
involved in the regulation of cell proliferation, cell differentiation, cell adhesion, cell 
senescence and angiogenesis in a wide range of cancer cells. It has also been shown to 
possess tumor suppressing capabilities in several types of cancers (Chen, Cui et al. 
2011). 
OCLN 8.03 2.65 8.46 OCLN is a gene that encodes the transmembrane protein called occludin. Occludin is 
involved in the formation and maintenance of tight junctions. It is for this reason that 
any alteration to the structure or loss of occluding could result in enhanced epithelial 
leakage thereby promoting metastasis in cancers. Changes in occludin expression have 
been shown to be associated with enhanced invasion, reduction in cell adhesion and 
decrease in tight junction composition in breast cancer tissue. In addition, evidence 
showed that patients with invasive tumors had considerably low occluding levels 
suggesting that proper tight junction function is essential in preventing metastasis 
(Martin, Mansel et al. 2010). 
PINX1 8.03 2.65 8.46 PINX1 has been shown to inhibit the function of telomerase and also plays a role in 
tumor suppression (Zhou and Lu 2001). Studies have also indicated that PINX1 is 
capable of inhibiting metastasis in breast cancer which subsequently has an effect on 
the development and advancement of the cancer (Shi, Cao et al. 2015). 
PPP1R15A 8.03 2.65 8.46 PPP1R15A codes for a protein that plays a role in inhibiting cell growth (Zhan, Lord et 
al. 1994) and is also involved in E.R (endoplasmic reticulum) mediated cell death 
(Sano and Reed 2013). Studies have demonstrated that PPP1R15A induces apoptosis 
in specific cell lines after the administration of alkylating agents and ionizing ration 
(Tanaka, Ito et al. 2015). 
a
 Cells treated with G. africana only 
b 
Cells treated with doxorubicin only 
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c
 Cells treated with a combination of G. africana and doxorubicin 
─ gene absent 
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Numerous studies have been conducted to investigate the effect of medicinal plants on the gene 
expression of human breast cancer cells. A study carried out to investigate the effect of 
Euphorbia tirucalli extracts in breast cancer cell lines revealed that the extracts inhibited cell 
proliferation in dose-dependent manner (Choene and Motadi 2016). It was established that the 
over-expression of p21 contributed to the proliferation inhibition. Furthermore, pro-apoptotic 
genes such as Bax and caspase-8 were significantly up-regulated in cells treated with plant 
extracts (Choene and Motadi 2016). Another study that investigated the effect of soy isoflavones 
on the gene expression of MCF-7, MDA-MB-231 and MCF-10a cell lines found that there was a 
significant change in the expression of about 246 genes. These genes played a role in cell 
communication, biodegradation, lipid metabolism, signal transduction and cell growth/death 
(Satih, Chalabi et al. 2010). Orangi et al. (Orangi, Pasdaran et al. 2016) investigated the 
cytotoxic effects of Scrophularia oxysepala methanolic subfractions as well as the mechanisms 
responsible for cell death in MCF-7 cells. They observed that caspase-8 was up-regulated while 
the expression of BCL-2 was down-regulated. A study evaluating the anticancer effect of 
Vernonia amygdalina in MCF-7 and MDA-231 cells showed that p53 and p21 were up-regulated 
and this resulted in cell growth arrest. It was also shown that cyclin D1 and cyclin E were down-
regulated. Apoptosis was considered to be caspase-dependent  (Wong, Woo et al. 2013).  
6.6 Conclusion 
This study demonstrated that G. africana had significant anticancer potential on the MCF-7 cells 
with minimal effects on the KMST-6 cells. The IC50 values for the KMST- cells were higher than 
those of the MCF-7 cells at the different time-points suggesting that the extract could have 
minimal effects on other normal cells. G. africana also had an effect on gene expression causing 
the up-regulation of genes involved in apoptosis and cellular senescence while causing down-
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regulation of genes involved in angiogenesis and metabolism. Evaluation of gene expression 
using the RT PCR array was a preliminary study and was used as a screening process. Further 
studies will be conducted based on these results. These results can subsequently be used to 
investigate the mode of action of G. africana. Future studies will include the use of at least three 
normal cells as controls as well as the detection of apoptotic markers to confirm whether the 
plant extract induces cell apoptosis. 
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7 CHAPTER 7: Conclusion and recommendations 
7.1 Overview 
Drug resistance is a global problem that arises when diseases no longer respond to therapeutic 
agents normally used in their treatment. Initially, drug resistance was observed in bacteria that 
exhibited reduced susceptibility to particular antibiotics. However, other microorganisms have 
also developed resistance to therapeutic agents. This trend can also be seen in diseases such as 
cancer (Housman, Byler et al. 2014). Treatment failure and deferred treatment often lead to high 
death rates (Kumar, Haery et al. 2006; Ferrer, Martin-Loeches et al. 2014). Unfortunately, new 
antimicrobial agents are not being produced fast enough to match the rate at which these 
microorganisms develop resistance to these drugs (Karam, Chastre et al. 2016).  
Medicinal plants have been used for centuries for the treatment of various ailments (Lixandru, 
Dracea et al. 2010). Reports have indicated that therapeutic drugs derived from medicinal plants 
have proved to be safer than synthetic drugs and produce no side effects (Bansod and Rai 2008). 
A number of medicinal plants have been investigated to assess their antimicrobial and anticancer 
activities. A study carried out by Rous and colleagues on the antibacterial and antifungal 
activities of essential oils showed that these oils had considerable antibacterial and antifungal 
activities against the tested pathogens including S. aureus, C. albicans and C. glabrata (Rouis, 
Abid et al. 2013). The assessment of medicinal plants for their cytotoxic effects against breast 
cancer cells lines revealed that they were cytotoxic against these cells and also had an effect on 
the structure of the cells (Vijayarathna and Sasidharan 2012).  
Galenia africana has been shown to possess various health benefits. It has been utilized in the 
treatment of wounds, relief of eye inflammation, venereal diseases, ringworms as well as in the 
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treatment of toothaches (Watt and Breyer-Brandwijk 1962). However, despite medicinal plants 
being used in the treatment of a vast number of diseases, investigation on the potential toxicity of 
these plants is limited even though numerous studies have been conducted to assess their health 
beneficial properties. Reports have indicated that a large number of medicinal plants result in 
severe toxicity when used (Fennell, Light et al. 2004; Wojcikowski, Johnson et al. 2004). As a 
result, more studies are being conducted to investigate the possible toxic effects of medicinal 
plants (Nath and Yadav 2015).  
The present study evaluated the potential antimicrobial, antifungal and anticancer properties of G. 
africana using various techniques. Prior to conducting the study, toxicity studies were conducted 
in order to ascertain the level of toxicity that G. africana may have. This was done using acute 
toxicity and skin irritation and sensitization studies.  
The evaluation of the toxicity of the ethanolic extract of G. africana was conducted according to 
the OECD guidelines and determined using the acute oral (OECD guideline No. 423 (OECD 
2001), acute dermal (OECD guideline No. 402 (OECD 1987; OECD 2015a) and skin 
sensitization toxicity studies (OECD test guideline No. 429 (OECD 2010) in animal models and 
skin irritation test in reconstructed human epidermis models (OECD 439 (OECD 2015b). The 
results of the acute oral and dermal toxicity studies showed that the median lethal dose (LD50) of 
the extract in the rats was higher than 2000 mg/kg. Furthermore, macroscopic analysis, at 
necropsy, revealed that there were no abnormalities observed. The skin sensitization study was 
done using the local lymph node assay (LLNA). Treatment with G. africana concentrations of 50, 
100 and 200 mg/ml resulted in stimulation index (SI) values of 1.3, 0.9 and 1.3, respectively. It 
was concluded that since the G. africana extract did not result in a SI value of ≥ 3 in any of the 
groups (50, 100 and 200 mg/ml, respectively), it was regarded as not having the potential to 
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cause skin sensitization. The results of the skin irritation assay revealed that both the 
concentrated and the diluted G. africana extracts were non-irritant to the EpiSkin® models. The 
outcomes of this study demonstrated that the ethanolic extract of G. africana did not result in any 
in vivo danger.  
The antibacterial activity of G. africana against methicillin-susceptible (ATCC 25923) and 
methicillin-resistant (ATCC 33591) S. aureus (MSSA and MRSA, respectively) was evaluated 
using the broth microdilution assay, checkerboard assay and Sensititre susceptibility test. The 
MBC of G. africana was also determined. The MIC obtained after treatment of the bacterial 
cultures with the ethanolic extract was 3.12 mg/ml for both strains The MBC of the ethanolic 
extract against MSSA (ATCC 25923) was 6.25 mg/ml while that of the MRSA (ATCC 33591) 
was 12.5 mg/ml. Results of the checkerboard assay revealed that there was an additive effect 
(FICI 0.64) between the extract and ampicillin against MSSA (ATCC 25923). However, the 
effect seen with the extract-ampicillin combination was indifference (FICI 1.002) against MRSA 
(ATCC 33591). The results from the Sensititre susceptibility test showed that the extract 
enhanced the antimicrobial activity of several drugs against both strains. 
The antifungal activity of G. afrciana against C. albicans (ATCC 90028) and C. glabrata 
(ATCC 26512) was assessed using the disk diffusion, broth microdilution assay, checkerboard 
assay and Sensititre susceptibility test. The effect of G. africana on fungal growth was evaluated 
by determining the MFC. The effect of the extract on the structure of the Candida cells was also 
investigated. After the incubation period, small zones of inhibition and micro-colonies were seen 
at G. africana concentrations of 15.6 to 250 mg/ml. No zones of inhibition were seen at 
concentrations of 7.8 and 3.9 mg/ml. The ethanolic extract produced an MIC of 6.25 mg/ml 
against both strains. The MFC of the ethanolic extract against C. albians (ATCC 90028) was 
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6.25 mg/ml and that of ethanolic extract against C. glabrata (ATCC 26512) was 12.5 mg/ml. 
Results of the checkerboard assay showed that the interaction between fluconazole and G. 
africana against C. albicans (ATCC 90028) was synergistic (FICI value of 0.36 which was ˂ 
0.5.) The effect of the combination of fluconazole and G. africana against C. glabrata (ATCC 
26512) produced an FICI value of 1.002, which was considered to be indifference as this value 
was in the range of 1 ˂ FICI ˂ 4. The Sensititre susceptibility testing results revealed that G. 
africana enhanced the antifungal activity of the antifungal agents as seen by a decrease in the 
MICs of the antifungal agents against the Candida species. Microscopic analysis revealed that 
cell structures appeared distorted, with leakages of cell constituents as well as loss of cell 
contents. Remnants of cells could also be seen under the microscope. The untreated Candida 
cells appeared round with smooth surfaces without any distortion to their morphology. The 
results obtained indicate that G. africana is a potential source of new antibacterial and antifungal 
agents.  
G. africana alone, doxorubicin alone as well as their combinations were tested for in vitro 
cytotoxicity, using MCF-7 and KMST-6 cells by the MTT assay. The effect of G. africana on 
gene expression was also assessed. The results demonstrated that G. africana had significant 
anticancer potential on the MCF-7 cells with minimal effects on the KMST-6 cells. The IC50 
values for the KMST- cells were higher than those of the MCF-7 cells at the different time-points 
suggesting that the extract could have minimal effects on other normal cells. G. africana also had 
an effect on gene expression causing the up-regulation of genes involved in apoptosis and 
cellular senescence while causing down-regulation of genes involved in angiogenesis and 
metabolism.  
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Collectively, these results show that G. africana has tremendous potential in complementary and 
alternative medicine for the treatment of bacterial and fungal infections as well as for the 
treatment of cancer. The toxicity studies also revealed that G. africana did not result in any 
adverse effects and there were no signs of toxicity in both the animal and human skin models.  
7.2 Recommendations 
The outcomes of this study demonstrated that the ethanolic extract of G. africana did not result 
in any in vivo danger. Pharmacological and biochemical investigations will be essential in 
elucidating the mechanism of action and will be beneficial in utilizing this plant as a therapeutic 
agent. Furthermore, a detailed experimental analysis of the chronic toxicities is important to 
support these findings. Toxicity assessment of medicinal plants already in use, including the ones 
not yet commercialized, is important in evaluating their safety and sensitizing potential at 
dosages for which these formulations are being used. Clinical trials have not yet been performed 
on this medicinal plant and will be essential. This study supplies additional information on the 
activity of G. africana and contributes to the knowledge of antimicrobial properties of plants 
commonly found in South Africa. However, additional research such as exploring the 
mechanism of action and performing in vivo studies to corroborate the antimicrobial potential of 
the extract alone and in combination with antibacterial and antifungal agents will have to be 
conducted. Evaluation of gene expression using the RT PCR array was a preliminary study and 
was used as a screening process. Further studies will be conducted based on these results. These 
results can subsequently be used to investigate the mode of action of G. africana.  
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8 APPENDICES 
APPENDIX I 
Certificate of Analysis for G. africana Extract 
 
 
 
 
 
   
323 
 
APPENDIX II 
GLP Certificate 
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APPENDIX III 
EpiSkin

 Technical Data, Safety Sheet and Certificate of Analysis 
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APPENDIX IV 
Certificate of analysis for G. africana 
 
 Oxidative Stress Research Centre 
Centre Manager Lab Manager 
Prof. Jeanine Marnewick Fanie Rautenbach 
Tel: (021) 953 8416 Tel: (021) 953 8418 
e-mail: marnewickJ@cput.ac.za e-mail: rautenbachF@cput.ac.za 
Fax: (021) 953 8490 
 
Certificate of Analysis 
Assay for: UWC – Kraalbos 
Jeremy Klaasen 
                                                          
 
 
 
 
 
 
 
 
 
N.D. = none detected 
 
Assay conditions 
HPLC column  : YMC - Pack Pro C18 
Mobile phase A: Water + 0.05% TFA 
Mobile phase B: Methanol + 0.05% TFA 
Mobile phase C: Acetonitrile + 0.05% 
TFA Runtime: 30 minutes 
Column Temperature : 30°C Flow 
rate : 1 mL/min 
UV detection : 280 and 320nm 
Injection                 : 20µL  
Sample preparation    : None 
 
Analysis date : 05/10/2015 
Analysed by : G.S. Rautenbach 
Authorised by  : J.L. Marnewick 
    
G.S. Rautenbach 
Laboratory Manage 
 
Sample Name 7-OH-Flav 
(mg/L) 
Pinocembrin 
(mg/L) 
2,4- 
Dihidrochalcone 
(mg/L) 
Chrysin 
(mg/L) 
Polyphenols 
(mg/L) 
20% ethanolic 
extract 
N.D. 741.60  
 
 
227.69 
 
530.10 
 
1740  
 
GA-MHB (G. 
africana in MHB) 
N.D. 36.46  
13.99 
 
8.96 
 
1119 
GA-RPMI (G. 
africana in RPMI) 
N.D. 50.22  
14.32 
 
6.031 
 
941  
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APPENDIX V 
Certificate of analysis for G. africana 
 
 Oxidative Stress Research Centre 
  Centre Manager Lab Manager 
Prof. Jeanine Marnewick Fanie Rautenbach 
Tel: (021) 953 8416 Tel: (021) 953 8418 
e-mail: marnewickJ@cput.ac.za e-mail: rautenbachF@cput.ac.za  
Fax: (021) 953 8490 
 
Certificate of Analysis 
 
Assay for: UWC – Kraalbos 
Jeremy Klaasen 
 
Sample Name 7-OH-Flav 
(mg/l) 
Pinocembrin 
(mg/l) 
2,4-
Dihidrochalcone 
(mg/l) 
Chrysin 
(mg/l) 
Polyphenols 
(mg/l) 
20% Crystals G. 
africana 
N.D. 8144 6292 1726 21976 
Sample Name 7-OH-Flav 
(mg/g) 
Pinocembrin  
(mg/g) 
2,4- 
Dihidrochalcone 
(mg/g) 
Chrysin 
(mg/g) 
Polyphenols 
(mg/g) 
20% Aqueous 
extract 
N.D. 8.84 4.67 1.34 20.21 
N.D. = none detected 
Assay conditions 
HPLC column  : YMC - Pack Pro C18 
Mobile phase A: Water + 0.05% TFA 
Mobile phase B: Methanol + 0.05% TFA 
Mobile phase C: Acetonitrile + 0.05% 
TFA Runtime: 30 minutes 
Column Temperature : 30°C Flow 
rate : 1 mL/min 
UV detection : 280 and 320nm 
Injection                 : 20µL  
Sample preparation    : None 
 
Analysis date : 05/10/2015 
Analysed by : G.S. Rautenbach 
Authorised by  : J.L. Marnewick 
    
G.S. Rautenbach 
Laboratory Manage 
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APPENDIX VI 
Summary of genes in RT² Profiler PCR Array 
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APPENDIX VI (Continued) 
Summary of genes in RT² Profiler PCR Array 
 
 
 
 
 
